








Angiogenesis is the creation of new blood vessels from the existing vasculature that
occurs through a complex series of interactions and is tightly regulated.
Glucocorticoids are acknowledged to inhibit angiogenesis at high concentrations but
whether endogenous glucocorticoid concentrations are sufficient to regulate
angiogenesis is unclear. Adrenal synthesis is not the sole determinant of
glucocorticoid tissue concentration however and 11 phydroxysteroid dehydrogenase
type 1 (lipHSDl) that is present in the vessel wall may regenerate active
glucocorticoids from 1 lketo-substrates and therefore amplify local tissue
concentrations. Thus it was hypothesised that endogenous glucocorticoids regulated
by lipHSDl inhibit angiogenesis.
In vitro C57B16 mouse aortic ring cultures established that physiologically relevant
concentrations of glucocorticoids inhibit angiogenesis in a glucocorticoid receptor
dependent manner. In addition vascular lipHSDl was found to modulate
glucocorticoid-induced angiostasis, for 1 ldehydrocorticosterone although angiostatic
in C57B16 aortae did not inhibit angiogenesis inl 1 pHSDl deficient animals.
In vivo using polyester sponge subcutaneous implants in mice, endogenous
glucocorticoids were found to inhibit angiogenesis: sponges in adrenalectomised
C57B16 mice grew more vessels compared to sponges from sham-operated animals.
lipHSDl regulated the angiostatic effects of glucocorticoids, for cortisone (the
human equivalent of 11 dehydrocorticosterone), although angiostatic in wild types
did not inhibit angiogenesis in lipHSDl deficient mice. In vivo it was also noted
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that in placebo-impregnated sponges angiogenesis was greater in 1lpHSDl deficient
compared to C57B16 mice.
In pathology in cutaneous wounds and infarcted myocardium, endogenous
glucocorticoids were found to inhibit angiogenesis. RU38486 (a glucocorticoid
receptor antagonist) enhanced angiogenesis in both tissues in comparison to placebo
treatment. In similar studies in C57B16 or 11(3HSD1 deficient mice, lipHSDl was
found to tonically repress angiogenesis and impair left ventricular remodelling post
infarction. Thus 1 lpHSDl deficient mice had increased myocardial revascularisation
and preserved left ventricular function.
In conclusion, by using in vitro, in vivo and pathological models, endogenous
glucocorticoids were seen to inhibit angiogenesis. In addition 1 lpHSDl regeneration
of glucocorticoids tonically repressed angiogenesis and influenced left ventricular
remodelling post myocardial infarction. Thus 1 lpHSDl appears to be an attractive
therapeutic target for the management of tissue revascularisation.
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Angiogenesis describes the proliferation, branching and remodelling of the existing
vasculature to form new blood vessels. It is an essential component of vessel wall
function and plays a key role in health and disease. New blood vessel formation in
health is tightly regulated by local vessel wall and systemic factors (Conway et al.
2001).
Glucocorticoids although recognised as systemic mediators of vascular function
through their effects on blood pressure, have received less attention as local
regulators of vessel wall activity. Nevertheless the potential for these compounds to
regulate vascular function locally has been demonstrated through their effects on
mediators of vascular tone (Ullian 1999). Furthermore the local vascular effects of
glucocorticoids may be influenced by the presence in the vessel wall of
1 lpHydroxysteroid dehydrogenase type 1 (11PHSD1) (Hadoke et al. 2001).
lipHSDl amplifies local glucocorticoid concentrations by regenerating active
glucocorticoids from inert substrates. Therefore either by altering systemic responses
or via vessel wall 11 PHSD activity; the potential exists for glucocorticoids to
modulate angiogenesis.
A therapeutic target
Angiogenesis regulation has been identified as an attractive target for therapeutic
intervention and both systemic and local factors have been used as potential
angiogenic regulators (Jain 2003). Fibroblast derived growth factor (FGF) and
vascular endothelial cell growth factor (VEGF) are mediators released by vessel wall
constituents during new vessel formation and have been used individually to improve
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ventricular revascularisation post myocardial infarction (Lopez et al. 1998; Iwakura
et al. 2003). Systemic angiogenesis therapies have also been investigated in this
setting; in particular stem cell therapy has been administered with some success in
laboratory and clinical studies (Orlic et al. 2001; Rafii et al. 2002). Indeed
myocardial revascularisation remains an attractive focus for angiogenesis research
because of the clinical improvement seen with revascularisation therapy in ischaemic
heart disease.
Stimulating angiogenesis for therapeutic benefit has also been explored in diabetic
and peripheral vascular ulcer diseases when cutaneous wound healing is impaired
(Graiani et al. 2004; Collinson & Donnelly 2004). The improvement in clinical and
laboratory outcomes following angiogenesis induction in these conditions suggests
an important role for angiogenesis in the healing response of the skin. Although
increasing angiogenesis can be therapeutically attractive in some conditions there are
other pathologies where the target for intervention has been the inhibition of
excessive new vessel formation.
Limitation of the prolific angiogenesis in primary vascular tumours such as
proliferating capillary haemangiomas has been a target of anti-angiogenic therapies.
In malignancies of other tissues increased angiogenesis occurs and although in this
situation the primary source of dysregulation and autonomous growth is not vascular
in nature; excessive angiogenesis is nevertheless a major determinant of tumour size
and haematogenous metastasis (Folkman 2001). Anti-angiogenic therapies have been
used to inhibit tumour growth for example glucocorticoids are administered
clinically in the treatment of proliferating capillary haemangiomas (Hasan et al.
2000). In addition recent clinical trials suggest that the anti-VEGF antibody
bevacizumab can safely and effectively be employed in colorectal cancer in
combination with anticancer agents (Willett et al. 2004). Thus in vascular and non¬
vascular tumours anti-angiogenic therapy serves as an adjunctive therapy to
traditional anti-cancer therapy.
Side effects oftherapy
It would be unattractive however to maintain anti-angiogenic agents in the long term
to prevent tumour progression since such agents would also delay tissue healing post
surgical resection or have effects on co-incidental illnesses such as ischaemic heart
disease. Furthermore the long-term effects of anti-angiogenic therapy on skeletal
muscle remodelling and on the female reproductive cycle have not been studied.
Thus although promising, the role of anti-angiogenic agents to treat tumour primary
growth or prevent secondary metastatic spread requires further development.
In addition to the concerns regarding the long-term use of anti-angiogenic agents in
tumour therapy other fears have arisen regarding the use of pro-angiogenic agents.
There are hypothetical concerns that agents, which stimulate angiogenesis, could be
tumorigenic. Furthermore in ischaemic heart disease, although angiogenic gene
therapy with VEGF improved myocardial revascularisation there was also an
increase in angiogenesis with atherosclerotic plaques (Schwarz et al. 2000). This
gave rise to apprehensions regarding the possibility of plaque expansion,




Despite these initial setbacks modulation of angiogenesis by systemic and local
factors continues to be a source of intense scientific and clinical research. Current
emphasis has been to explore the possibility of targeting angiogenic modulators to
the site of pathology whether by using endothelial cell markers for specific tissues or
identifying specific angiogenic factors expressed in tumour cells (Sullivan &
Bicknell 2003). Less attention has been directed at the important ability of the vessel
wall to self regulate for example by modulating the effects of systemic angiogenesis
factors. Therefore in this thesis we will study the regulation of angiogenesis by
glucocorticoids and compare the effects of systemic glucocorticoids released by the
adrenal cortex with the regeneration of glucocorticoids locally within the vessel wall
by lipHSDl. We will argue that local regulation of glucocorticoids concentrations
by 11 pHSD 1 is an important determinant of angiogenesis responses. In particular we
consider these effects in the contexts of myocardial revascularisation following
infarction and in the cutaneous wound healing response.
This introductory chapter describes glucocorticoid physiology and examines how
11 pHSDs modulate glucocorticoid action locally within tissues. The process of
angiogenesis is detailed and the evidence for a modulatory role of glucocorticoids is
discussed. Finally, a list of the aims of this thesis is presented.
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Angiogenesis, the formation of new blood vessels from existing ones, is an essential
component in the development of a vascular network but also plays a key role in the
pathogenesis of many diseases (Conway et al. 2001). Clarification of the
mechanisms that regulate angiogenesis is important for extending our understanding
of the physiological control of new vessel growth and for developing tools for
therapeutic manipulation of this process (Carmeliet & Jain 2000).
It is well established that angiogenesis can be inhibited by glucocorticoids (McNatt
et al. 1999; Hasan et al. 2000; Hasan et al. 2003; Ingber et al. 1986; Hori et al. 1996;
Folkman & Ingber 1987) (steroid hormones released from the adrenal cortex) but the
mechanisms involved are unclear; possibilities include inhibition of inflammation,
inhibition of vascular cell proliferation or migration. Many studies, however, have
used pharmacological concentrations of glucocorticoids to demonstrate their
angiostatic effects. Consequently, the influence of endogenous glucocorticoids, and
their pre-receptor metabolism in target tissues, on angiogenesis has not been
established. The presence of the enzyme 1 l(3-hydroxysteroid dehydrogenase type 1
in the smooth muscle cells (Christy et al. 2003) suggests that glucocorticoids are
generated from inert metabolites within the vascular wall itself. The work described
in this thesis was designed to determine whether pre-receptor glucocorticoid
generation in the vascular wall influences angiogenesis.
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1.1 Glucocorticoids
Glucocorticoids (Cortisol in man, corticosterone in rodents) are known
therapeutically for their anti-inflammatory and immunosuppressive actions (Barnes
1998) but have much wider-ranging effects on body physiology. These are most
clearly demonstrated in the clinical syndromes of Cushing's or Addison's diseases
(Addison 1855) where altered glucocorticoid availability creates a diffuse clinical
picture involving many organ systems.
1.1.2 Steroid Hormone Structure
Glucocorticoids, in common with other steroid hormones, contain a common
backbone molecule with three 6-carbon hexane rings and a single 5-carbon pentane
ring. Carbon atoms within steroids are numbered starting in the A ring and steroids
with a ketone group at C-l 1 are known as 11-ketosteroids (Figure 1.1).
1.1.3 Biosynthesis
Glucocorticoids are synthesised, from cholesterol, in the inner zones of the adrenal
cortex (predominantly in the zona fasciculata, with a smaller contribution from the
zona reticularis). Adrenal hormone production is catalysed by members of the CYP
oxidative enzyme family (previously labelled cytochrome P450) located in the
membranes of the mitochondria, cytosolic microsomes and endoplasmic reticulum
(ER).
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The carbon atoms are numbered in a sequence commencing with ring A. C2i steroids have
either glucocorticoids or mineralocorticoid properties.
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1.1.4 Secretion
Glucocorticoid synthesis by the adrenal cortex is controlled by hormonal interactions
among the hypothalamus, pituitary and adrenal glands (Jacobson & Sapolsky 1991;
Jacobson 2005). Intra-adrenal glucocorticoid storage is minimal thus biosynthesis is
closely associated with adrenal secretion.
Neural stimulation of the hypothalamus (e.g. in response to stress) causes the release
of corticotrophin releasing hormone (CRH) from hypothalamic neurons into the
hypothalamic-hypophyseal portal system and thence to the pituitary. At the pituitary,
stimulation of CRH receptors on corticotrophs of the anterior pituitary results in the
rapid release of adrenocorticotrophic hormone (ACTH) into the systemic circulation
(Jacobson & Sapolsky 1991; Jacobson 2005).
ACTH is synthesised as part of the precursor polypeptide pro-opiomelanocortin
(POMC) and acts via plasma membrane receptors (melanocortin-2-receptors) on
adrenocortical cells, to stimulate steroidogenesis in an acute and chronic fashion
(Clark et al. 2003; Beuschlein et al. 2001). Acutely, ACTH increases the conversion
of cholesterol to pregnenolone; this effect is mediated by activation of cholesterol
delivery to the inner mitochondrial membrane. Chronically ACTH increases the
expression and activities of most of the enzymes of the steroidogenic pathway and
can also stimulate adrenal hyperplasia and hypertrophy.
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Glucocorticoids are also secreted in a diurnal fashion in response to a circadian
stimulation of ACTH release (Jacobson & Sapolsky 1991; Jacobson 2005). Circadian
rhythm is usually synchronised to sleep-wake cycles; thus glucocorticoid secretion
peaks 2-4 hours before awakening, and then decreases to almost zero just before
sleep. ACTH is secreted in brief pulses that raise plasma ACTH and glucocorticoids:
plasma glucocorticoids stay elevated longer than ACTH because of slower clearance.
ACTH secretion is further regulated by glucocorticoids via a negative feedback loop
(Aguilera et al. 2001; Jacobson & Sapolsky 1991; Jacobson 2005). Feedback occurs
at both pituitary and hypothalamic levels. ACTH secretion is suppressed at the
hypothalamus by inhibiting CRH synthesis and release, and at the level of the
pituitary by inhibiting CRH receptor expression, ACTH secretion and POMC
transcription. Glucocorticoids also affect ACTH secretion indirectly by blocking the
stimulatory effects ofCRH on POMC transcription and ACTH release.
1.1.5 Glucocorticoids in plasma
Glucocorticoids are transported in plasma bound to corticosteroid-binding protein
(CBG) and albumin, with only 5-10% unbound in the plasma (Hammond et al.
1990). Protein binding improves the transport of glucocorticoids (which are insoluble




Inactivation of glucocorticoids occurs largely by metabolism within the liver
followed by conjugation and excretion in the urine. There are five possible initial
fates for Cortisol/ corticosterone in primary inactivation reactions (Figure 1.2):
1. Hepatic reduction of the A4 double bond of the A-ring by 5a- or 5P-
reductases; this is the major route of glucocorticoid metabolism. Subsequent
hepatic reduction by 3a-hydroxysteroid dehydrogenase (3a-HSD) yields
tetrahydro-metabolites.
2. Reduction by 20a- and 20p-hydroxysteroid dehydrogenases to produce 20-
hydroxy derivatives. These enzymes can also reduce tetrahydro-derivatives
further to yield cortols and cortolones.
3. Oxidative side chain removal produces 19-carbon steroids with a 17-ketone
group (e.g. 11-Hydroxyandrostenedione from Cortisol).
4. Hepatic hydroxylation to produce 6p-hydroxy Cortisol (corticosterone).
5. Interconversion of corticosterone (Cortisol) with its inert 11-keto-metabolite
11-dehydrocorticosterone (cortisone) by the 1 lp-HSD isozymes.
Further transformations of metabolites are required to improve their solubility in
water and, therefore, they undergo several additional modifications, including:
reduction, oxidation, hydroxylation and conjugation. Hepatic metabolism of
glucocorticoids can be influenced by hormones (e.g. thyroxine), age (metabolism























Figure 1.2 Hepatic Metabolism of Glucocorticoids
There are five initial fates for corticosterone (B) upon hepatic metabolism. The predominant
mode of inactivation is by 5p/5a reductase. SCC, side chain cleavage; 6POHASE, 6p-
hydroxylase; 20HSD, 20a hydroxysteroid dehydrogenase; 3aHSD, 3a hydroxysteroid
dehydrogenase; 11PHSD 1 iphydroxysteroid dehydrogenase.
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1.1.7 Action of Glucocorticoids
Glucocorticoids, as members of the steroid family of hormones, exert their effects
predominantly by binding to and activating specific transcription factors that alter the
expression of several genes. Glucocorticoids probably enter target cells by passive
diffusion of the free hormone (although possible transport systems have been
described) (Lan et al. 1984). Once inside the cell the steroid binds to and activates
intracellular receptors, either glucocorticoid or mineralocorticoid receptors. For the
remainder of this discussion we will consider the action of glucocorticoids at
glucocorticoid receptors.
The glucocorticoid receptor has splice variants; GRa and GRp. GRp is believed to
act as a dominant negative inhibitor of GRa action (Oakley et al. 1996) but this is
not expressed at significant levels in most species and tissues studied. The inactive
receptor complex consists of GR bound to 2 molecules of heat shock protein 90
(hsp90), a 59kDa immunophilin protein (hsp59) and other inhibitory proteins
(CyP40) and a 23kd acidic protein) (Pratt 1993). The hsp90 molecules act as
molecular chaperones preventing the unoccupied GR localising to the nucleus. Upon
corticosterone binding, the inhibitory heat shock proteins are displaced from the
receptor, thus allowing translocation of the ligand-receptor complex to the nuclear
compartment. Dimerisation of GR-ligand complexes in the nucleus permits binding
of GR to specific palindromic DNA consensus sequences termed glucocorticoid
response elements (GRE) that are found in the 5'-upstream promoter region of
glucocorticoid-responsive genes. Gene transcription may be activated or repressed by
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GR binding depending on the availability and mode of action of other transcription
factors.
Glucocorticoids may also have non-genomic effects that are further sub-classified as
either specific or unspecific (Buttgereit 2000). Specific non-genomic effects on
second messenger systems are considered to be mediated by steroid selective
membrane receptors or via CBG activation of adenylate cyclase. Glucocorticoid
binding sites have been described in rat neuronal membranes (Liposits & Bohn 1993)
human leukaemic cells (Gametchu et al. 1999) and human endothelial cells
(Moghadam et al 2002).
Unspecific non-genomic effects occur at high glucocorticoid concentrations and are
believed to result from direct interactions with biological membranes that affect the
activities of membrane-associated proteins (Buttgereit 2000). High concentrations of
methyl prednisolone for example are observed to inhibit cation cycling in activated
thymocytes with little effect on protein synthesis and independent of reductions in
ATP (Buttgereit 2000). The physiological relevance and clinical significance of these
non-genomic actions remain unclear.
1.1.8 Effects of Glucocorticoids
Glucocorticoids serve the purpose of basal regulation of metabolic processes and
adjustment of these processes to stresses such as injury and infection (Barnes 1998).
During these stresses, increased GCs liberate fuels, divert energy from unhelpful
processes such as growth and reproduction, protect against cardiovascular shock, and
provide the crucial brake to prevent bystander damage from the innate and adaptive
immune responses. In their latter role, GCs have many anti-proliferative effects
(Longenecker et al. 1984). If sustained in the longer term, these useful short-term
adaptations become maladaptive, resulting for example in the features of Cushing's
syndrome (Cushing 1912). These features include adverse cardiovascular effects
(Walker & Williams 1992) and poor wound healing (Gordon et al. 1994). In this
context, glucocorticoids have been shown to inhibit angiogenesis (Folkman et al.
1983). A recent key development in our understanding of glucocorticoid physiology
has been the recognition that the effects of glucocorticoids are modulated within each
target tissue by enzymes which control the balance between inert and active steroids
(Seckl & Walker 2001). These lipHSDs have been demonstrated in the vessel wall
and, crucially, appear to increase local GC action in inflamed or injured tissues (Cai
et al. 2001; Christy et al. 2003; Hadoke et al. 2001). Manipulation of these enzymes
may offer an approach to manipulate angiogenic responses in a tissue-selective way,
without preventing the physiological effects of glucocorticoids in other tissues.
1.1.8.1 Effects on the Cardiovascular System
Glucocorticoids may influence many aspects of vascular function including: vascular
tone, haemostasis, vessel wall inflammatory responses and angiogenesis. Many of
these effects have been observed in the presence of large concentrations of
glucocorticoids and the question of whether they have physiological relevance has
received little attention. There is however, evidence from clinical conditions of
altered glucocorticoid secretion to suggest that endogenous concentrations of
glucocorticoids alter vascular tone (Whitworth 1994).
Blood pressure- Classically glucocorticoids were thought to cause hypertension as a
result of salt and water retention in the kidneys. Although these hormones can
directly influence sodium handling and are important for the regulation of
angiotensinogen, AVP and atrial naturetic peptide (ANP) (Montrella-Waybill et al.
1991; Raff 1987)) (Shields et al. 1988) - each of which can effect renal sodium/
water handling. It is now also appreciated that glucocorticoids directly affect
vascular tone (Whitworth 1994; Ullian 1999).
Vascular Tone- Although their exact cellular locations remain controversial both
glucocorticoid and mineralocorticoid receptors are found in the vessel wall (Ullian
1999). Glucocorticoids increase vascular contractility to several agonists, including
noradrenaline and angiotensin II, by increasing receptor expression and improving
coupling of second messenger systems (Ullian 1999; Yang & Zhang 2004).
Endothelium-dependent relaxation may also be impaired by glucocorticoids since
nitric oxide production is reduced in endothelial cells cultured in the presence of
glucocorticoids and a number of mechanisms have been proposed including
alterations in L-arginine availability or transport, endothelial nitric oxide synthase
down regulation and reduced co-factor availability (Simmons et al. 1996; Whitworth
et al. 2002; Christy et al. 2003; Rees et al. 1990; Radomski et al. 1990).
Coagulation and Fibrinolysis- Patients with Cushing's disease are recognised to
have an increased risk of pulmonary embolism and have been found to have
abnormally high levels of both liver (for example XII, XI, IX, VIII) and endothelial
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cell (Von Willebrand Factor and plasminogen activator inhibitor-1) synthesised
haemostatic factors (Patrassi et al. 1985; Jacoby et al. 2001; Casonato et al. 1999).
However it is unclear whether the alterations in haemostasis in Cushing's disease
reflects a direct effect on coagulation/fibrinolysis factors or whether the observed
changes in fact reflect other aspects of the condition for example insulin resistance
and hypertension- both of which might be expected to alter endothelial cell function.
To date attempts using cell culture techniques in vitro to dissect the potential
mechanisms of glucocorticoids to alter haemostasis have used large, supra-
physiological concentrations of glucocorticoids and thus the physiological relevance
of these findings is difficult to interpret (Yamamoto et al. 2004).
Vascular Inflammation- Vessel wall inflammation contributes to the formation,
growth and complications of atherosclerotic plaques but also influences vessel
remodelling following angioplasty. The effects of glucocorticoids on vessel
inflammation have been studied in both of these situations.
Animal data examining the influence of glucocorticoids on vascular remodelling post
intraluminal injury is difficult to interpret, some groups have found benefit from
glucocorticoid coated stents in reducing neointimal hyperplasia and in-stent
restenosis, others have found no effect (Villa et al. 1994; Strecker et al. 1998). The
differences in outcome may reflect the differences in vessels injured, the species used
and differences in the pharmacology of the stent and eluting agents.
In clinical trials adjuvant systemic prednisolone, given to patients undergoing
coronary artery stenting, decreased neointimal lesions and restenosis (Versaci et al.
2002). The mechanism of glucocorticoid action in preventing neointimal hyperplasia
and/or vessel recoil is uncertain. Intimal anti-inflammatory effects would be expected
to play a role but glucocorticoid interactions in the adventitia may also be important.
Angiogenesis- Clinically, large doses of glucocorticoids have been used to inhibit
angiogenesis in vascular tumours; for example, in the treatment of proliferating
capillary haemangiomas (Hasan et al. 2000; Hasan et al. 2003). The mechanism of
glucocorticoid-induced angiostasis is unclear but may involve anti-inflammatory,
anti-proliferative and anti-migratory influences (Folkman & Ingber 1987). As will be
described below, this thesis focuses on the anti-angiogenic effects of glucocorticoids.
These are reviewed in detail in section 1.4. A major question was the possible role of
11 PHSDs in modulating glucocorticoid actions within the vessel wall, for which a
fundamental review of the role of 11 PHSDs is required.
1.2 UpHydroxysteroid Dehydrogenases
The isozymes of 11PHSD catalyse inter-conversion of active glucocorticoids and
their inert 11 -keto metabolites. This provides a mechanism for pre-receptor
metabolism of glucocorticoid within target cells. Thus, these enzymes have the
potential to alter local glucocorticoid levels without altering systemic concentrations
and may significantly influence tissue metabolic, immune, and maturation responses.
1.2.1 Physiological Relevance of 11 pHSDs
11 pHSDs were initially thought to be a single enzyme, involved in the clearance of
glucocorticoids (Amelung et al. 1953). More recently it was appreciated that within
mineralocorticoid target tissues (for example the distal nephron) lipHSD
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metabolism of glucocorticoids also has a significant physiological role (Arriza et al.
1987). In these tissues 11(3HSD metabolism of glucocorticoids acts as a barrier to
prevent glucocorticoids accessing the mineralocorticoid receptor. This is important
since physiologically glucocorticoids are found in 100-1000 fold excess of
mineralocorticoids and mineralocorticoid receptors are able to bind glucocorticoids
and mineralocorticoids with comparable affinity (Arriza et al. 1987). Thus to allow
mineralocorticoids access to their receptors it is necessary for 11PHSD to metabolise
glucocorticoids.
For example the importance of lipFISD enzyme activity in the distal nephron was
demonstrated by the Syndrome of Apparent Mineralocorticoid excess (SAME)
(Ulick et al. 1979; Stewart et al. 1988). This rare, autosomal recessive, congenital
disorder presents with signs and plasma biochemistry characteristics of excessive
activation ofmineralocorticoid receptors, including severe hypertension, low plasma
renin and hypokalaemia despite low plasma aldosterone levels. Furthermore patients
with SAME have high concentrations of urinary Cortisol metabolites
(tetrahydrocortisols and cortols) in comparison to those of cortisone
(tetrahydrocortisone and cortolones) (Ulick et al. 1979) suggesting that altered
lipHSD glucocorticoid inactivitation in the distal nephron might be responsible for
the syndrome.
A condition similar to SAME was also observed in patients prescribed
carbenoxolone (active ingredient: a hemi-succinate derivative of glycyrrhetinic acid)
or following excessive consumption of liquorice (contains glycyrrhetinic acid)
(Epstein et al. 1977). Administration of dexamethasone or the mineralocorticoid
receptor (MR) antagonist spironolactone ameliorated the signs of liquorice-induced
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mineralocorticoid excess (Shackleton et al. 1980; Doll et al. 1968; Hoefnagels &
Kloppenborg 1983) whilst physiological doses of Cortisol exacerbated the features of
SAME (Oberfield et al. 1983) suggesting that an ACTH-dependent adrenal MR
agonist was responsible for these syndromes. This was supported by earlier findings
that had demonstrated liquorice-induced mineralocorticoid excess to be dependent
upon intact adrenal function (Borst et al. 1953).
Confirmation that the mode of action of liquorice was to inhibit 11(3HSD activity
(Stewart et al. 1987; MacKenzie et al. 1990) explained how MR could be selective in
the presence of both aldosterone and Cortisol and led to the description of the
mechanism involved in SAME (Stewart et al. 1996). Hence, it was proposed that the
physiological role of 11PHSD was to protect MR from illicit activation by
glucocorticoids and allow them to bind aldosterone.
Further evidence for the influence of 11PHSD2 in mineralocorticoid target tissues
has been obtained through the development of 11PHSD2 null (-/-) transgenic mice.
Transgenic deficiency of 11 pHSD2 in mice results in a collection of physiological
findings similar to SAME with severe hypertension and hypokalaemia (Kotelevtsev
et al. 1999).
11PHSD2 is also expressed at high levels in sites where mineralocorticoid receptors
are not abundant but a barrier to glucocorticoids is still required: for example, in the
placenta where 11PHSD2 activity is believed to protect the foetus from deleterious
effects of maternal corticosteroids (Brown et al. 1996a). This is supported by
findings in neonatal rats where foetal exposure to dexamethasone (a poor substrate
for 11PHSD2) or inhibition of 11PHSD2 by carbenoxolone during pregnancy,
reduces birth weight (Benediktsson et al. 1993; Lindsay et al. 1993). Furthermore
administration of 11PHSD inhibitors to pregnant rats produces effects in the
offspring that are consistent with increased glucocorticoid exposure in utero
including growth retardation and subsequent hypertension and glucose intolerance
(Nyirenda et al. 1998). Thus through these and other studies the prominence of
11 PHSD has altered from an obscure route of glucocorticoid catabolism to an
enzyme with significant physiological function and important effects on
glucocorticoid activity.
1.2.2 Two isozymes: 1ipHSD Typel and 2
The existence of two isozymes of 1 lpHSD was suggested from evidence in SAME
patients since these individuals had lost the ability to metabolise Cortisol to cortisone
yet were still able to convert oral cortisone to Cortisol (Ulick et al. 1979; Stewart et
al. 1988). In addition, with the cloning of the enzyme from rat liver (Agarwal et al.
1989) it became clear that lipHSD enzyme activities in liver and kidney had
different kinetic, regulatory and immunohistochemistry characteristics. Liver
11 PHSD- termed 11 PHSD 1 from this point forward - is a low affinity NADP(H)-
dependent enzyme and is expressed in a wide range of tissues including the liver,
lung, adipose tissue, gonads and the CNS (Krozowski et al. 1990). Kidney 1 lpHSD
enzyme - named 11PHSD2 - is a high affinity, NAD-dependent enzyme. The limited
tissue distribution of 11PHSD2 is consistent with a role in MR protection; it is
expressed in renal cortical collecting tubules, the distal colon, sweat glands and the
placenta (Agarwal et al. 1994) (Brown et al. 1996a).
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1.2.3 11 pHSD directionality: reductase, dehydrogenase or both
In initial studies lipHSDl in the rat liver was found to have both reductase and
dehydrogenase activities although the reductase activity was unstable in vitro (Seckl
& Walker 2001). Subsequently it has been demonstrated that lipHSDl functions
predominantly (if not exclusively) as a reductase in vivo and in intact cell systems,
converting inactive 11-keto metabolites into active glucocorticocoids (Rajan et al.
1996; Kotelevtsev et al. 1997; Jamieson et al. 1995; Jamieson et al. 2000). There are,
however, a few studies where 1 lpHSDl dehydrogenase activity has been reported in
intact cell preparations, with the direction of llpHSDl activity dependent upon
physiological or developmental status of the particular cell type. In human omental
adipose stromal cells, 1 lpHSDl changes from a dehydrogenase to a reductase when
these cells differentiate into adipocytes and in Leydig and neuronal cells, both
lipHSD-1 reductase and dehydrogenase activities have been reported (Bujalska et
al. 2002; Gao et al. 1997).
Whenever cells are disrupted, however, or the enzyme purified, reductase activity is
lost. It has been postulated that the change in directionality between intact cells and
homogenates reflects the intracellular localization of lipHSDl within the lumen of
the endoplasmic reticulum (ER), where neighbouring enzymes may be powerful
generators of the reduced co-substrate NADP phosphate (NADPH) (Seckl & Walker
2001). Upon addition of an NADPH regenerating system employing the cytosolic
enzyme glucose-6-phosphate dehydrogenase it is possible to regain reductase activity
from tissue homogenates and purified enzyme (Walker et al. 2001; Agarwal et al.
1990), implying that reductase activity predominates in intact cells as a consequence
of large concentrations of NADPH within the ER lumen. The enzyme hexose- 6-
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phosphate dehydrogenase (H6PDH) has recently been shown to serve this crucial
role in generating NADPH levels in the ER (Draper et al. 2003).
In contrast, 11(3HSD2 exclusively catalyses the dehydrogenation of 11(3-
hydroxyglucocorticoids, has a nanomolar Km for glucocorticoids, utilizes NAD+ as a
cofactor, and is localized in the endoplasmic reticulum membrane with a cytoplasmic
orientation of its catalytic domain (Albiston et al. 1994; Brown et al. 1993; Stewart et
al. 1994; Kataoka et al. 2002). The enzyme exhibits cell-specific expression in
mineralocorticoid target tissues, such as epithelial cells from colon or renal cortical
collecting tubules, where its main function is to protect the non-selective
mineralocorticoid receptor from activation by glucocorticoids (Stewart et al. 1995).
1.2.4 Regulation of 11pHSDs
The complex tissue- and species-specific biology of lipHSDl and 11PHSD2
indicates that the expression of these isozymes is regulated rather than constitutive
(Moisan et al. 1992b; Yang et al. 1992; Brown et al. 1996b). Numerous factors have
been shown to regulate lipHSD 1 expression and there is increasing evidence that
llpHSD 2 expression is also regulated (Lanz et al. 2001; Alikhani-Koopaei et al.
2004; Heiniger et al. 2003).
The mechanisms controlling tissue- and species-specific regulation of lipHSD
expression are not fully understood. Analysis of the rat 11P-HSD 1 gene transcripts
suggested tissue-specific differential promoter usage in liver and kidney (Moisan et
al. 1992a), which is possibly due to the differential tissue expression of regulatory/
transcription factors. Furthermore the promoter region of the human 1 ipHSD2 gene
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has also been examined and an inverse correlation between promoter methylation and
11PHSD2 expression is apparent when placenta, skeletal muscles, liver, lung, and
renal proximal and distal tubules are compared (Alikhani-Koopaei et al. 2004).
Altered transcription factor binding to methylated promoter regions (e.g. as observed
with Spl/Sp3) could be a mechanism for these observed differences.
Several initiating factors that trigger alterations in the expression and activity of
llpHSDl and 2 have also been identified. Enhanced expression of 11PHSD2 has
been observed with the transcription factor nuclear factor I (NFI) and decreased
11PHSD2 expression has been observed with various stimuli including: hypoxia
(Heiniger et al. 2003), shear stress (Lanz et al. 2001), angiotensin II (Lanz et al.
2003) and TNF-a (Heiniger et al. 2001). The corresponding signal transcription
pathways and some relevant transcription factors have been identified (Heiniger et
al. 2003). In addition reduced lipHSD2 activity has been linked to renal sodium
retention in liver cirrhosis (Escher et al. 1998), nephrotic syndrome (Kerstens et al.
2003) and hypoxia (Heiniger et al. 2003).
lipHSDl has a broader tissue expression than 11PHSD2 and the factors that
regulate expression and activity of lipHSDl appear to possess tissue and species
specificity. Variations in lipHSD 1 expression within tissues and between species
are observed with sex steroids, insulin, and thyroid hormone (Seckl & Walker 2001;
Tomlinson et al. 2004b; Sandeep & Walker 2001).
In general, lipHSDl activity and expression is lower in tissues from female
compared with male animals. The sexual dimorphism of lipHSDl expression is
mediated by the influence of oestrogen on growth hormone (GH) secretory patterns
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(Low et al. 1994a). Upon reaching sexual maturity, oestrogen in females increases
the frequency of GH pulsatile secretion (Lanz et al. 2003). This results in greater
constant circulating GH concentrations in females compared to males (Eden 1979)
and the elevated GH in females reduces lipHSDl activity and expression (Painson
et al. 1992; Smith & Funder 1991).
There are data to suggest that other hormones may regulate llpHSDl expression
however the effects of these hormones are inconsistent and are influenced by
experimental conditions and appear to be tissue dependent (Tomlinson et al. 2004b).
For example insulin represses expression in rat hepatocytes in vivo (Liu et al.
1996)and human skin fibroblasts in vitro (Hammami & Siiteri 1991) yet had no
effect on human omental preadipocytes (Bujalska et al. 1999). Thyroid hormone
decreases rat pituitary lipHSDl activity (Whorwood et al. 1993) but the opposite
effect was seen in rat testis (Nwe et al. 1997). And thyroid hormone in rats decreases
hepatic lipHSDl activity in vivo (Whorwood et al. 1993), but not hepatocyte
activity in vitro (Ricketts et al. 1998).
More consistent regulatory influences across species and tissues are observed with
glucocorticoids, inflammatory cytokines and leptin (Tomlinson et al. 2004b).
Glucocorticoids increase lipHSDl expression or activity both in human fibroblast
cell cultures and in rat vascular smooth muscle cells and hepatocytes in vitro
(Hammami & Siiteri 1991; Jamieson et al. 1999; Takeda et al. 1994a). In vivo,
glucocorticoids induce lipHSDl in liver and hippocampus, whist adrenalectomy
decreases hepatic lipHSDl mRNA and activity (Low et al. 1994b; Walker et al.
1994b).
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Inflammatory cytokines are known to increase the activity and expression of
lipHSD 1 in vitro. Tumor necrosis factor-a (TNF-a) increases renal llpFISDl
activity (Escher et al. 1997), interleukins increase lipHSDl activity in granulosa
cells (Evagelatou et al. 1997), and interleukinlp and TNF-a increase lipHSDl
expression in vascular smooth muscle cells (Cai et al. 2001).
Leptin has also been shown to increase 1 lpHSDl activity and expression in vitro and
in vivo. In vivo in mouse liver leptin induced 1 lpHSDl expression (Liu et al. 2003).
In vitro human omental preadipocytes and mouse hepatocytes both exhibited
increases in 1 lpiTSDl expression and activity in the presence of leptin (Tomlinson et
al. 2001; Liu et al. 2003).
There are many other single studies examining the effects of different factors on
lipHSDl expression and/or activity for example PPAR a or y agonists, protease
inhibitors and others (Tomlinson et al. 2004b). The tissue and species specificity of
1 lpHSDl responses however suggests that these results should be corroborated with
further investigations to determine the physiological and clinical influence of the
factors used.
1.2.5 UpHSD 1 modulation of glucocorticoid activity
Local tissue expression of lipHSDl creates the possibility that within the local
environment of enzyme expression glucocorticoid levels may fluctuate without
overtly effecting systemic glucocorticoid concentrations. lipHSDl thus is a pre-
receptor determinant of glucocorticoid action and may influence a broad range of
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glucocorticoid actions from tissue energy metabolism to tissue maturation and
growth responses (Tomlinson et al. 2004b).
Amplification of local glucocorticoid concentrations is, in part, conditional on the
availability of 11J3HSD1 substrate. The main source for 1 lketo steroids (cortisone or
I ldehydrocorticosterone) is 1 ipHSD2 in the kidney. In humans, cortisone circulates
in the plasma largely unbound to plasma proteins at concentrations of 50-100nmol/L
without a pronounced diurnal variation (Seckl & Walker 2001). However in the
mouse plasma 11 dehydrocorticosterone levels are lower at 3-5nmol/L as a
consequence of increased clearance (Seckl & Walker 2001). In comparison to
cortisone, 95% of Cortisol is bound to plasma proteins such that free plasma Cortisol
levels are around l-100nmol/L. Therefore circulating cortisone levels are in excess
of, or at least at parity with, Cortisol levels for some (if not all) of the day (Seckl &
Walker 2001).
II PHSD 1 has been shown to amplify the effects of glucocorticoids by local
regeneration and evidence for this comes largely from studies on the liver.
Physiologically, in hepatocytes, glucocorticoids oppose the effects of insulin and
increase glucose production; for example, by up regulating key gluconeogenic
enzymes such as PEPCK. Clinical studies with non-selective inhibitors of 11PHSD
demonstrate a reduction in hepatic glucocorticoid effects and improved insulin
sensitivity (Walker et al. 1995). Furthermore, in lipHSDl deficient transgenic mice
glucocorticoid antagonism of insulin is attenuated resulting in blunted
hyperglycaemia during stress or high fat feeding (Kotelevtsev et al. 1997). The
influence of amplified hepatic glucocorticoid concentrations has been studied in
transgenic mice over expressing hepatic 11 PHSD 1. These animals demonstrate
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insulin resistance as well as dyslipidaemia and hypertension (Paterson et al. 2004),
thus indicating that amplification of local glucocorticoid concentrations within the
liver by 11|3HSD1 can antagonise the effects of insulin and modulate fuel
metabolism.
1 lpHSDl is also expressed in adipose tissue where it functions predominantly as a
reductase (Napolitano et al. 1998) and may also antagonise the effects of insulin and
contribute to the metabolic syndrome. In clinical and animal studies of obesity,
adipose 1 lpHSDl is dysregulated (Wake & Walker 2004) and it is hypothesised that
1 lpHSD 1 plays a role in the development of central obesity (Wake & Walker 2004;
Livingstone et al. 2000b; Masuzaki et al. 2001; Morton et al. 2001; Rask et al.
2002). There are however studies examining lipHSDl expression in rodent models
and lipHSDl activity in human studies that have shown none or converse changes
in lipHSDl in obesity (Tomlinson et al. 2001; Tomlinson et al. 2004a; Tomlinson
et al. 2004b). The apparent discrepancies of these data may reflect the different
techniques and assays to determine lipHSDl activity or the small sample sizes in
the clinical studies.
Glucocorticoids also modulate developmental, metabolic and neuronal signalling
within the brain via both GR and MR (McEwen et al. 1986). Since lipHSDl is
expressed in cerebellum, pituitary and hippocampal neurones and other regions of
the CNS (Moisan et al. 1992b; Sakai et al. 1992) investigators have examined the
influence of local glucocorticoid regeneration at these sites. In vitro in hippocampal
neurones 1 lpHSDl acts as a reductase to amplify glucocorticoid concentrations and
in lipHSDl knockout mice the absence of lipHSDl in these cells decreases
corticosterone levels within the hippocampus and appears to protect from age-related
learning impairment (Yau et al. 2001). Other brain centres altered in 11(3HSD1
knockout mice include the HPA axis. 1 lpHSDl knockout mice exhibit abnormalities
of the HPA axis with elevated corticosterone and ACTH levels, enhanced responses
to stress, and insensitivity of HPA axis suppression with exogenous Cortisol
(Kotelevtsev et al. 1997; Harris et al. 2001).
1 lpHSDl is also expressed in human bone and primary osteoblast cultures (Cooper
et al. 2000) and it functions primarily as a reductase to amplify local glucocorticoid
concentrations. From clinical studies it would appear that 1 lpHSDl influences bone
remodelling; inhibition of lipHSD activities with carbenoxolone had no impact on
bone formation but did result in suppression of bone resorption (Cooper et al. 2000).
lipHSDl is expressed in human and rodent ovaries although the function of the
enzyme at this site is undetermined (Thomas et al. 1998; Tetsuka et al. 1999; Hillier
& Tetsuka 1998). A switch from lipHSD type 2 to type 1 isozyme expression is
thought to account for the increase in intra follicular Cortisol concentration after the
LH surge prior to ovulation (Hillier & Tetsuka 1998). The increase in active
glucocorticoid may serve to mature the developing oocyte and/or limit the
inflammatory wound healing response of the ovary. In the mouse the relevance of
ovarian 1 lpHSDl remains unclear since lipHSDl transgenic deletion does not
impair reproduction and ovarian function appears to be intact.
lipHSDl and 2 are also expressed in the blood vessel wall and with the
development of transgenic mice deficient in either 1 lpHSDl or 1 ipHSD2 further in
sight has been gained as to the vascular functions of these isozymes (Christy et al.
2003; Hadoke et al. 2001). Modulation of vascular function by lipHSD will be
discussed in the following section.
1.2.6 Vascular 11P-HSD1 Activity and Expression
Vascular lipHSD activity was first described in rabbit aorta and rat mesenteric
arteries (Kornel et al. 1982; Funder et al. 1989) and has subsequently been
investigated in vessels and cultured vascular cells from several species (Hatakeyama
et al. 1999; Hadoke et al. 2001; Walker & Williams 1992)). Localisation studies
have examined the location of lipHSD expression within the vessel wall by RT-
PCR and identified the lipHSDl isozyme in mouse aortic vascular smooth muscle
cells (VSMC) (Christy et al. 2003). This corroborated findings from earlier studies
that had examined rat mesenteric and aortic vessels and found lipHSDl expression
within VSMC (Takeda et al. 1994b; Brem et al. 1995; Walker et al. 1991; Brem et
al. 1998). Immunohistochemical studies of rat vessels have suggested this isozyme is
also expressed in adventitial fibroblasts (Brereton et al. 2001).
In VSMC from mouse aorta 1 ipHSD2 mRNA was not identified by RT-PCR studies
(Christy et al. 2003). However it appears from other localisation studies that
11PHSD2 expression in VSMC could be species and vascular bed specific (Brem et
al. 1998; Hatakeyama et al. 1999; Smith et al. 1996; Kyossev et al. 1996).
The expression of lipHSD isozymes is less clearly defined in endothelial cells.
Recent evidence from RT-PCR studies using intact mouse aorta suggested that
1 lpHSD type 2 and not type 1 expression is localised to the endothelium (Christy et
al. 2003). However data from other studies are not in complete accordance with these
findings and suggest that there are species and specific vascular bed differences in
isozyme endothelial expression. RT-PCR and activity studies indicate that both
lipHSDl and 11PHSD2 are expressed in rat aortic endothelial cells (Brem et al.
1998), yet in situ hybridisation and immunohistochemistry did not identify 1 lpHSDl
endothelial cell-specific expression of this isozyme (Walker et al. 1991).
Furthermore, although 11PHSD2 was detected in human glomerular endothelial cells
this isozyme was not detected in endothelium from other human blood vessels
(Smith et al. 1996).
In addition to the controversy regarding specific cellular localisation of 11 pHSD
isozymes there is also debate concerning which isozyme is responsible for activity in
vascular preparations. Furthermore, the direction of the isozyme in vivo has not been
clarified. Vascular 11PHSD2 is believed to be a unidirectional enzyme metabolising
glucocorticoids to their inactive 1 lketo-metabolities (Souness et al. 2002). In
contrast, the directionality of lip-HSDl is less clear: for whilst this enzyme is
thought to be an exclusive reductase in vivo (Kotelevtsev et al. 1997; Jamieson et al.
1995; Jamieson et al. 2000) it exhibits bi-directional activity in VSMC homogenates,
cultured VSMCs, and in intact rat aortic rings in vitro (Brem et al. 1995; Monder &
Lakshmi 1989; Brem et al. 1998; Souness et al. 2002). It has been postulated that
the change in directionality between intact cells and homogenates reflects the
intracellular localization of 1 lpHSDl within the lumen of the endoplasmic reticulum
(ER), where neighbouring enzymes may be powerful generators of the reduced co-
substrate NADP phosphate (NADPH) (Leckie et al. 1998; Seckl & Walker 2001). It
is possible that described 'bidirectionality' of lipHSDl may reflect cell disruption
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through tissue homogenisation or in vitro preparations and release of 1 lpHSDl in to
assay media.
1.2.7 Effect of 11 pHSD Inhibition/ Deficiency on Vascular Function
Whilst discrepancies in the literature exist with regard to the cellular localisation of
11PHSD and activity direction in vitro and in vivo there is general agreement that
these isozymes alter vascular function (Brem et al. 1998; Hadoke et al. 2001;
Souness et al. 2002). 11 PHSDs modulate the influence of glucocorticoids on blood
pressure (Walker & Williams 1992) and non-specific inhibitors of 11 PHSDs increase
the contractile responses to adrenoreceptor agonists and angiotensin II in vitro
(Walker et al. 1994a; Brem et al. 1997) and in vivo (Teelucksingh et al. 1990; Ullian
et al. 1996).
Initially, the influence of non-specific 11 PHSD inhibitors was thought to be as a
consequence of inhibiting 11 PHSD 1 dehydrogenase activity. With the cloning of
1 ipHSD2 (Albiston et al. 1994; Agarwal et al. 1994) and appreciation of the almost
exclusive reductase activity of 1 lpHSDl in vivo, the role of 11PHSD2 to influence
vascular tone has been acknowledged. More recently with the development of mice
deficient in 11 pHSDl or 11PHSD2 the effects of 1 lpHSD isozymes on the vascular
tone has become clearer (Kotelevtsev et al. 1997; Kotelevtsev et al. 1999). 11PHSD2
deficient mice are hypertensive, have increased vascular contractility to Ang II and
norepinephrine and reduced endothelial dependent relaxation with altered nitric
oxide metabolism (Hadoke et al. 2001; Christy et al. 2003). Whilst an in vitro paper
using rat aorta incubated with 1 lpHSDl anti-sense RNA oligomers had suggested
that lipHSDl would influence vascular contractile responses (Souness et al. 2002)
lipHSDl deficient mice had no abnormalities of vascular tone in vitro or in vivo
(Hadoke et al. 2001).
Whilst the vascular phenotype of 11 pHSDl deficiency is not clear, there are data that
suggest vascular function could be influenced by lipHSDl in ischaemia and
following vessel wall injury. In these patho-physiological situations, the
inflammatory cascade that glucocorticoids traditionally modulate (Perretti &
Ahluwalia 2000; Barnes 1998), plays an important role and that could be influenced
by 1 lpHSDl (Cai et al. 2001; Longenecker et al. 1982; Longenecker et al. 1984).
Indeed lipHSDl expression and activity was increased in vascular smooth muscle
cells in culture in the presence inflammatory cytokines (Cai et al. 2001). Perhaps
indicating that the vessel wall responds to local vascular injury by regenerating
glucocorticoids through 1 lpHSDl to modulate any inflammatory reaction.
In addition vessel wall proliferative responses in atherogenesis or following
intravascular injury could be influenced by vessel wall lipHSDl for glucocorticoids
are recognised to decrease vascular smooth muscle cell mitosis in culture
(Longenecker et al. 1982; Longenecker et al. 1984). Such anti-proliferative
responses have been suggested to account for the effect of glucocorticoids to
diminish restenosis after angioplasty (Berk et al. 1991; Lincoff et al. 1997; Radke et
al. 2004; Reimers et al. 1998; Versaci et al. 2002) but may equally alter other mitotic
responses of the vessel wall for example angiogenesis.
The absence of any angiogenic phenotype in 1 lpHSDl deficiency is not contrary to
these conclusions since it has been observed with other vascular factors that the
angiogenic influence of these factors only becomes apparent in the presence of vessel
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injury or patho-physiological stimulus (Carmeliet et al. 2001; Hodivala-Dilke et al.
1999; Bader et al. 1998; Carmeliet & Collen 2000; Carmeliet et al. 1998).
11(3HSD1 may therefore contribute to the vascular control of inflammation and
influence processes such as atherosclerosis, restenosis or angiogenesis. Furthermore
since angiogenesis involves a series of interactions known to be regulated by
glucocorticoids, for example cell proliferation, migration, collagen deposition; and
occurs often in the context of inflammation, it is perhaps most likely to be influenced
by local regeneration of glucocorticoids by 1 lpHSDl.
1.3 Angiogenesis
Angiogenesis, the formation of new vessels from existing ones, occurs as a result of
a complex series of interactions between the vessel wall, the extracellular matrix and
cell signalling cytokines (Figure 1.3).
1.3.1 Formation of the vasculature: angiogenesis and vasculogenesis
Successful embryonic development depends upon the formation of a functional
complex network of capillary plexuses and blood vessels through vasculogenesis
(Conway et al. 2001; Carmeliet 2000). This process describes how endothelial cell
precursors (angioblasts) migrate, differentiate and assemble into endothelial cell
cords to later become a plexus (Conway et al. 2001; Carmeliet 2000). The
subsequent growth, expansion and remodelling of this network is described by
angiogenesis. Both processes contribute to the development of the embryonic
vascular tree.
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Adult new vessel formation was traditionally thought to occur solely by angiogenesis
but it is now recognised that vasculogenesis (through differentiation of circulating
bone marrow or organ derived stem cells) may be possible in the mature animal (Jain
2003 ). Whether initiated by vasculogenesis or angiogenesis, vessel development in
the adult is influenced by common factors in a series of processes involving:
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Figure 1.3 Vasculogenesis And Angiogenesis
Vasculogenesis is the formation of new vessels de novo in the embryo. Angiogenesis is the
formation of new vessels from the existing vasculature. VEGF vascular endothelial growth
factor, VEGFR VEGF receptor, Ang-1 Angiopoeitin 1, PGE2 prostaglandin E2, TxA2
thromboxane A2l PA plasminogen system, MMP matrix metalloproteinases.TIMP tissue
inhibitors of MMP, TGFp tissue growth factor beta.
Branching! angiogenic; bridging;
invagination





1.3.2 Formation of immature vessels
Vasculogenesis- Inception of an embryonic vascular supply requires the formation of
a vascular plexus and the production of blood cells. In the embryo, endothelial and
haematopoietic cells share a common progenitor: the haemangioblast. In the
embryonic yolk sac haemangioblasts differentiate: the inner population become
haematopoietic precursors; the perimeter cells become angioblasts. Vascular
endothelial growth factor (VEGF), VEGF receptor (VEGFR) 2 and basic fibroblast
growth factor (bFGF) influence angioblast differentiation whereas VEGFR 1
suppresses haemangioblast commitment (Conway et al. 2001; Carmeliet 2000).
Vasculogenesis and haemopoiesis are also influenced by Transforming growth factor
(TGF)-pl and TGF-(3 receptor 2 (Dickson et al. 1995). Thus CD31+, CD34 +,
VEGFR-2 positive angioblasts migrate extensively and differentiate to assemble
primitive plexuses (Jain 2003). Genes identified to influence the fate of
haemangioblast include Ets-s, Hex, Vezfl, Hox and GATA family members, basic
helix loop helix factors and their inhibitors of differentiation. These genes are also
thought to be involved in the angiogenic switch that promotes branching in a mature
quiescent vessel (Jain 2003).
1.3.3 New vessel formation
Angiogenic sprouting is facilitated by low tissue oxygen tension that generates
hypoxia inducible factors (HIFs), specific transcription factors for many genes whose
products are involved in angiogenesis; these include endothelial nitric oxide
synthase, VEGF and angiopoietin-2 (Pugh & Ratcliffe 2003). These factors promote
the steps associated with initiation of vessel budding. Nitric oxide synthase produces
nitric oxide that initiates vasodilation that is an initial phase in the loosening of
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vessel wall fabric that allows endothelial cells to migrate (Conway et al. 2001;
Carmeliet 2000). This process is continued by VEGF release that increases vascular
permeability and extravastation of plasma proteins to construct a temporary scaffold
(Jain 2003). Angiopoetin-2 (Ang-2) facilitates endothelial cell sprouting by
detaching smooth muscle cells and loosening underlying matrix (Conway et al. 2001;
Carmeliet 2000). In the environment that is established, proliferating endothelial
cells may migrate through the vessel wall. Transition of endothelial cells from a
quiescent non-mitotic phase of the cell cycle to a state of proliferation is tightly
regulated. VEGF, Ang-1, FGF, TNF-a, prostaglandin E2 and monocyte chemotactic
protein (MCP)-l are recognised positive inducers of endothelial cell proliferation
(Conway et al. 2001; Carmeliet 2000). Endogenous inhibitors of endothelial cell
proliferation include thrombospondin, angiostatin, endostatin, antithrombin III,
interferon-P and platelet factor 4 (Conway et al. 2001; Carmeliet 2000). Angiogenic
stimuli including inflammation and hypoxia modulate the expression of many of
these factors and are thus key determinants of endothelial cell fate.
Adaptation of the environment surrounding the vessel wall occurs to accommodate
the new vessels. VEGF and other cytokines, including bFGF, tissue necrosis factor a
(TNFa), and interleukin-1 (IL1), induce expression of proteolytic proteinases
including urokinase and tissue Plasminogen Activators (u-PA and t-PA) and matrix
metalloproteinases (MMPs) 1, 3 and 9 (Pepper 2001). Other cytokines limit the
angiogenic response by up-regulating the expression of proteolytic inhibitors, for
example plasminogen activator inhibitor (PAI)-l and tissue inhibitors of matrix
metalloproteinases (TIMPs) 1 and 2 (Hanemaaijer et al. 1993). In this manner a
dynamic proteolytic balance in angiogenesis facilitates basement membrane and
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matrix dissolution, whilst allowing matrix remodelling and support of vascular buds.
The proteolytic balance of the extracellular matrix is one of the factors that
determines endothelial cell proliferation and migration (Kraling et al. 1999).
Migration of proliferating endothelial cell buds is directed by signalling through
integrins ayp3, ctiPi, (X2P1 aspi, platelet endothelial cell adhesion molecule
(PECAM)-1 thromboxane A2, ephrins, fibronectin and vitronectin (Conway et al.
2001; Jain 2003; Carmeliet 2000). Cell-cell and cell-matrix interactions co-ordinated
by these molecules direct endothelial cells to form solid cords that subsequently form
a lumen.
1.3.4 Branching, Remodelling and specialisation
Newly formed vessels are stabilised by the recruitment of mural cells and
extracellular matrix support. Chemoattractants involved in the procurement of peri-
endothelial cells include platelet derived growth factor (PDGF)-B, sphinogosine- 1-
phosphate-1 (S1P1), Ang-1 and TGF-P (Conway et al. 2001; Carmeliet 2000).
Many cells including endothelial and mural cells secrete these factors but it is the
presence of specific receptor subtypes on mural cells that determines their
proliferation and migration during vascular stabilisation (Jain 2003). The mural
smooth muscle cells are derived from different sources; they may differentiate from
mesenchymal or endothelial cells or from bone marrow precursors or macrophages
(Conway et al. 2001; Carmeliet 2000). Coronary vein smooth muscle cells are
derived from atrial myocardium whilst epicardial myocardium contributes potential
mural cells to the coronary arteries (Conway et al. 2001; Carmeliet 2000). Pericytes
39
are derived from mesenchymal cells that differentiate under the influence of the
developing endothelium (Hirschi & D'Amore 1996).
Extracellular matrix support and basement membrane deposition are established
through the activities of TIMPs 1 and 2, PAI-1, angiostatin and endostatin with
elaboration of collagen, fibrillin and elastin from mural cells (Conway et al. 2001;
Carmeliet 2000). The inhibition of MMP activity during vessel stabilisation enables
scaffold construction and initiates the resolution phase of angiogenesis. The final
arrangement of the vascular network will be determined by vessel growth, branching
and remodelling.
Vessel branching: Branching may occur by several methods: new branches may
sprout in an angiogenic fashion; vessels may split into daughter vessels divided by
transendothelial bridges; or vessels may branch via intussusceptions with
invagination by a cord of extracellular matrix and partitioning of the mother vessel
(Conway et al. 2001; Carmeliet 2000). VEGF, Ang-1, acidic FGF and renin are all
thought to influence vessel branching (Jain 2003). Extracellular matrix factors
including basement membrane proteases and their inhibitors also modulate vessel
branching through influencing endothelial cell survival (Jain 2003).
Vessel specialisation: Differentiation of new vessels into arteries and veins followed
by organ specific specialization occurs as a result of micro-environmental factors
(Conway et al. 2001; Carmeliet 2000), interacting with the extracellular matrix and
differences in shear stress (Jain 2003). Arteriogenesis involves the recruitment and
proliferation of mural smooth muscle cells and the adaptation of the vessel interstitial
matrix. Smooth muscle cells in response to bFGF, PDGF-B and TGF-pi released
from activated endothelial cells proliferate and "muscularize" immature vessels.
Interstitial matrix components provide the developing artery with viscoelastic
properties (elastin and fibrillin-2) and structural strength (collagen and fibrillin-1)
(Pepper 2001). Specializations of cell-cell junctions in the endothelium are
determined by host tissue microenvironments. The continuous endothelium of
capillaries in the blood brain barrier is successfully established only in the presence
of pericytes, astroglial cells expressing glial fibrillary acidic protein and
physiological angiotensinogen levels (Lindahl et al. 1998). In contrast, VEGF and
endocrine gland derived (EG)-VEGF are thought to be essential for the production of
discontinuous endothelial cells and fenestrated capillaries of endocrine organs that
facilitate hormone synthesis and subsequent release (Jain 2003).
1.3.5 Angiogenesis in pathology
Controlled angiogenesis occurs following pathological insults such as skin laceration
or tissue infarction. This type of angiogenesis-in-pathology is initiated by changes in
tissue metabolic homeostasis including hypoxia, low pH and abnormal shear stresses
(Topper & Gimbrone, Jr. 1999; Semenza 2003). Similar to the processes of
embryonic angiogenesis, HIFs, VEGF and NO influence the repairing vascular
network (Jain 2003). Following tissue injury there is input from activated platelets
that release PDGF and TGF-[3 (Jain 2003) and also the influence of inflammatory
cytokines and matrix proteinases from granulocytes, monocytes and fibroblasts
(Tomasek et al. 2002). In the initial stages of wound healing, large numbers of
immature vessels form. Later some are reabsorbed and the remaining vessels mature
(Zawicki et al. 1981).
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Aberrant, uncontrolled, pathological angiogenesis is observed in primary vascular
malignancies and also in tumours of non-vascular origin (Jain 2003). Tumour vessels
are distributed in a chaotic manner and do not follow the hierarchical branching
pattern of normal vascular networks. The disturbance of vessel spatial organisation is
one of the consequences of malignant growth that is not restrained by cell-cell
contact or governed by diffusion distances. Vessel wall structure is also abnormal in
tumours. Endothelial cells often form an imperfect irregular lining, pericytes have
abnormal morphology and mural cells exhibit a patchy distribution (Jain 2003a;
Fukumura & Jain 1998; Brown et al. 2001). As a result of the abnormal organisation
and ultrastructure of tumour vessels the blood flow in tumour vessels is chaotic and
the vessels are leaky (Jain 2003b; Hobbs et al. 1998; Gazit et al. 1997). The tumour
micro-environment is thought to be responsible for aberrant angiogenesis. HIFs,
VEGF, TGF-P and their receptors are disturbed in malignancy such that restrained
dynamic pro and anti-angiogenic processes are uncoupled (Ramanujan et al. 2000).
The importance of angiogenesis in the progression and metastasis of cancerous
growths has led to the development of chemotherapies that target tumour vasculature
(Carmeliet & Jain 2000). Identification of specific tumour vessel markers not present
on normal vasculature may in the future herald more selective chemotherapies
(Huminiecki et al. 2002; Sullivan & Bicknell 2003).
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1.4 Models of Angiogenesis
The complexity of angiogenesis has given rise to the development of unique
experimental assays that study different aspects of angiogenesis. Ideally an assay
would be technically straightforward, reliable, reproducible, easy to quantify and
physiologically relevant.
In vitro assays of angiogenesis include endothelial cell proliferation, migration, tube
formation or explant assays (e.g. aortic ring, endometrium) (Auerbach et al. 2003).
Generally these are technically straightforward, reliable, reproducible and easy to
quantify. Many of these models allow separation of different aspects of angiogenesis
and are useful in identifying specific modes of action of putative angiogenesis
inhibitors, for example examining the role of test substances to influence VEGF
signalling in endothelial cells. However, the physiological relevance of findings from
these assays ought to be assessed with consideration to the limitations of the model.
For example isolated effects on endothelial cell signalling or tube formation or
migration or proliferation in vitro may not limit angiogenesis in vivo where a
combination of the events is required and controlled by cytokines and systemic
factors (Staton et al. 2004). The explant assays are recognised to come closest to
mimicking the in vivo situation (Staton et al. 2004; Auerbach et al. 2003). The aortic
ring model (Nicosia et al. 1997) assesses endothelial cell proliferation, migration and
tube formation; it uses non-proliferating endothelial cells at the time of explantation
and includes peri-endothelial cells and supporting matrix. Notwithstanding these
benefits, the aortic ring assay does have limitations, angiogenesis is a microvascular
event and the use of large explant vessels is not ideal, furthermore by explanting
aortic rings from in vivo the effects of systemic factors cannot be assessed.
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ideal, furthermore by explanting aortic rings from in vivo the effects of systemic
factors cannot be assessed.
Probably the most widely used in vivo angiogenesis assay is the chick chorio-
alloantoic membrane (CAM) model (Staton et al. 2004). A test substance is
implanted onto the CAM through a window cut carefully in the eggshell (Staton et
al. 2004). It is technically relatively simple and inexpensive. In vivo angiogenesis
assays in rodents include the corneal angiogenesis assay, Matrigel or sponge
subcutaneous implant models and chamber assays. Subcutaneous sponge
implantation was chosen in this thesis because it was technically undemanding,
reliable, reproducible, humane and did not require lengthy incubation times (Staton
et al. 2004). The sponge implant model however may cause non-specific immune
responses that may themselves lead to an angiogenic reaction (Dellian et al. 1996).
To avoid non-specific responses and generate physiological angiogenesis reactions in
vivo pathological models of angiogenesis can be used. For example angiogenesis
may be studied in cutaneous wound healing, tumour implantation or in the
myocardium following myocardial infarction.
Tumour models of angiogenesis have been used to assess the anti-angiogenic activity
of potential chemotherapeutic agents. Tumours can be grown syngenetically (e.g.
subcutaneous), orthotopically (in the tissue of origin) or as xenografts in
immunodeficient rodents (Staton et al. 2004). Quantification of vessel growth is
reliable and reproducible and tumour implantation is relatively simple. The patho¬
physiological relevance of some of these models has been questioned because the
tumour microenvironment that determines the chaotic vascular structure in tumours
is altered through grafting procedures (Staton et al. 2004). In contrast, angiogenesis
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in wound healing and following infarction is tightly regulated and establishes an
organised, hierarchical, vascular network in the healing tissue. This appears to hold
true whether the injury is induced experimentally or not (Singer & Clark 1999).
The number of angiogenesis models available is an indication of the complexity of
the process but also the acknowledgement of the necessity to test putative angiogenic
substances in a number of environments. In a current review of angiogenesis assays
it was recommend, that to understand and interpret the effects of a particular test
substance, the use of more than 1 in vitro assay using endothelial cells from different
sources followed by more than 1 in vivo assay is required (Staton et al. 2004).
1.5 Modulation of Angiogenesis by Glucocorticoids
During the development of the chick chorioallantoic membrane assay glucocorticoids
were discovered to be anti-angiogenic at supraphysiological concentrations (Folkman
et al. 1983). Further experimental work identified other steroid metabolites of
glucocorticoids to be anti-angiogenic and as a group these became known as
angiostatic steroids (Folkman & Ingber 1987). The initial investigators identified
steroid-induced histological changes in: inflammation, cell migration, cell
proliferation and extracellular matrix integrity (Figure 1.4) (Folkman & Ingber
1987).
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Figure 1.4 Proposed Angiostatic Mechanisms ofGlucocorticoids
Anti-inflammatory, anti-proliferative, anti-matrix or anti-migratory activities are postulated
mechanisms for the angiostatic effects of glucocorticoids. Interactions between
glucocorticoids and key mediators of these responses (which are listed) are reported.
NO nitric oxide, TNFa Tissue necrosis factor alpha, IL-6 interleukin 6, PGE2 prostaglandinE2,
TXA2 thromboxane A2, NF-Kp nuclear factor kappa beta, VEGF vascular endothelial growth
factor, BH4 tetrahydrobiopterin, MMP matrix metalloproteinases, TIMP tissue inhibitors of
MMP, PAI-1 plasminogen activator inhibitor 1.
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1.5.1 Inhibition of Inflammation
Physiological and pathological angiogenesis are intimately related to inflammation
and share many common mediators (Haas et al. 2000; Kayisli et al. 2002; Walsh
1999; Campochiaro et al. 1999; Colville-Nash & Scott 1992). Similar processes
govern the initiation of inflammation and angiogenesis; common to both are
vasodilation, increased vascular permeability and migration of inflammatory cells
(Barnes 1998; Conway et al. 2001). Nitric oxide, VEGF, TNF a, IL-6, prostaglandin
E2(PGE2) thromboxane A2 (TxA2) and transcription factor NFk|3, are pro-angiogenic
mediators that are up-regulated by inflammation and suppressed by large
concentrations of glucocorticoids (Wallerath et al. 1999; Grose et al. 2002; Hasan et
al. 2000; Barnes 1998; Yossuck et al. 2001; Beer et al. 2000; Blomme et al. 2003).
Constitutive eNOS and inducible iNOS expression and activity are reduced by
glucocorticoids in vitro (Whitworth et al. 2002) in part by decreasing the availability
of L-arginine and tetrahydrobiopterin (BH4) (Simmons et al. 1996; Wallerath et al.
1999). Clinical studies in Cushing's syndrome patients suggest that vascular nitric
oxide metabolism is similarly impaired in vivo in the presence of excess
glucocorticoids (Saruta et al. 1986). VEGF is an important angiogenic cytokine
expressed by vascular smooth muscle cells and other cells in response to cytokines,
reduced oxygen tension and cell differentiation (Conway et al. 2001).
Glucocorticoids inhibit VEGF mRNA expression and stability in different cell
culture systems (Gille et al. 2001; Wen et al. 2003) and physiologically relevant
concentrations of cortisone and Cortisol (lOnM) inhibited VEGF mRNA expression
in human vascular smooth muscle cells (Nauck et al. 1998). An important concept in
studies examining the expression of VEGF is to consider the influence of hypoxia.
Hypoxia is an important angiogenic stimulus through induction of hypoxia-inducible
transcription factors (Pugh & Ratcliffe 2003), the modulation of these responses by
glucocorticoids is reported but with conflicting results depending on the model,
degree of hypoxia, steroid concentration and angiogenic factor assessed
(Michalopoulos et al. 2003; Fischer et al. 2001; Klekamp et al. 1997; Yossuck et al.
2001). Pro-angiogenic cytokine TNF a expression is also induced by hypoxia and is
suppressed by pharmacological concentrations of glucocorticoids in vivo in rodent
hypoxia-induced retinopathy (Yossuck et al. 2001). Glucocorticoid-induced changes
in transcription commonly occur via antagonism of the effects of transcription factors
AP-1 and NF-kB. Studies to examine the effects of glucocorticoids on these
transcription factors in hypoxia have been performed and it would appear that
dexamethasone induced AP-1 expression does not regulate VEGF expression in
hypoxia (Finkenzeller et al. 1995). Nevertheless glucocorticoids at therapeutic
concentrations inhibit angiogenesis in vivo in hypoxic conditions for example in
tumours (Hasan et al. 2000; Penhaligon & Camplejohn 1985; Ziche et al. 1985;
Folkman et al. 1983). It is possible that in physiological hypoxic systems other
processes like tissue necrosis may inhibit angiogenesis through release of angiogenic
inhibitors from the extracellular matrix (Ortega & Werb 2002) (for example
endostatin, thrombospondins and tumstatin) and contribute to the effect of angiostatic
steroids.
In vivo wound healing models in mice have investigated whether endogenous
glucocorticoids are sufficient to tonically repress inflammation (Grose et al. 2002).
In comparison to wild type controls, in a cutaneous wound healing model the
expression of IL-6 expression but not TNFa was increased in transgenic mice that
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had defective glucocorticoid receptors which were unable to bind to DNA (Grose et
al. 2002). This glucocorticoid receptor dependent glucocorticoid effect was
associated with an initial increase in wound granulation tissue and mature wounds
with normal histological appearance. Other studies have examined the influence of
endogenous steroids to regulate inflammation using RU38486 (a glucocorticoid
receptor antagonist) and found conflicting results when comparing humans with
rodents (Laue et al. 1988; Laue et al. 1990; Leech et al. 2000a). This may reflect
differences in the complexity of the immune systems, the dose of drug administered
or extent of injury sustained. Attempts have been made to develop in vivo angiogenic
models to distinguish glucocorticoid angiostatic and anti-inflammatory responses
(Hori et al. 1996; Kenyon et al. 1996). To date however this has not been possible
and probably reflects the degree of commonality in the cascades governing both
responses. Arachidonic acid metabolites PGE2 and TxA2 are good examples of
factors shared by both processes and whose production is suppressed by
glucocorticoids in vitro and in vivo through phospholipase A2 and cyclo-oxygenase-
2 inhibition (Blomme et al. 2003; Leahy et al. 2000; Herschman 1994; Masferrer &
Seibert 1994).
The anti-inflammatory effects of glucocorticoids although initially employed to
improve the efficiency of an in vivo angiogenesis model appear to influence the
processes of angiogenesis (Folkman et al. 1983; Hori et al. 1996). The importance of
the anti-inflammatory effects to the overall angiostatic effects of glucocorticoids is
difficult to assess but in light of the extent of inflammation in processes involving
angiogenesis such as wound healing, tumour growth and also endometrial cycling
and muscle hypertrophy it is likely that this is an influential component.
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1.5.2 Inhibition of Cellular Migration
Angiogenesis requires the movement of endothelial and peri-endothelial cells
through the vessel wall and into the extracellular matrix (Conway et al. 2001;
Carmeliet 2000). Inflammatory and pro-angiogenic cytokines such as IL6 and VEGF
promote changes in vascular structure, cellular activity and extracellular matrix
integrity to facilitate new vessel sprouting (Conway et al. 2001; Perretti & Ahluwalia
2000; Carmeliet 2000). Chemokine concentration gradients, cell surface integrins,
adhesion molecules and matrix proteolysis determine the direction of vessel growth
and cell migration (Sottile 2004; Perretti & Ahluwalia 2000). This interplay between
cell adhesion, migration and matrix proteolysis has been targeted by pharmaceutical
companies for anti-angiogenic therapies and involves processes regulated by
glucocorticoids (Pitzalis et al. 2002; Preissner et al. 1997; Polat et al. 2002).
Glucocorticoids influence cell migration through anti-inflammatory effects and by
direct effects on integrins and adhesion molecules (Pitzalis et al. 2002; Wang et al.
2002; Schoeler et al. 2003). Integrins provide a physical connection for endothelial
and other cells to extracellular matrix proteins and some have been identified as pro-
angiogenic whereas others appear to inhibit new vessel formation (Preissner et al.
1997; Hynes 2002). Integrin expression is increased in an inflammatory environment
(Pitzalis et al. 2002; Schoeler et al. 2003) as occurs in angiogenesis and
glucocorticoids would be expected to antagonise such induction. Glucocorticoids are
also associated with altered integrin expression likely to produce an angiostatic
influence for example pro-angiogenic integrin oqpi and subunits an, and pi
expression was suppressed in several different cell lines (Zoppi et al. 1998; Zhang et
al. 1993; Ryu et al. 1999; Gronowicz & McCarthy 1995; Gohel et al. 1995; Brandt
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& Vanaman 2000) whereas in others increased expression of anti-angiogenic
integrins av(35 and avP3 was observed (Cheng et al. 2000). Significantly much of
this data was recorded using physiologically relevant concentrations of
glucocorticoids, for example lOOnM Cortisol reduced human placental
cytotrophoblast an integrin subunit expression (Ryu et al. 1999).
The environment that new vessels project into is also an important determinant of
cell migration and angiogenesis (Sottile 2004; Pepper 2001; Bellon et al. 2004). Key
modulators of the extracellular proteoglycan milieu are matrix metalloproteinases
(MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) (Sottile 2004;
Pepper 2001; Bellon et al. 2004). Disturbances of the dynamic balance between
MMPs and TIMPs are associated with impaired new vessel formation: angiogenesis
in implanted tumours and post myocardial revascularisation was severely impaired in
urokinase plasminogen activator (uPA) homozygous deficient mice (Heymans et al.
1999; Soff et al. 1995). Glucocorticoids are recognised to alter MMP and TIMP
expression and synthesis (Pitzalis et al. 2002; Wang et al. 2002; Perretti & Ahluwalia
2000) and angiostatic steroids are associated with suppression of plasminogen
activator activity via increased production of plasminogen activator inhibitor-1 (PAI-
1) in bovine aortic endothelial cells (BAECs) (Blei et al. 1993). Similar increases in
PAI-1 have been observed in human umbilical vein endothelial cells (HUVECs)
incubated with glucocorticoids (Zoellner et al. 1993) and clinically chronic
glucocorticoid therapy is associated with increased plasma concentrations of PAI-1
(Patrassi et al. 1997). Other MMP/TIMP systems influenced by glucocorticoids
include MMP-2 and its inhibitor TIMP-2 (Pross et al. 2002; Wang et al. 2002).
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Bovine choroidal endothelial cell exposed to large concentrations of trimacinolone
exhibited reduced migration, reduced endothelial tube formation and reduced
expression ofMMP-2 (Wang et al. 2002). Primary cultured rat aortic smooth muscle
cells in vitro similarly had reduced migration in the presence of dexamethasone
(lOOnM) and this was associated with reduced MMP-2 and increased TIMP-2
expression (Pross et al. 2002). Differences may exist between rodents and humans in
the regulation of cell migration since in the same study human aortic vascular smooth
muscle cells were not influenced by dexamethasone and MMP/TIMP expressions
were not altered (Pross et al. 2002). Similarly leucocyte migration was influenced by
endogenous glucocorticoids in rodents but not in clinical studies (Laue et al. 1988;
Laue et al. 1990; Leech et al. 2000a).
From the initial observation of endothelial cells exposed to steroids a description of
cellular "rounding-up" with retraction of cytoplasmic extensions and detachment
from the basement membrane was recorded (Folkman & Ingber 1987). In the context
of current understanding of the role of integrins and extrapolation from consistent
findings in inflammatory models but also from cutaneous keratinocytes, dendrocytes,
cytotrophoblasts, and tumour cells lines (Bator et al. 1998; Ryu et al. 1999; Zhang et
al. 1993), glucocorticoids appear to influence integrin expression and matrix
proteases. Thus limitations of cell migration and matrix dissolution are potential
factors contributing to the angiostatic effects of glucocorticoids.
1.5.3 Influence on Extracellular Matrix: collagen and heparans
Extracellular matrix is a heterogenous layer of proteins, glycocoproteins and
proteoglycans that supports established vessels and provides a skeletal scaffold for
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new vessels (Ortega & Werb 2002). Constituents of this layer and some of their
proteolytic fragments have emerged as important regulators of angiogenesis for
example collagen, fibronectin, laminin, thrombospondins and vitronectin (Sottile
2004). Glucocorticoids have been shown to interfere with the synthesis of some of
these components in angiogenesis, wound healing, bone formation and skeletal
muscle models (Maragoudakis et al. 1989; Gu et al. 2001; Profita et al. 2004;
Hernandez et al. 2004; Ahtikoski et al. 2004). It is therefore probable that some of
the angiostatic effects of glucocorticoids are due to reduced synthesis of extracellular
matrix components.
Collagen expression and post-translational modification are inhibited by
glucocorticoids (Kucharz 1988). Supra-physiological concentrations of cortisone and
other angiostatic steroids reduced collagen synthesis and angiogenesis in vivo in the
chick chorioallantoic membrane model (Maragoudakis et al. 1989; Ingber et al.
1986). In this model collagen IV is the major component of the collagenous proteins
(Maragoudakis et al. 1989). Collagen IV is an important constituent of basement
membrane a specialized area of extracellular matrix that supports and maintains
existing vessel and provides scaffold for the migration of endothelial cells
angiogenesis (Ortega & Werb 2002). In a rodent wound healing study endogenous
glucocorticoids did not influence collagen IV but did reduce mRNA levels of another
basement membrane component, fibronectin (Grose et al. 2002). Similarly
pharmacological doses of dexamethasone but not endogenous glucocorticoids
reduced collagen I and III expression in rodent cutaneous wounds (Grose et al. 2002;
Oishi et al. 2002).
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Proteolysis of extracellular matrix collagens liberates anti-angiogenic fragments for
example endostatin is formed by the cleavage of collagen XVIII (Kalluri 2002).
Clinical studies examining the levels of endostatin in airway secretions in steroid
treated asthmatics or joint fluid from steroid treated rheumatoid arthritis patients
suggests that glucocorticoids do not alter the levels of these endogenous inhibitors of
angiogenesis (Nagashima et al. 2000; Profita et al. 2004). Pharmacological doses of
glucocorticoids were however observed to induce expression of Thrombospondin -1
another extracellular matrix inhibitor of angiogenesis in human and murine
trabecular mesh cells (Flugel-Koch et al. 2004).
In the initial description of angiostatic steroids Folkman recognised that these
compounds disturbed the integrity of the basement membrane (Folkman et al. 1983;
Crum et al. 1985). This appeared to be an early effect that initiated endothelial cell
contraction and detachment from the membrane scaffold. In these experiments
Folkman observed a synergistic effect of heparin on angiostasis that was in contrast
to the pro-angiogenic effect of heparin alone. Pleparin is recognised to bind to many
angiogenic factors with high affinity and has been used to isolate VEGF and bFGF
(Folkman & Shing 1992). It is suggested that heparin pro-angiogenic effects are
mediated by a variety of influences including acting as an angiogenic factor
chaperone, or by stabilising growth factors or by preventing degradation of
angiogenic factors by binding to them in the extracellular matrix (Folkman & Shing
1992). Whether in vivo endogenous heparans, heparin sulphate, dermatan sulphate
and related polysaccharides in the extracellular matrix or endothelial glycocalyx
serve a similar function or facilitate glucocorticoid angiostatic influence is unclear.
In the chick chorioallantoic membrane (CAM) in vivo assay used by Folkman,
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exogenous heparin was required for the angiostatic effect of glucocorticoids.
However, in other in vivo assays angiogenesis is inhibited by glucocorticoids in the
absence of exogenous heparin (Hori et al. 1996; Illanes et al. 2002; Penhaligon &
Camplejohn 1985; Ziche et al. 1985). Variations in the dependency of glucocorticoid
angiostasis on exogenous heparin is not solely a reflection of the assay used but may
also reflect the type of glucocorticoid (Lemus et al. 2001) (betamethasone did not
require heparin to inhibit angiogenesis in this in vivo study) or the source of heparin
(Folkman et al. 1983).
Glucocorticoid effects on the extracellular matrix to disrupt collagen metabolism and
other proteoglycan components appear to contribute to glucocorticoid angiostatic
influence. The majority of evidence for these effects is from the use of large
concentrations of glucocorticoids and the influence of endogenous glucocorticoid to
determine matrix regulation of angiogenesis is largely unexplored.
1.5.4 Inhibition of Cellular Proliferation
During angiogenesis endothelial, vascular smooth muscle and other peri-endothelial
cells proliferate to form new vessels (Conway et al. 2001). Stimuli for the angiogenic
switch that determines the evolution of a cell from a quiescent stabilised existence to
a mitotic, unstable form are complex (King & Cidlowski 1998). Inflammatory
cytokines and hypoxia have been identified, as key inducers of the angiogenic switch
(Carmeliet 2000). Glucocorticoids inhibit inflammatory cytokine generation
(Almawi et al. 2002; Wen et al. 2003; Gille et al. 2001) but also appear to have
direct anti-proliferative effects on endothelial cells (Sakamoto et al. 1987;
Longenecker et al. 1982) and have been used as anti-mitotic agents in myeloid and
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lymphoid haematological malignancies and prostate cancer (Gaynon & Lustig 1995;
Wielckens et al. 1987; Fakih et al. 2002). Similarly glucocorticoids have been used
clinically and in animal models of vascular remodelling following intravascular
injury to reduce vascular smooth muscle cell proliferation and reduce rates of
restenosis (Radke et al. 2004; Berk et al. 1991). The ability of glucocorticoids to
influence endothelial proliferation in vitro and in vivo and vascular smooth muscle
cell mitosis post angioplasty suggests that the angiostatic effect of glucocorticoids
may be determined by influences on cell proliferation, apoptosis and cell survival.
Clinically glucocorticoids are used to inhibit angiogenesis in haemangiomas and
biopsy data from such patients indicate that glucocorticoids regulate survival and
apoptosis mechanisms (Hasan et al. 2000; Hasan et al. 2003). Glucocorticoid
induced increased expression of mitochondrial cyt b was associated with capillary
regression in vitro and lesion resolution clinically (Hasan et al. 2000; Hasan et al.
2003). These results are concordant with the traditional view of mitochondria as key
organelles in the marshalling of pro-survival and pro-apoptotic factors (Frankfurt &
Rosen 2004) and consistent with the mechanism of action of glucocorticoid anti¬
mitotic activities in haematological malignancies (Frankfurt & Rosen 2004). Other
data from haemangioma studies suggest that glucocorticoids influence different
aspects of apoptosis (Hasan et al. 2003). Increased expression of clus/apoJ, a
glycoprotein associated with programmed apoptosis was recorded following
glucocorticoid therapy and associated with capillary regression (Hasan et al. 2003).
In vivo cortisone in supra physiological concentrations inhibited endothelial cell
proliferation (Sakamoto et al. 1987). A mechanism for repression of endothelial cell
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proliferation could be the influence of glucocorticoids on the synthesis of
tetrahydrobiopterin. Tetrahydrobiopterin is a co-factor for the production of nitric
oxide and has been shown to be important in the proliferation of endothelial cells
(Marinos et al. 2001). Glucocorticoids reduce the production of tetrahydrobiopterin
through inhibiting of the expression of a rate-limiting enzyme, GTP cyclohydrolase
(Johns et al. 2001).
Glucocorticoid effects on cell proliferation, survival and apoptosis interplay with the
many factors contributing to the processes of angiogenesis. Few studies indicate a
direct anti-proliferative effect of large concentrations on endothelial cell proliferation
(Sakamoto et al. 1987) but clinically therapeutic glucocorticoids induce apoptosis in
proliferating capillary haemangiomas (Hasan et al. 2000; Hasan et al. 2003) and
reduce restenosis post angioplasty (Versaci et al. 2002). Regulation of cell cycling is
a genetically controlled event that would be susceptible to glucocorticoid modulation
although other factors may provide steroid targets such as co-factor availability
(Johns et al. 2001)and mitochondrial function (Hasan et al. 2000; Hasan et al. 2003).
The diversity of glucocorticoid action and evidence from clinical and in vivo studies
suggest that anti-proliferative effects of glucocorticoids would contribute to their
angiostatic properties.
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In summary- Consistent observational evidence exists for an angiostatic effects of
glucocorticoid at supra physiological concentrations. Although there is a vast amount
of circumstantial evidence for the effects of glucocorticoids on relevant pathways,
few studies have directly examined possible mechanisms mediating angiostasis. This
may reflect the complexity of angiogenesis in conjunction with the diversity of
glucocorticoid actions. The circumstantial evidence suggests that glucocorticoids
influence angiogenesis through anti-inflammatory, anti-migratory, anti-extracellular
matrix and anti-proliferative mechanisms. Whether these are all relevant or all equal
in importance to angiogenesis in vivo requires further investigation. The influence of
endogenous glucocorticoids on angiogenesis has not been assessed and is the subject
of this thesis. Some of the circumstantial evidence for glucocorticoid effects on
inflammation, matrix interactions and anti-proliferative data does rely on
physiologically relevant steroid concentrations and may well have relevance to the
findings of this thesis.
1.5.5 Modulation of Angiogenesis by 1 ipHydroxysteroid Dehydrogenases
lipHSD isozymes in the vessel wall may influence the angiostatic effects of
glucocorticoids by altering steroid concentrations locally at the site of angiogenesis.
1 lpHSDl amplification of glucocorticoid effects could produce an anti-mitotic effect
and an anti-prolifertive role has been described for lipHSDl in rat osteosarcoma
cells (Rabbitt et al. 2003). In contrast 11PHSD2 deactivation of glucocorticoids may
produce increases in cell proliferation and a pro-mitotic effect has been described for
11PHSD2 in several endocrine cancers (Rabbitt et al. 2003).
58
No abnormalities of vascular development have been detected in transgenic mice
deficient in either lipHSD type 1 or 2 (Kotelevtsev et al. 1997; Kotelevtsev et al.
1999). Whilst 11J3HSD1 deficient mice have no apparent vascular phenotype it is not
unusual for deficiencies of angiogenic factors to be revealed only in pathology
(Carmeliet & Collen 2000). Angiogenesis in pathology is influenced by
inflammation and it is therefore noteworthy that vascular smooth muscle cell
1 lpHSDl was recently observed to be up regulated by inflammatory cytokines (Cai
et al. 2001). Thus lipHSDl in the vessel wall is ideally located and regulated to
respond to angiogenic stimuli.
1.6 Hypothesis & Aims
It is evident that glucocorticoids have the ability to attenuate the growth of new
blood vessels. What is less clear, however, is whether endogenous glucocorticoids
have a clinically significant influence on angiogenesis and, furthermore, whether this
influence is modulated by the activity of lipHSD activity within the vascular wall.
Given that altered angiogenesis is central to many disease pathologies and, thus,
responsible for considerable morbidity and mortality it is obviously desirable to
clarify these relationships. Increased knowledge of the roles of glucocorticoids and
lipHSDs in regulation of vascular growth will extend our understanding of the
processes leading to disease development and may identify potential targets for
therapeutic manipulation of angiogenesis. Consequently, the work described in this
thesis addresses the hypotheses that endogenous glucocorticoids induce a
glucocorticoid receptor-dependent inhibition of angiogenesis that is modulated by
1 lpHSDl activity within the vascular wall.
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In order to investigate this hypothesis, the following aims were addressed:
1. To develop methods for assessing the effects of glucocorticoids on angiogenesis
in vitro, in vivo and in disease pathology.
2. To determine whether endogenous glucocorticoids inhibit angiogenesis by
stimulation of the glucocorticoid receptor.
3. To determine whether 11(3HSD1 activity in the vascular wall amplifies






Unless otherwise stated all chemicals, reagents and drugs were purchased from
Sigma, UK. All HPLC grade solvents were purchased from Rathburn Chemicals,
UK. All radioactivity was purchased from Amersham, UK. Different sources are
otherwise indicated.
2.1 Buffers and Solutions
Phosphate buffered Saline (PBS): 0.1M phosphate buffer with 137mM NaCl,
2.7mM KC1 in distilled water, pH 7.4, autoclaved before use.
Krebs'-Ringer Bicarbonate (KRB) Buffer: 118mM NaCl, 3.8mM KC1, 1.19mM
KH2PO4, 2.54mM CaCl2, 1.19mM MgS04, 25mM NaHC03 in distilled water, pH
7.4. Stored at 4°C and supplemented with 0.2% glucose immediately before use.
Borate Buffer: 0.133M Boric acid, 67.5mM NaOH + HCL, pH7.4 containing 0.5%
bovine serum albumin, 1% methanol and 0.1% ethylene glycol.
Tris-Buffered Saline (TBS): 0.05M Tris-HCl, 0.15M NaCl pH 7.6
Buffer C: 300mM NaCl, ImM EDTA, 50mM Tris pH 7.7, containing 10% glycerol
Modified Buffer C: 50mM Na acetate, ImM EDTA, 50mM Tris pH 6, containing
10% glycerol
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2.2 Drugs and Steroids used in in-vitro studies
Carbenoxolone: 61.47mg carbenoxolone was made up to 10ml with ethanol (10" M
solution), then lOpl was added to 10ml deionised water (10"5M solution). Stored at
-20°C in 1ml eppendorf tubes.
Cortisol: 36.25mg Cortisol was made up to 10ml with ethanol (10" M solution), then
I Opil was added to 10ml deionised water (10"5M solution). Stored at -20°C in 1ml
eppendorf tubes.
Corticosterone: 34.65mg corticosterone was made up to 10ml with ethanol (10" M
solution), then lOpl was added to 10ml deionised water (10"5M solution). Stored at
-20°C in 1ml eppendorf tubes.
II Dehydrocorticosterone: 34.44mg 11 dehydrocorticosterone was made up to 10ml
9 c
with ethanol (10" M solution), then lOpl was added to 10ml deionised water (10" M
solution). Stored at -20°C in 1ml eppendorf tubes.
Indomethacin: 35.78mg dissolved in 30ml distilled water (final concentration 10"
9
M). 1ml aliquots stored at -20°C in 1ml eppendorf tubes.
Nco-Nitro-i-Arginine (L-NNA): 21.92mg dissolved in 30ml distilled water (final
concentration 10"2M). 1ml aliquots stored at -20°C in 1ml eppendorf tubes.
63
RU38486: 42.96mg RU38486 was made up to 10ml with ethanol (10"2M solution),
then lOpl was added to 10ml deionised water (10"5M solution). Stored at -20°C in
lml eppendorf tubes.
Spironolactone: 41.66mg spironolactone was made up to 10ml with ethanol (10" M
solution), then 1 OjliI was added to 10ml deionised water (10"5M solution). Stored at -
20°C in 1 ml eppendorf tubes.
Vascular Endothelial Growth Factor (VEGF): Human recombinant Vascular
Endothelial Growth Factor Ai65 (Sigma, UK) was reconstituted according to
manufacturers instruction: 10pg added to 10ml phosphate buffered saline containing
0.1% bovine serum albumin lml aliquots stored at -20°C in lml eppendorf tubes.
Fura-2AM\ lOOpg of Fura-2AM (Calbiochem, UK) was dissolved in lOOpl of
dimethyl sulphur oxide (DMSO) (Sigma, UK).
2.3 Animals
Male C57Black 6 mice were obtained from Charles River, UK at 10-12 weeks of
age. Homozygous null male 11(3HSD1 (bred to be congenic) were bred in-house at
the MFAA, University of Edinburgh, or the Biomedical Research Facility, Western
General Hospital, Edinburgh, UK.
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Animals were maintained under controlled conditions of light and temperature (21-
22°C), and allowed free access to standard chow (Special Diet Services, UK) and
drinking water.
2.4 Angiogenesis in vitro: Mouse Aortic Ring Assay
The aortic ring in vitro model of angiogenesis was chosen because it accurately
represents the major processes of angiogenesis: endothelial cell proliferation,
migration and branching capillary network formation (Auerbach et al. 2003; Staton
et al. 2004). Initial descriptions of this model using rat tissue included electron
microscopy data describing the formation of luminised capillary tubes consisting of
endothelial and peri-endothelial cells (Nicosia & Ottinetti 1990).
2.4.1 Aortae Collection
Mice 10-12 weeks old were killed humanely and under sterile conditions the thoracic
aorta was removed, washed in serum free MCDB 131 medium (Invitrogen, UK) at
room temperature, cleaned of periadventitial tissue and divided into 1-3 mm rings
(time from death to tissue embedding in Matrigel approximately 30min).
2.4.2 Culture conditions
Aortic rings were embedded in Matrigel (Becton Dickinson, UK) in 24 well plates
(VWR International, UK) and incubated at 37°C for 7-14 days. Matrigel was
prepared by liquefying overnight on iced water at 4°C; 100f.il was used as basal layer
in each well of a 24 well plate and allowed to gel by incubating at 37°C for 20mins.
1 aortic ring was placed in each well, covered with 200 pi of Matrigel and incubated
at 37°C for 20mins. Once the Matrigel had gelled the embedded aortae were
cultured in 1ml of serum free MCDB 131, containing heparin, ascorbic acid,
GA1000 (supplied as aliquots product number CC3162, Cambrex Biosciences, UK)
and vehicle or treatment compound. Media were changed every 48hours. For each
set of conditions 3 wells were used thus experiments were performed in triplicate.
2.4.3 Quantification of Angiogenesis
Aortic rings were viewed in the 24 well plates using a Karl Zeiss Axioskop inverted
light microscope at x 50 magnification. Image analysis was performed using image
analysis software [The Microcomputer Imaging Device (MCID) (Imaging Research
Inc, Canada)] and a Pentax 250 live-feed camera.
Measurements were taken of aortic ring circumference, diameter and area. The
number of vessels was counted daily and computer image analysis calculations of
total area occupied by new vessels, and the maximum and average diameters of the
total area occupied by new vessels were recorded.
2.4.4 Vessel characterization
The endothelial nature of the new vessel was confirmed using fluorescent labelled
acetylated low-density lipoprotein (Dil-Ac-LDL) (Biogenesis, UK) (Rohan et al.
2000). On day 7 culture medium was changed, 50pl of Dil-Ac-LDL stock
(200pg/ml) added to each well and incubated in standard conditions for 48 hours.
Wells were washed with probe free media and rings examined using Hamamatsu
Orca ER CCD camera with Chroma 83000 filter set (with Texas Red excitation).
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Images were captured using in house scripts in iPLab spectrum (Scanalytics Ltd,
UK).
2.5 11PHSD1 activity in intact aortic rings in vitro
The ability of lipHSDl to act as a reductase or a dehydrogenase has made it
difficult to distinguish the functional directionality of the isozyme in vessels. Usually
in tissue homogenate activity assays the particular 1 lpHSD isozyme responsible for
dehydrogenase activity can be distinguished by co-factors (NADP or NAD), however
in mice co-factor specificity is less exclusive. Thus to determine 1 lpHSDl functional
directionality in vessels activity assays were performed using intact aortic rings.
Aortic rings from 3-6 wild type mice were incubated (24 hours; 37°C) in 1ml of
DMEM-F12 medium (Invitrogen, UK) containing 3H-steroid (as below)
supplemented with fetal bovine serum (1%), streptomycin (lOOpg/ml), penicillin
(lOOunits/ml) and amphotericin (0.25pg/ml) (Souness et al. 2002). 11 P-Reductase
activity was determined by adding lOpmol [ H4]-l 1-dehydrocorticosterone
(synthesised in house from l,2,6,7-[ LLJ-corticosterone (Amersham Biosciences,
UK) using rat placental homogenate (Brown et al. 1993). Mouse liver and medium
alone were used as positive and negative controls, respectively. 11 p-Dehydrogenase
activity was determined by adding lOpmol l,2,6,7-[3H4]-corticosterone. Mouse
kidney slices and medium alone served as positive and negative controls.
Experiments were performed in duplicate.
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After incubation, steroids were extracted from media using Cis Sep-pak columns
(Waters Millipore, UK). Aortic rings, which contain 2-3% of the added radioactivity
"5
were not included in the extraction (Souness et al. 2002). [ FUJ-Corticosterone and
*3
[ H4]-11-dehydrocorticosterone were separated by HPLC and quantified by on-line
liquid scintillation counting (Walker et al. 1991). Enzyme activity was expressed as
conversion after subtraction of apparent conversion in negative control wells.
2.6 Intracellular Calcium Responses to VEGF
Pilot studies were conducted to investigate the influence of glucocorticoids on VEGF
stimulated calcium transient in human umbilical vein endothelial cells in order to
explore the direct angiostatic effects of glucocorticoids.
2.6.1 Human Umbilical Vein Endothelial cell culture
Miss Katherine Shaw cultured HUVECS (Cell Systems, UK) until passage 3 in T-
25ml flasks (Clonetics, UK).
At confluence cells were soaked in 5ml E1BSS (Clonetics, UK) and separated from
the flask by incubating with 5ml trypsin/EDTA at 37°C 10 minutes (Reagent Pack
subculture Reagent Kit Cambrex, UK). Trypsin/EDTA was removed and neutralised
by adding 5ml of trypsin neutralising solution (TNS) to the flask. The cells were
decanted into a 10ml sterile Falcon tube (BD Biosciences, UK) centrifuged at
lOOOrpm for 5minutes at 18°C, the supernatant drained and the pellet re-suspended
in 1ml of MCDB131 medium. A 10pl aliquot of cell suspension was added to 190p.l
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of 0.4% trypan blue solution. 10pl were placed into a haemocytometer and the
number of cells counted. Cells were diluted to give a final concentration of 0.5
million cells/ml. 1ml of cell suspension was subcultured onto a fibronectin (20
micrograms/ ml) coated glass coverslip in a 6 well plate and incubated until
confluent. Once confluent (7 days), cells were incubated in serum free MCDB131
supplemented with heparin, GA 1000 and ascorbic acid (EGM-2 Bullet Kit Cambrex
Biosciences, UK) overnight. In the morning, cells were treated with vehicle or
Cortisol (600nM or 16pM) and incubated in serum free conditions, for a further 6
hours. Cells were washed with Krebs-Ringer solution with Cortisol (600nM or
16p,M) or vehicle and loaded with Fura-2AM (5pM) (Calbiochem, UK) for 20
minutes. Cells were washed with and then bathed in Kreb's-Ringer bicarbonate
solution in the presence or absence of Cortisol (600nM or 16pM). The fura-2AM
loaded coverslips were mounted on a coverslip case and placed in a temperature
controlled cell perfusion chamber (Intral Cel UK) on the stage of an (Nikon Diaphot)
inverted fluorescence microscope.
2.6.2 Intracellular calcium measurement
Fura-2 fluorescence was excited at 340 and 380 nm and fluorescence emission
measured at 509nm using a spectrophotometer with a data acquisition rate of 0.125
Hz. The ratio of intensities obtained from 340/380 excitation pairs was used as
2_|_
measure of [Ca" ]i (Grynkiewicz et al. 1985). For each experiment baseline
fluorescence was established followed by the addition of lOng/ml (Faehling et al.
2002) human recombinant Vascular Endothelial Growth Factor ai65 (Sigma, UK).
Acquisition of data was continued for 8 minutes.
2+Calibration of the [Ca ]i was performed by monitoring the change in fluorescence at
• 9-b •
minimal and maximal [Ca ]i responses by adding 5mM sodium-EDTA in the
2_j_ . , 2+
presence of 1.3mM Ca followed by the addition of lOmM Ca in Kreb's Ringer
bicarbonate solution and 20p,M ionomycin. The Grynkiewicz equation (Grynkiewicz
9+
et al. 1985) was then used to calculate [Ca ]i:
Ca2+ (nm) =Kd. [3 [(R-Rmin)/(Rmax-R)
Kd is the dissociation constant for FURA-2 this is 224 nm
R is the ratio of flouresence (f340/f380)
Rmin is the ratio of fluorescence when the dye is completely free of Ca2+
Rmax is the ratio of fluorescence when the dye is completely saturated with Ca2+
P is the ratio of fluorescence of saturated to free fluorescence at 380nm (fSat/fFree)
Mean Rmin, Rmax and p for control cells was: 0.3351, 1.4503 and 2.75 respectively
Mean Rmin, Rmax and P for Cortisol treated wells was: 0.3749, 1.3597 and 2.82. The
mean of the P values was used in further calculations.
2.7 Angiogenesis in vivo: subcutaneous sponge implantation assay
To validate the in vitro findings, which had been observed in the absence of systemic
factors such as inflammation, the influence of endogenous glucocorticoids and
1 lpHSDl were investigated in vivo.
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2.7.1 Drugs and Steroids used in polyurethane sponge implantation studies
Corticosterone, Cortisol, cortisone, RU38486 or spironolactone were mixed with
Silastic elastomer (Silastic 20 medical grade, Dow Corning Corporation, USA) to
produce pellets which have been shown to release their steroid at a constant rate for 4
weeks (Cleasby et al. 2003). Polyurethane sponge grade XE1700V was obtained as
kind gift from Caligen Foam Ltd., UK
Corticosterone: 550mg of corticosterone were added to lg Silastic elastomer mixed
and centrifuged at 13000rpm for 10 seconds. lOOmg of curing agent was added,
mixed and centrifuged at 13000rpm for lOseconds. The mixture was drawn into a
lml syringe and allowed to cure overnight at 25°C. Once cured the steroid-
impregnated elastomer was removed from the syringe and divided into 50mg pellets.
Cortisol: 275mg of Cortisol were added to lg Silastic elastomer mixed and
centrifuged at 13000rpm for 10 seconds. lOOmg of curing agent was added, mixed
and centrifuged at 13000rpm for lOseconds. The mixture was drawn into a lml
syringe, injected into capillary tubing (1.22mm external diameter: 0.76mm internal
diameter) (Portex Ltd, UK) and allowed to cure overnight at 25°C. Once cured the
steroid- impregnated elastomer pellet was removed from the tubing divided into 10-
12mg pellets (containing 2.5-3mg of Cortisol) and inserted into 1cm x 0.5 cm
polyurethane sponge cylinders. Pellets were inserted using a 200pl micropipette tip
to pierce the sponge and guide the pellets into the centre of the cylinder.
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Cortisone: 300mg of cortisone were added to 1.1 Og Silastic elastomer mixed and
centrifuged at 13000rpm for 10 seconds. llOmg of curing agent was added, mixed
and centrifuged at 13000rpm for 10 seconds. The remainder of the procedure was
performed as for Cortisol pellets. 10-12 mg pellets containing 2.5-3mg of cortisone
were used.
RU38486: 166mg of RU38486 were added to 300mg Silastic elastomer mixed and
centrifuged at 13000rpm for 10 seconds. 33mg of curing agent was added, mixed
and centrifuged at 13000rpm for 10 seconds. The remainder of the procedure was
performed as for Cortisol pellets. 10-12 mg pellets containing 5-6mg of RU38486
were used.
Spironolactone: 166mg of spironolactone were added to 300mg Silastic elastomer
mixed and centrifuged at 13000rpm for 15 seconds. 33mg of curing agent was
added, mixed and centrifuged at 13000rpm for 15 seconds. The remainder of the
procedure was performed as for Cortisol pellets. 10-12 mg pellets containing 5-6mg
of spironolactone were used.
Placebo: 1.1 Og of Silastic gel was added to llOmg of curing agent, mixed,
centrifuged at 13000rpm for 10 seconds, drawn into a 1ml syringe, either injected
into capillary tubing or left in the syringe, and cured at 25 °C overnight. Post curing
procedure was performed as for corticosterone or Cortisol pellets as appropriate.
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2.7.2 Adrenalectomy
The influence of endogenous glucocorticoids was examined by implanting placebo-
impregnated sponges into mice that had undergone adrenalectomy or sham operation.
Dr Patrick Hadoke kindly performed the surgery for these animals. Adrenalectomy
was performed as described (Livingstone et al. 2000b) and during this procedure
animals had bilateral placebo impregnated sponges implanted using the incision
created for bilateral adrenalectomy. Following surgery sham and adrenalectomy
animals were maintained on 0.9% saline (Livingstone et al. 2000b).
2.7.3 Subcutaneous sponge implantation
C57B16 and congenic 1 lpHSDl male mice 8-10 weeks old were anaesthetized with
halothane. A 1cm longitudinal incision was made on the lower back and a
subcutaneous tunnel was formed, using blunt forceps, from the incision site to each
flank. Through the tunnels a sterilized polyurethane sponge (lcmx 0.5cm) cylinder
was inserted subcutaneously to each flank. Every animal received 2 sponges.
Intervention agents (vehicle, Cortisol, corticosterone, cortisone, RU38486,
spironolactone) were administered to the sponges as Silastic implants in 2 different
ways. In preliminary experiments implants were placed adjacent to the sponges, in
latter experiments Silastic implants were inserted into the sponge. Animals received
a placebo-impregnated sponge on one flank as control and a steroid impregnated
sponge on the opposite flank.
The skin wound was closed with clips and 0.05ml/Kg subcutaneous (s.c.)
buprenorphine analgesia was administered subcutaneously. Mice recovered on a
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heating pad at 30°C until moving freely. Normal chow and water was supplied ad
lib, animals were weighed and had their water intake monitored daily.
Twenty days following sponge implantation mice were euthanised by decapitation;
trunk blood was collected in lithium heparin and placed on ice. Thymus, adrenal
glands and spleen were removed and weighed. The sponges were removed and
bisected for histology or quantification of protein and steroid content.
2.7.4 Quantification of angiogenesis in polyurethane sponges
Half of the sponge for histological examination was placed immediately into 10%
formalin for 1 hour, transferred to 75% alcohol for 30 minutes and stored in 90%
alcohol prior to paraffin embedding. Paraffin wax processing was performed using
program 1 of Tissue Tek Vacuum In filtration Processor (VIP).
Paraffin wax embedded samples were stored at room temperature prior to sectioning.
7pm sections were cut using a microtome (Ernest Leitz 1512) floated in a water bath
at 30°C and mounted onto positive electrostatically charged frosted glass slides
(BDH Laboratory slides, VWR International, UK). The slides were dried at room
temperature placed in an oven at 37°C for 24 hours and stained with haematoxylin
and eosin.
Vessels were readily identified by their characteristic shape and from the presence of
erythrocytes within their lumens. Two cross sections from each sponge were
examined using low power (xlOO) and Chalkley counting at high power (x250) (Fox
et al. 1995). Chalkley counting is performed using a 25-point Chalkley eyepiece
reticule (Graticules Ltd, Kent UK). At low power the 3 most vascular areas were
identified and analyzed using the graticule at 250x magnification. The graticule was
rotated until the highest number of Chalkley reticule points were aligned with vessels
and a score out of 25 was achieved. From each section three Chalkley scores were
recorded thus a total of six Chalkley scores were obtained for each sponge and the
mean of these was used as the Chalkley count.
2.7.5 Polyurethane sponge protein and steroid quantification
The half of the sponge for protein and steroid quantification was placed in ice cold
PBS, the Silastic insert was removed and the sponge was homogenized in 2ml ice-
cold PBS for 5mins using an Ystral mechanical homogeniser (Scientific Instruments
Centre, UK). The homogenate was centrifuged at 2000rpm 4°C for 30 minutes. 40pl
of the supernatant was processed for protein content using the Bradford assay
(Bradford 1976). A further 750pl of the supernatant was removed, added to7.5ml of
ethyl acetate, vortexed and allowed to settle for 5mins. 7ml of the supernatant was
removed and dried at 60°C. Samples were then stored at -20°C until steroid
radioimmunoassay was performed.
2.7.6 Sponge Protein determination: the Bradford assay
The protein concentration of tissue homogenates was determined colorimetrically by
the Bradford assay (Bradford 1976) using a Bio-Rad protein assay kit (Bio-Rad,
UK). A range of protein standards (0.1-1.2mg/ ml) was prepared in duplicate in
distilled water from the provided protein standard (bovine serum albumin). Protein
assay dye reagent (Coomassie Blue G-250) was diluted 1:4 in distilled water and
filtered through Whatman No. 1 filter paper prior to use. Diluted protein assay dye
reagent (1.96 ml) was added to 40pl of protein standard or appropriately diluted
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tissue homogenate in a borosilicate tube, vortexed and left at room temperature for
15 min-1 hour to allow colour development. Absorbance of samples at A.=595nm
was measured using a Shimadzu UV/ visible recording spectrophotometer and the
concentration of protein in each sample was estimated from the standard curve.
2.7.7 Steroid quantification: Radio-lmmuno assay
Plasma preparation: Trunk blood collected onto ice in a lithium heparin containing
tube was centrifuged at 3000rpm for lOmins at 4°C the supernatant was removed and
stored at -80°C. Stored plasma samples were defrosted and diluted ten fold with
borate buffer and heated at 80°C for 30 minutes to denature corticosterone-binding
globulin.
Polyuretliane Sponge extract preparation: Dried polyurethane sponge steroid
extracts were re-suspended in borate buffer and xlO and xlOO serial dilutions made.
Steroid standards preparation: Depending on the steroid being assayed
corticosterone, Cortisol or cortisone standards were made with serial dilution.
In a 96 well Falcon Microtest flexible assay plate 20pl of standard or diluted plasma
or diluted steroid extract were incubated with 25pl primary antibody (diluted
1:10,000) [polyclonal rabbit anti-corticosterone or polyclonal sheep anti-cortisol or
• 3*3* 3
polyclonal rabbit anti-cortisone, 25pl H steroid [ H corticosterone (1.5nM), H
Cortisol (1.5nM), 3H cortisone (1.5nM)] and 25pi anti-primary antibody scintillation
proximity assay reagent (Amersham). Sample and standards were incubated at room
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temperature for 10-15 hours and counted in an LKB Wallac Microbeta counter. A
standard curve was constructed and concentrations from sponge extracts and plasma
calculated. The lower limit of accurate detection for this assay was 50 nmol/1
(Cleasby et al. 2003).
2.7.8 High pressure liquid Chromatography
The high-pressure liquid chromatography (HPLC) system comprises an auto-sampler
and mobile phase pump (Waters, UK), a symmetry shield RPis 5pm column (Waters,
UK) and a radioactivity monitor linked to a scintillation fluid pump (Berthold, UK).
The system is controlled by the Winflow computer programme (JMBS
Developments, France).
Anti-cortisone antibodies in the radio-immuno assay used to detect cortisone cross-
react with Cortisol therefore the sponge extract from sponges in animals that had
received cortisone were passed through the HPLC column. To separate cortisone
from Cortisol, steroid extracts from the sponges were re-suspended in 1ml mobile
phase (60% water, 15% acetonitrile, 25% methanol). A 180pl aliquot of each sample
was injected into the HPLC system. The flow rate of the mobile phase was 1ml/ min.
The column temperature was 35°C to maintain stability of retention times. 1M
standards of cortisone and cortisone were injected at the start of each study to define
the retention times for each steroid. The approximate retention times for Cortisol and
cortisone were 17-19 min and 14-16 min, respectively (variation reflects slight
differences in mobile phase composition and column condition). Mobile phase
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containing steroid was collected at the appropriate time points and stored at 4 °C
prior to steroid extraction using ethyl acetate.
Following separation of Cortisol and cortisone by the column homogenised sponge
samples from 1 l^HSD-l -/- mice were subjected to ultra violet lamp detection. Ultra
violet light absorption can be used to distinguish steroids quantitatively. In this
fashion it was possible to determine the presence or absence of cortisone or Cortisol
in sponge samples.
HPLC with on-line scintillation counting was used to quantify [ H]-corticosterone
and [ H]-l 1-dehydrocorticosterone in culture medium from aortic ring incubations to
determine lipHSD-1 activity.
Steroid extracts were re-suspended in 1ml mobile phase (60% water, 15%
acetonitrile, 25% methanol). A 180pl aliquot of each sample was injected into the
HPLC system. The flow rate of the mobile phase was 1ml/ min and the flow rate of
the scintillant (Quicksafe Flow 2; Zinsser, UK) was 2ml/ min to achieve optimal
mixing and counting efficiency. The column temperature was 35°C. Radioactive
standards were injected at the start of each batch of samples to determine peak
• •3* 3
identity. The approximate retention times for [ H]-corticosterone and [H]-ll-
dehydrocorticosterone were 7-9min and 10-12min respectively, with greater than
lmin between the two peaks. Peaks were less than lmin 30s wide and peak height
was at least 50x background.
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Following chromatography, the area under each peak was integrated using the
Winflow software and used to quantify the percentage conversion of [3H]-
corticosterone to [3H]-11-dehydrocorticosterone i.e. lip-HSD activity. The
percentage conversion in each tissue sample was corrected for the "apparent
conversion" occurring in tissue blanks included in each experiment, which was
always <4%.
2.8 Angiogenesis in Pathology: chronic coronary artery ligation
Experience at mouse chronic coronary ligation and sham procedures was obtained
through direct observation, and the performance of non-recovery procedures under
the supervision of Dr Isam Sharif Centre of Cardiovascular Sciences University of
Edinburgh. A formal assessment of technique was made by Dr Jane Conole
University of Edinburgh Veterinary Surgeon.
2.8.1 RU38486
Wild type mice received a subcutaneous lOmg implant (Cleasby et al. 2003)
containing either vehicle or 5.25mg of RU38486 (manufactured as in 2.7.1) 1 week
prior to sham or coronary artery ligation. 7 days following the coronary procedure
animals were re-anaesthetised echocardiographied and euthanised. Blood was
obtained by intra-cardiac puncture for the measurement of plasma corticosterone and
RU38486, hearts and cutaneous wounds were collected and processed for histology.
79
2.8.2 Mouse Coronary Artery Ligation Surgery
Male C57/B16 wild type and lipHSDl -/ mice, 12-14 weeks old, were used. Mice
were anaesthetised with an intra-peritoneal (i.p.) injection of xylazine (0.018mg/kg),
ketamine (lOOmg/kg), and atropine (600mcg/kg) (Mora et al. 2003). Surgery was
performed as previously described (Lutgens et al. 1999). The thorax was clippered
(Wah cordless trimmer, Harvard Apparatus Ltd, Kent UK) and endotracheal
intubation was performed using a blunted 12 G needle.
Once intubated, mice were ventilated (HSE-Harvard MiniVent, Harvard Apparatus
Ltd, Kent UK) at 120 breaths-a-minute with stroke volume 200pl, breathing oxygen-
enriched air.
Buprenorphine (0.05mg/Kg) was administered subcutaneously and eyes were coated
with Lacrilube ointment. The shaved skin was cleaned with an antiseptic wipe and
under sterile conditions on a heat pad using a microscope at lOx magnification a 1
cm subcutaneous incision was made at the 4th intercostal space anterior axillary line,
extending medially. With blunt dissection subcutaneous tissue was separated from
fascia covering pectoralis transversus, pectoralis profundus and medial fibres of
pectoralis profundus pars abdominalis. The lateral border of pectoralis profundus was
lifted with toothed forceps and blunt-dissected from lateral fibres of pectoralis
profundus pars abdominalis. A 5.0 mersilk suture was used to tie back the lateral
border of pectoralis profundus into a medial position to reveal the medial edge of
pectoralis profundus pars abdominalis that was bluntly dissected from fascia of the
ribs and intercostal muscles. A 5.0 mersilk suture was used to tie back the medial
edge of pectoralis profundus pars abdominalis in a lateral position. In this fashion the
deep fascia covering the ribs and intercostal spaces was revealed. The respiratory
movement of the left lung and the beating heart could be observed at this stage, deep
to the intercostal muscles. The fourth intercostal space was confirmed by observing
the curvature of the medial border of the left lung. Inferior to the 4th intercostal space
the medial border sharply turns to meet the lateral border; superiorly to the 4th inter¬
space the medial border arches laterally. The landmarks were confirmed by locating
an extra-thoracic, emerging branch of the internal thoracic artery parasternally at the
5th intercostal space.
An incision was made in the 4th intercostal muscle. Great care was taken to avoid the
underlying viscera by lifting the 5th rib and making first a puncture with blunt curved
forceps; the forceps were then rotated such that the long axis of their curve was laid
parallel to the intercostal space away from the heart. Sharp scissors cut through the
intercostal muscle in a lateral direction towards the forceps tip.
The magnification was increased at this stage to 16x. A 1cm tissue clamp was
inserted in the 4th intercostal space at the site of the incision. The heart, and medial
border of the left lung were visible. The pericardium was carefully lifted as a straight
edge by two forceps and delicately moved in a lateral direction. A small hole was
made in this sheet near the point of contact with the heart at an area where the
pericardium was thin. The sheet was pulled more laterally to rotate the heart on its
long axis as required to visualise the origin of the left main descending artery
(LMDA). Controlling the illumination and elevating the left atrium using fine
smooth tipped forceps assisted identification of the LMDA. The LMDA was
typically found appearing beneath the left atrium at the atrial notch coursing from a
posterior-lateral direction towards the anterior aspect of the left ventricle; rapid
pulsation of bright red blood was seen in its walls.
A 6.0 proline suture was inserted into the myocardium 2-3mm inferior to the
intersection of LMDA with the left atrial notch. The suture was passed beneath the
artery but not into the ventricular cavity and brought out l-2mm medial to the
insertion site. The suture was tied, the heart rhythm was immediately noted to alter
and the ventricular myocardium seen to pale.
The pericardium was replaced, the clamp removed and the intercostal space sutured
using 5.0 mersilk with discontinuous sutures. The mersilk ties in the borders of
pectoralis profundus and pectoralis profundus pars abdominalis were removed; the
muscle borders were teased into their former positions. Negative pressure was
created with the chest cavity with gentle digital pressure and this held the muscles in
place over the 4lh intercostal space.
The skin was closed with 5.0 mersilk with continuous sutures. On completion of
surgery animals received intraperitoneal atipamazole (AntiSedan, an a-adreno-
receptor antagonist) (5mg/kg). Recovery sufficient for extubation was characterised
by self-breathing movements, whisker twitching and myoclonic jerks. Animals were
transferred to a recovery cage with heating pad, oxygen (delivered by funnel into
which the mouse head was placed) and ad lib saline. The oxygen was removed; the
cage remained on a heat pad for the next 24 hours. Animals post operative care and
analgesia was performed in accordance with Edinburgh University Biological
services surgery guidelines.
At days 1, 3, 5, 7, or 14 animals were anaesthetised i.p. with ketamine, xylazine and
atropine as before, underwent echocardiography and prior to recovery were
euthanised by cervical dislocation. The heart was removed, bisected across the long
axis, weighed, placed in 10% formalin for 24 hours and stored in 70% alcohol.
2.8.3 Quantification of Left ventricular remodeling by echocardiography
Mouse echocardiography was performed using a Diasus ultrasound machine
(Dynamic Imaging Livingston UK) (Mora et al. 2003). A 10-22MHz transducer was
applied parasternally to the shaved chest wall and manoeuvred to obtain 2-
dimensional (2-D) images in a parasternal long-axis view of the left ventricle. Images
were stored on an optical disk and analysed offline using Diasus software (Dynamic
Imaging). Left ventricular (LV) parameters were measured at the mid- papillary level
on live 2-D images and averaged from 2 cardiac cycles. Ventricular septal thickness
was previously noted not to be affected by left descending coronary artery ligation
and thus was not assessed in this study (Lutgens et al. 1999).Other measurements
taken of LV parameters included left ventricular end diastolic diameter (LVEDD),
LV end systolic diameter (LVESD), LV end diastolic area (LVEDA), LV end
systolic area (LVESA), posterior wall thickness at end diastole (PWD) and posterior
wall thickness at end systole (PWS)]. Left ventricular ejection fraction (EF)
([(LVEDA-LVESA)/LVEDA] x 100) and fractional shortening (FS) ([(LVEDD-
LVESD)/LVED] x 100) were used as measures of left ventricular function (Mora et
al. 2003).
2.8.4 Histological quantification of infarct size and angiogenesis
Excised hearts were fixed in 10% formalin, paraffin embedded and sectioned at 8pm
and mounted on positively charged BDH Superfrost glass slides (BDH laboratory
supplies, supplied by VWR International Lutterworth UK). Sections were stained
with haematoxylin and eosin to measure infarct size (Virag & Murry 2003), or Van
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Gieson stain to identify the deposition of collagen or Anti-Von Willebrand factor
antibody (Dakocytomation, UK) to label endothelial cells and quantify angiogenesis.
Vessels were counted (Virag & Murry 2003) at x 400 magnification (Karl Ziess
Axioskop) in the 4 most vascular fields, 2 endocardial 2 epicardial, using a
2 • ...0.0625mm reticule; the borders of the reticule were within the infarct.
2.8.5 Immunohistochemistry
Mounted sections were deparaffinised in xylene 2x5 minutes taken through 2x5
minutes in 100% ethanol to be rehydrated and rinsed in water for 2 minutes.
Rat anti -mouse anti-CD 31 antibodies (Pharmingen) were initially used to identify
endothelial cells. Endogenous peroxidases were quenched by placing deparaffinised,
rehydrated slides in 3% H2O2 in methanol for 20 min. 1:100 and 1:500 primary
antibody concentrations were used with comparisons of incubation times (overnight
or 2 hours), and different antigen retrieval methods. Attempted CD31 antigen
retrieval included using 5 min microwave boiling in TBS buffer or a digest in trypsin
(Sigma) 1 mg/ml in distilled H2O for 45 min at 37°C or a digest in 20pg/ml
proteinase K (Sigma) in TBS for 15 min at 37°C or incubation for 5 minute
microwave boiling in antigen retrieval solution (Dakocytomation) in TBS. A
secondary antibody from a Vector kit (Vectastain Elite ABC kit, Vector, UK) was
used that contained an anti-biotin antibody attached to a horseradish peroxidase
moiety. The secondary antibody was applied at maximum recommended
concentration (lOpg/ml) and incubated at room temperature for 30 minutes. Slides
were washed x2 in TBS and 200j.il of Diaminobenzidine (DAB) (Vector, UK) was
used as the chromogen substrate to visualise the peroxidase. Slides were then
washed, dehydrated with 70 % alcohol for 3 minutes followed by 2x 5 minute soaks
in xylene and coverslip mounted using a permanent mounting media.
These methods did not successfully identify CD-31 antigen staining. For this reason
anti-von Willebrand antibody was used to identify an alternative endothelial antigen.
Antigen retrieval by incubation with trypsin was performed. 50ml of Tris-Buffered
saline (TBS, Dakocytomation, UK) was heated to 37°C (medium heat, 850 Watt
microwave, 20 seconds) 0.5ml was removed. 1 porcine trypsin tablet (Sigma, UK)
was dissolved in 1ml distilled water; 0.5ml was removed and added to the 45ml of
TBS at 37°C. Slides were placed into this solution and incubated for 90 minutes at
37°C. Subsequently slides were mounted in a Sequenza platform and rinsed x2 with
TBS. 200pl of rabbit anti-human von- Willebrand factor (Dakocytomation, UK)
(1:200, diluted in TBS and 1% bovine serum albumin) were added to the coverslip
reservoir of each slide and incubated at room temperature for 2 hours (1:400 primary
antibody dilution was also tried but proved to be unsuccessful). Slides were washed
with TBS x2 and 200pl secondary antibody added to the coverslip reservoir and
incubated for 30 minutes; an EnVision (Dakocytomation, UK) kit was used that
contained a secondary anti-rabbit antibody attached to alkaline phosphatase moiety.
Slides were washed x2 in TBS and removed from the coverslips. 200pl of Fast red
solution (Dakocytomation, UK) that reacts with alkaline phosphatase to produce a
red stain was applied to the slides and incubated for 2-5minutes. Slides were rinsed
in tap water and coverslip mounted using an aqueous medium.
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2.8.6 Plasma Analysis
Plasma for corticosterone was quantified by radio immuno assay as described in
section 2.8.7. Plasma RU38486 was assayed using liquid chromatography mass
spectrometry (LC/MS/MS). 100 uL of alfaxalone (Sigma, UK) at 2pg/ml was added
as internal standard to 0.5 mL of plasma. The solution was acidified with 100 pL of
1M hydrochloric acid; extracted once using 2 mL of ethyl acetate, dried down under
nitrogen and reconsituted in 1 mL of mobile phase. A set of standards was prepared
using analytic standard RU38486 (Sigma, UK) and alfaxalone following the
extraction procedure outlined. Dr Natalie Homer performed the LC/MS/MS
quantification technique on a Thermoelectron TSQ Quantum Discovery with
attached Surveyor HPLC.
Samples were reconstituted in 75pl mobile phase (70:30 methanol: 5 mM
ammonium acetate) and 10 pL were injected onto a CI8 column (BDS Hypersil,
Thermofinnigan, 50 mm, 2.1mm id, 5pm pore size). Analytes were eluted under a
gradient of 70% methanol increasing to 90% over 10 minutes at a flow rate of 300
pL/min at 35°C. Ionisation was achieved by positive ion electrospray, using a spray
voltage of 3000 V, sheath gas pressure of 60 psi, auxiliary gas pressure of 5 psi,
capillary temperature of 300°C, collision pressure of 1.5. MS/MS was performed on
the [M+H]+ ion of alfaxalone (333 m/z) with tube lens voltage of 136 V and a
collision energy of 18 V monitoring for the ion fragment at 297 m/z. Single Reaction
Monitoring of the [M+H]+ ion of RU34846 (430 m/z) gave a dominant product ion at
372 m/z at a collision energy of 18V. Utilising this technique the calibration range of
the assay was 0.5-30ng RU34846.
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2.8.7 11 pHSD Activity
An assay developed for use in tissue homogenates was used to assess 11 pHSD
activity in the heart (Jamieson et al. 1995). As 11 PHSD 1 functions as a reductase
and dehydrogenase in tissue homogenates (Sandeep & Walker 2001), and reductase
and dehydrogenase 11 PHSD are affected by inflammatory cytokines (Cai et al.
2001) both reductase and dehydrogenase activities were assessed. Heart tissue from
C57B16 mice that had undergone coronary artery ligation or sham 7 days previously
and stored at -80°C was thawed on ice placed in 600pl of buffer and homogenized
until liquid. lOpl of homogenate was taken for protein quantification as described
Section 2.4.4.1. Sample protein concentration was used to standardize the amount of
sample added to the assay. Sufficient sample was added to Modified buffer C (for
reductase) or Buffer C (for dehydrogenase) to produce a working solution containing
0.2mg/ml of protein. A reductase reaction was established by adding 10ml of 3H-
11 dehydrocorticosterone to 50ml of cofactor NADPH (2nM) and 190pl of
sample/Modified buffer C mixture. Conversely a dehydrogenase reaction was
established by adding 10ml of H-Corticosterone to 50ml of cofactor NAD (2nM)
and 190pl of sample/ buffer C mixture.
Samples were incubated in a water bath at 37°C for 2.5 or 5 hours for the reductase
reaction and 5 or 24 hours for the dehydrogenase response. The reactions were
terminated by placing the samples on ice. Steroids were extracted with ethyl acetate
dried, resuspended in ethanol, separated by TLC and estimated by scintillation
counting. Enzyme activity in each direction was expressed as the percent conversion
to product (Jamieson et al. 1995).
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2.8.8 Infarct size measurement
The area of left ventricle affected by infarction was determined as a percentage of
left ventricular wall area (Lutgens et al. 1999) and measured at direct light
microscopy; images were captured using Research Systems Photometric camera and
analysed using in-house scripts.
2.9 Cutaneous Wound Healing
Thoracotomy wounds from mice undergoing chronic coronary ligation that had been
sutured with 5.0 mersilk (Ethicon, Johnson & Johnson, UK) using a 1mm round-
bodied needle were used in these studies. At sacrifice 7 days following chronic
coronary ligation the thoracotomy cutaneous wounds were removed by wide
excision, placed in 10%formalin and processed for histology. Paraffin embedded
skin was sectioned (8pm) and stained with haematoxylin and eosin for
morphological analysis or with an endothelial cell marker to quantify angiogenesis.
2.10 Statistics
Data are mean ± SEM. Comparisons were made by ANOVA with least squares
difference post hoc tests. Inter-assay- and intra-assay coefficients of variation in wild
type mice were 17 % (n=32) and 22 % (n=18), respectively for vessel number in
aortic rings after 7 days in culture; 12 % (n= 6) and 12 % (n= 6) for vessel density in
sponge implants; 7 % (n=6) and 25% (n=6) in day 7 infarcts and 7% (n=4) and 12%
(n=4) for day 7 wounds.
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Chapter 3





Despite extensive literature indicating that glucocorticoids inhibit angiogenesis in
vitro, (Nicosia & Ottinetti 1990) in vivo (Hori et al. 1996) and clinically (Hasan et al.
2000) the mechanism for these effects are not understood. In addition the potential of
vessel wall lipHSDs to modulate the angiostatic effects of glucocorticoids has not
been considered.
Until now therapeutic concentrations of glucocorticoids have been used in
angiogenesis assays with a view to using steroids as anti-angiogenesis therapy
(Folkman et al. 1983). Criticisms of this work concern the concentrations or type of
glucocorticoid used and that mechanistic in vitro studies are qualitative not
quantitative (Folkman & Ingber 1987; Illanes et al. 2002; Hori et al. 1996; Crum et
al. 1985). No previous studies have examined the effects of endogenous
glucocorticoids to modulate angiogenesis despite reports of impaired wound healing
in conditions of chronically elevated endogenous glucocorticoids (Gordon et al.
1994) and reduced vascularity in glucocorticoid producing adrenal cortex adenomas
in comparison to normal adrenal cortex (Bernini et al. 2002).
Angiostatic effects of high concentrations of glucocorticoid have been observed in
rat aortic ring assays of angiogenesis (Nicosia & Ottinetti 1990). This model is
unique as an in vitro assay for it contains all the cellular elements of the vessel wall,
and provides a model that incorporates cell proliferation, migration, tube formation
and tube luminisation (Nicosia & Ottinetti 1990). The model is recognised to be a
useful in vitro representation of the in vivo process because of the representation of
all these different facets of angiogenesis (Staton et al. 2004; Auerbach et al. 2003).
New vessel formation in the aortic ring assay is not influenced by systemic
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inflammation and therefore presents an opportunity to investigate the angiostatic
effects of glucocorticoids without systemic inflammatory involvement. As a mouse
model the assay provides an opportunity to investigate the influence of gene
deletions on angiogenesis. The effects of lipHSDl on angiogenesis can thus be
examined using aortae from transgenic lipFISDl null mice. Previously it has been
difficult to study the vascular effects of lipHSDl as there are no available selective
inhibitors of this isozyme (Hadoke et al. 2001) and the available non-selective
inhibitor carbenoxolone is toxic to endothelial cells (Ullian et al. 1996).
In vitro assays to examine the molecular mechanisms of glucocorticoid-induced
angiostasis have used therapeutic concentrations and generally have been
observational studies (Ingber et al. 1986; Sakamoto et al. 1987; Cariou et al. 1988).
No study has examined the effect of endogenous concentrations of glucocorticoids
on key angiogenesis factors for instance endothelial cells or VEGF. Endothelial cells
are central to new vessel formation, are relatively straightforward to culture and
exhibit readily measurable intracellular calcium transients in response to VEGF
stimulation (Cunningham et al. 1999). Inhibition of VEGF provoked calcium
responses in endothelial cells impaired cell proliferation and migration (Cunningham
et al. 1999; McLaughlin & De Vries 2001). Furthermore several endogenous
inhibitors of angiogenesis use this mechanism of action (Jiang et al. 2001). No
previous study has considered the effects of endogenous glucocorticoids on
endothelial cell calcium responses to VEGF.
Therefore the aims of this study were to establish 2 assays to investigate the effects
of glucocorticoids on angiogenesis. An in vitro model of angiogenesis using mouse
aortic ring cultures was established to examine the influence of endogenous
glucocorticoids to modulate angiogenesis. In addition this model was used to
investigate the effects of vessel wall lipHSDl to determine the influence of
glucocorticoids on new vessel formation. A further assay was developed to begin to
explore the mechanisms of glucocorticoid and lipHSDl influence on angiogenesis
by examining endothelial cell responses to VEGF.
3.2 Methods
3.2.1 Development of an angiogenesis assay using mouse aortic rings
To obtain an in vitro model in which to investigate the influence of glucocorticoids
on angiogenesis, extensive methodological development was undertaken. The mouse
aortic ring assay was selected to be developed because this model is acknowledged to
incorporate most of the components of in vivo angiogenesis including cell
proliferation, migration and tube formation (Auerbach et al. 2003). This model is not
technically demanding in terms of tissue preparation, is easy to use to investigate
putative angiogenic compounds, lends itself to be used in transgenic models and
allows monitoring and quantification of growth. The intention through assay
refinement was to produce an aortic ring angiogenesis in vitro assay that provided
sufficient quantifiable growth in a short space of time that would allow the study of
inhibitors of new vessel formation. It was important in establishing the assay to
select media and supporting matrix conditions to promote growth without the use of
excessive exogenous growth factors that might mask the influence of angiostatic
compounds. In addition, because of the subject of this thesis it was important to
determine the direction of 11PHSD activity in intact aortic rings in culture.
Using modifications of protocols from rat (Nicosia & Ottinetti 1990) and mouse
(Rohan et al. 2000) angiogenesis models, several different incubation conditions,
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time courses and methods of quantification were tested before a satisfactory
experimental protocol was established. These are outlined in the following section.
3.2.1.1 Aortic ring preparation (See section 2.4.)
In these studies 10-12 weeks old C57B16 and homozygous null 11|3-HSD 1 (bred to
be congenic) male mice were used. Animals were killed by schedule 1 methods and
thoracic aortae were removed, washed in serum free MCDB 131 medium
(Invitrogen, UK), cleaned of periadventitial tissue and divided into 1 -3 mm rings.
3.2.1.2 Culture medium
Aortic rings were incubated in MCDB-131 a specially formulated endothelial cell
medium developed for endothelial cell growth in a low serum environment (Knedler
& Ham 1987). Previously this medium had been used in conjunction with the EGM-
2 Bullet kit of growth factors (Clonectics Biowhittaker, UK) to promote endothelial
cell growth (Rohan et al. 2000). Whilst accurate concentrations of factors with the
EGM-2 kit are unavailable from the company because of patent constraints, details
regarding the final concentration range of most of the growth factors have been
obtained (Table 3.1).
Preliminary experiments established the optimum medium for angiogenesis and
defined the standard media conditions to be used in subsequent experiments this
comprised: modified MCDB-131 supplemented with EGM-2 aliquots ascorbic acid,
heparin and GA1000 as described in section 2.4. Under these conditions sufficient
angiogenesis occurred to allow accurate quantification and investigation of the
angiostatic effects of glucocorticoids.
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Growth Factor EGM-2 Bullet Kit
Concentration range
Retained in standard culture conditions
Heparin l-5pg/ml YES
Ascorbic acid 1 lOOmg/ml YES
GA1000 Not disclosed YES
IGF-1 5-50ng/ml Not retained
VEGF l-5p,g/ml Not retained
hFGF 5-20ng/ml Not retained
hEGF 5-10ng/ml Not retained
Hydrocortisone Not disclosed Not retained
FBS Not disclosed Not retained
Table 3.1 Contents of EGM-2 Bullet Kit
Bio-Whittaker UK supplied the concentrations of bullet kit components under patent
constraints. Heparin, ascorbic acid and GA 1000 were retained to supplement MCDB-131
standard culture conditions. IGF-1 human recombinant insulin like growth factor-1, VEGF
vascular endothelial growth factor, hFGF human fibroblast growth factor, hEGF human
epidermal growth factor, FBS fetal bovine serum.
3.2.1.3 Embedding Matrix
Matrigel a commercially available collagen matrix was used to support angiogenic
growth from the aortic rings. Matrigel is produced in a standard formulation,
(Matrigel) and in a growth factor reduced (GFR-Matrigel) form (Table 3.2). Both
preparations are steroid free as a consequence of a dialysis step in their purification
processes (Communication from Bio-Whittaker). In preliminary experiments a
comparison was made of the angiogenic response of aortic rings embedded in
Matrigel versus GFR-Matrigel. As a result of these experiments standard Matrigel
was used in subsequent investigations.
Aortic rings embedded in Matrigel and incubated in standard media conditions
developed numerous outgrowths resembling vessels. The outgrowths first appeared
from the second day in culture and continued to develop at an exponential rate over
the first week. Media was changed every 48 hours, and experiments were performed
in triplicate.
3.2.1.4 Characterisation of Aortic ring outgrowths
The endothelial nature of outgrowths was determined by Dil fluorescently labelled
acetylated low-density lipoprotein (Dil-Ac-LDL) (Biomedical technologies, USA) as
detailed in Section 2.5.4. Initially 50j.il of the stock 200jag/l Dil-Ac-LDL was
incubated with a sample aortic ring in 1ml of medium for 4 hours according to
manufacturers instructions. A second protocol extending the incubation time to 48
hours was used to optimise cellular up-take of fluorescent probe.
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Range of Typical
concentration Average growth factor concentration
Growth in Matrigel concentration in Matrigel in GFR Matrigel
factor matrix matrix matrix
EGF 0.5-1.3ng/ml 0.7ng/ml <0.5ng/ml
bFGF <0.1-0.2pg/ml n.a. n.d.
NGF <0.2ng/ml n.a. <0.2ng/ml
PDGF 5-48pg/ml 12pg/ml <5pg/ml
IGF-1 11 -24ng/ml 16ng/ml 5ng/ml
TGF-P 1,7-4.7ng/ml 2.3ng/ml 1.7ng/ml
Table 3.2 Amounts of growth factors present in Matrigel versus Growth factor
reduced Matrigel (GFR-Matrigel)
The values are supplied by manufacturer on the product information details. EGF epidermal
growth factor, bFGF basic fibroblast growth factor, NGF nerve growth factor, PDGF platelet
derived growth factor, IGF-1 insulin like growth factor-1, TGF-p Transforming growth factor
beta.
n.a.-not applicable, n.d.- not determined.
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3.2.1.5 Quantification and time course of angiogenesis
Quantification of growth was performed with direct light microscopy and by image
analysis (For imaging details see section 2.4.5). At light microscopy (x50) new
vessels were counted using the methodology described by Nicosia et al (Rohan et al.
2000). In addition to this established method a variety of assessments were used to
determine whether the accuracy and consistency of quantification could be improved.
Additional assessments of angiogenesis were performed using computer-assisted
analysis of photographed aortic ring cultures. Images were captured from a live feed
camera and assessed using The Microcomputer Imaging Device (MCID) (Imaging
Research Inc, Canada). MCID measured area of growth, maximum and average
diameter of growth and vessel density. The vessel density measurement was derived
using computer analysis of pixel density (vessels can be distinguished from
background using colour adaptation and the number of colour pixels divided by the
area of growth).
New vessel counting by direct light microscopy (x50) was used to assess the time
course of the angiogenic response. New vessels were seen from days 2-3 in culture.
The rate of new vessel growth achieved a plateau at day 7 and in subsequent
experiments angiogenesis was measured at this time point.
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3.2.2 Influence of glucocorticoids on angiogenesis in the aortic ring assay
Prior to embarking on investigations to explore the influence of glucocorticoids as
putative inhibitors of angiogenesis, the model was used to examine the effects of
recognised angiogenesis inhibitors under these conditions.
3.2.2.1 Nitric Oxide and prostanoid influence on angiogenesis in vitro
Studies were performed to examine the angiogenic influence of endothelial
mediators nitric oxide and prostanoids by incubating aortic rings from C57B16 mice
in the presence or absence of the nitric oxide synthase inhibitor A^-nitro-L-arginine;
(LNNA) (10"4M) (Alderton et al. 2001) or the cyclo-oxygenase inhibitor
indomethacin (10°M) (Leyssac et al. 1975) in standard incubation conditions.
3.2.2.2 Influence of glucocorticoids on angiogenesis in vitro
Aortic rings from C57B16 and homozygous null 11(3-HSD 1 mice were obtained as
described in section 2.1.2. The angiostatic effect of physiologically relevant
concentrations of glucocorticoids was examined by incubating aortic rings under
standard conditions in the presence and absence of corticosterone (3nM, 30nM,
300nM, 600nM) and 11 dehydrocorticosterone (300nM, 600nM). As steroids had
been dissolved initially in ethanol and then diluted into aqueous solutions, vehicle
control conditions were established that contained equivalent aqueous dilutions of
ethanol. Vehicle or steroid was added to the culture medium at the start of the
experiments and media replaced every 48 hours. Experiments were performed in
triplicate; paired concomitant controls were performed for each set of conditions.
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3.2.2.3 Identification of the receptor responsible for glucocorticoid-induced
angiostasis
Aortic rings from C57B16 mice were incubated in standard conditions in the presence
of the endogenous mineralocorticoid aldosterone (10~8M) or the mineralocorticoid
receptor antagonist spironolactone (10"5and 10~6M) or the glucocorticoid receptor
antagonist, RU38486 (10"6M) or vehicle.
3.2.2.4 Influence of 11 pHSD-1 on the angiostatic effect of glucocorticoids
A dual approach of pharmacological inhibition and transgenic deletion was adopted
to investigate whether 11 pHSD-1 in the aortic wall influenced the effects of
glucocorticoids to modulate angiogenesis. Both pharmacological inhibition of
1 l(3HSDs with carbenoxolone and 11 PHSD-1 transgenic deletion were used.
Pharmacological inhibition of llfHSDs- Aortic rings from C57B16 mice were
incubated in standard conditions with corticosterone (600nM) or
I ldehydrocorticosterone (600nM) in the presence of the non-selective lipHSD
inhibitor carbenoxolone (CBX; 10"4andl0"6M) or vehicle.
Transgenic deletion of 11J3HSD1 - Aortic rings from C57B16 and homozygous null
lipHSDl (-/-) mice were incubated with corticosterone (600nM) or
II dehydrocorticosterone (600nM) using standard conditions.
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3.2.3 11 pHSD activity assay in intact aortic rings
To determine the direction of 1 tpHSD activity in intact aortic rings in vitro a method
(Souness et al. 2002) was adapted by Dr Anna Dover and Mrs Eileen Miller.
Aortic rings were collected as described previously in section 2.4. and cultured for
24 hours in DMEM-F12 medium (Invitrogen, UK) supplemented with fetal bovine
serum (1%), streptomycin (lOOpg/ml), penicillin (lOOunits/ml) and amphotericin
(0.25pg/ml) and lipiTSD activity was established by the conversion of El-steroid.
1 ip-Reductase activity was determined by adding lOpmol [3H4]-11 -
dehydrocorticosterone. Mouse liver and medium alone were used as controls. 11 P~
Dehydrogenase activity was determined by adding lOpmol l,2,6,7-[ H4]-
corticosterone. Mouse kidney slices and medium alone served as positive and
negative controls.
After incubation, steroids were extracted from media; [ EEJ-Corticosterone and
[3H4]-11 -dehydrocorticosterone were separated by EIPLC and quantified by on-line
liquid scintillation counting (Walker et al. 1991). Enzyme activity was expressed as
conversion after subtraction of apparent conversion in negative control wells.
3.2.4 The influence of glucocorticoids on calcium signaling in endothelial
cells
A possible mechanism for glucocorticoid-induced inhibition of angiogenesis was
investigated by assessing the intracellular calcium response to VEGF in the presence
of glucocorticoids or vehicle. Please refer to section 2.6.
too
3.2.4.1 Human Umbilical Vein Endothelial cell culture
Confluent monolayers of endothelial cells at passage 4 on fibronectin coated glass
coverslips (a gift from Miss Catherine Shaw) were incubated in serum free
conditions. Cells were loaded with Fura-2AM (5pM) and incubated with vehicle or
Cortisol (16pM, 600nM) for 6 hours and placed on the stage of an inverted
fluorescence microscope. For each experiment baseline fluorescence was established
followed by the addition of lOng/ml (Faehling et al. 2002) human recombinant
VEGFa,65 (Sigma, UK). Data were acquired for 15 minutes for preliminary
experiments (Faehling et al. 2002); in later work this was reduced to 8 minutes to
reflect the time scale of the response.
The ratio of intensities obtained from 340/380 excitation pairs was used as a measure
of [Ca2+]i (Grynkiewicz et al. 1985). Calibration of the [Ca2+]i was performed by
9+
monitoring the change in fluorescence at minimal and maximal [Ca ]i responses as
detailed in section 2.6.2.
3.2.5 Statistics
Data are mean ± SEM. "n" refers to the number of different mice, where possible all
measurements of angiogenesis in vitro were made in triplicate. Comparisons were
made by ANOVA with least squares difference post hoc tests. Inter-assay- and intra-
assay coefficients of variation were 17 % (n=32) and 22 % (n=18), respectively for
vessel number in aortic rings after 7 days in culture.
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3.3 Results
3.3.1 Development of an angiogenesis assay using mouse aortic rings
Culture Medium- Initial experiments indicated that incubation of embedded aortic
rings in culture medium alone without EGM-2 bullet kit did not promote sufficient
spontaneous angiogenesis to measure the effect of an angiostatic compound (data not
shown).
Further experiments were performed using the bullet kit and comparing angiogenesis
in the presence or absence of FBS. This work indicated that FBS inclusion produced
excessive growth that could not be quantified beyond 3 days of incubation. Owing to
the inability to quantify angiogenesis under these conditions this particular series of
incubations was discontinued after two experiments. In the absence of FBS a
vigorous angiogenic response was observed that could be quantified however in
these conditions physiologically relevant concentrations of glucocorticoids did not
influence angiogenesis (Figure 3.1). Further method refinement investigated the
effects of glucocorticoid on angiogenesis in the presence of heparin, ascorbic acid
and GA1000 without VEGF, IGF-1, hEGF and hFGF. Under these conditions growth
of new vessels was quantifiable and sufficient, 100-150 new vessels were counted
after 7 days in culture (Figure 3.4). In addition in the presence of glucocorticoids
(300nM) angiogenesis was impaired. Therefore these conditions were adopted as
standard incubating media in all further studies (see Table 3.1).
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Time (Days)
-Q- Vehicle 300nM Corticosterone
Figure 3.1 Angiogenesis in mouse aortic rings: the influence of glucocorticoids in
the presence of exogenous growth factors
C57BI6 aortic rings incubated in MCDB131 (supplemented with EGM-2 bullet kit excluding
hydrocortisone and FBS) in the presence (solid circle) or absence (open squares) of
corticosterone. Angiogenesis was quantified as the number of vessels. Data represent mean




Initial observations using standard Matrigel had raised concerns regarding the
prolific nature of the angiogenic response compared with previous studies (Rohan et
al. 2000; Nicosia & Ottinetti 1990). Similar vigorous angiogenic responses were seen
with either standard or GFR Matrigel matrix, (data not shown). In light of initial
results with standard Matrigel, and practical difficulties with obtaining GFR
Matrigel, standard Matrigel was used throughout.
3.3.1.2 Characterisation of Aortic ring outgrowths
Using the manufacturers recommended incubation time of 4 hours Dil-Ac-LDL did
not label aortic ring outgrowths. Extension of the incubation time to 48hours resulted
in fluorescent probe uptake by both cells within the aortic ring and by vascular
outgrowths (Figure 3.2)
3.3.1.3 Assay variability
Inter-assay coefficients of variation for vessel counts on day 7 in control aortic rings
was measured by calculating the mean, standard deviation and SEM for all controls
(n=32) and using these figure performing the function (SEM/standard
deviation)* 100. The inter-assay variation was calculated to be 17 % (n=32 mice).
Intra-assay variation for vessel counts on day 7 in control aortic rings was assessed
by calculating the co-efficient of variation of experiments using the same animal but
performed on different culture plates (n=18 mice). The mean of these values was
taken as the intra-assay variation and calculated as 22 % (n=18).
Figure 3.2 Characterisation of aortic ring outgrowth by uptake of Dil-Ac-LDL
shown by fluorescence microscopy
C57BI6 aortic ring incubated for 7 days in standard conditions in the absence of
glucocorticoids (a) low power (x50) magnification (white scale bar is 0.2 mm) demonstrating
aortic ring explant (thick white arrows) with labelled endothelial cells (black arrows) and out
growths similarly with labelled endothelial cells (thin white arrows) (b) Aortic ring outgrowth
at high magnification (x100) thin white arrows indicate endothelial cells, aortic ring explant
can also be seen (thick white arrow) (white scale bar is 0.02mm).
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3.3.1.4 Quantification and time-course of angiogenesis
Under standard incubation conditions (see section 2.1) wild type aortic rings
sprouted new vessels from days 2-3. Subsequently new vessel growth occurred
exponentially from day 3 to day 7 then reached a plateau (Figure 3.3). Although the
longevity of new vessel survival was not formally tested, on one occasion vessels
were kept for 23 days without deterioration.
Methods for the quantification of angiogenesis were assessed with regard to their
reliability, reproducibility and consistency. Computer generated measurement of
vessel density proved to be an unreliable and inconsistent method of measurement
and was discontinued. Quantification of angiogenesis by total growth area, average
diameter or maximum diameter was comparable to quantification by vessel counting
as assessed by measuring the angiogenesis response in the presence of
glucocorticoid. All 4 methods detected similar patterns of new vessel growth; all
detected inhibition of angiogenesis by glucocorticoids and the degree of inhibition
was comparable across all parameters (Figure 3.4 a-d). Vessel counting was
technically less demanding, required only the use of light microscopy, was reliable
and the most widely used parameter of angiogenesis in the literature (Rohan et al.
2000; Nicosia & Ottinetti 1990) therefore subsequent quantification of angiogenesis
was performed by this method.
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Time (Days)
Figure 3.3 Time course of angiogenesis.
Results from C57BI6 aortic rings incubated with vehicle in standard conditions. Preliminary
experiments found new vessels present from day 2-3 in culture; growth occurred




Figure 3.4 (a-b) Comparison of quantification methods using the angiostatic
effects of glucocorticoids
Wild type aortic rings incubated in standard conditions in the presence of vehicle (open
circles), corticosterone (300nM) (solid triangles). Glucocorticoids inhibited angiogenesis
consistently using 4 methods of quantification: (a) number of vessels, (b) total area of new


































d) Maximum diameter of growth (mm)
0.00-
n =4-6 **p<0.01
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Time (days)
Figure 3.4(c-d) Comparison of quantification methods using the angiostatic
effects of glucocorticoids (continued)
Wild type aortic rings incubated in standard conditions in the presence of vehicle (open
circles), corticosterone (300nM) (solid triangles). Glucocorticoids inhibited angiogenesis
consistently using 4 methods of quantification: (c) average and (d) maximum diameters of
total growth. Data are expressed as means ± SEM. **p< 0.01, n=4-6.
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3.3.2 Influence of glucocorticoids on angiogenesis in the aortic ring assay
3.3.2.1 Nitric Oxide and prostanoid influence on angiogenesis in vitro
Following 7 days in culture angiogenesis was impaired in aortic rings incubated with
L-NNA (107.4 ± 4.5 vessels) but not in those incubated with indomethacin (157.1 ±
14.3 vessels) compared to vehicle (153.2 ± 17.0 vessels; n=6; p<0.03) (Figure 3.5).
3.3.2.2 Influence of glucocorticoids on angiogenesis in vitro
Incubation of aortic rings in the presence of glucocorticoids at concentrations across
the physiological range (30-600nM) inhibited angiogenesis (Figure 3.6). A threshold
for this response was found to be ~ 3nM corticosterone. At similar concentrations
(300-600nM) the inert 11-keto compound 1 ldehydrocorticosterone, a substrate for
1 lpFlSD-1 also impaired angiogenesis (Figure 3.6).
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Time in Culture (Days)
-O Vehicle LNNA (10"4M) * Indomethacin (10"5M)
Figure 3.5 Nitric Oxide and prostanoid influence on angiogenesis in vitro
Angiogenic responses in aortic rings from wild type mice incubated in the presence of
vehicle (open square) or LNNA (10"4M) (solid diamonds) or indomethacin (10"5M) (line
crosses). In comparison to vehicle treated aortic rings angiogenesis was inhibited by the
presence of LNNA but was not influenced by indomethacin (* p<0.03 vs vehicle Comparison
was by repeated measures ANOVA). Data points are mean ± SEM (n=6).
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Vehicle 3nM 30nM 300nM 600nM 300nM 600nM
Corticosterone Udehydro-
corticosterone
Figure 3.6 Influence of physiologically-relevant concentrations of
glucocorticoids on angiogenesis
(a) Aortic ring incubated for 7 days without glucocorticoid, (b) Aortic ring incubated for 7 days
in the presence of corticosterone (600nM) (white scale bar is 0.2 mm). Thick white arrows
indicate the aortic ring; thin white arrows indicate new vessels, (c) Aortic rings from C57BI6
mice incubated in the presence of glucocorticoids. Corticosterone or
11dehydrocorticosterone inhibited angiogenesis. A threshold for the influence of
corticosterone was 3nM. Data are expressed as mean ± SEM #p< 0.01.
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3.3.2.3 Receptor dependency for glucocorticoid induced angiostasis
The glucocorticoid receptor antagonist RU38486 did not influence angiogenesis in
comparison to vehicle but eliminated the angiostatic effects of both corticosterone
and 11-dehydrocorticosterone (Figure 3.7).
High concentrations of mineralocorticoid antagonist spironolactone (10oM) (66.4 ±
24.7 vessels) impaired angiogenesis in comparison to vehicle (185.6 ± 17.8 vessels)
(n=6, p<0.001). At a lower concentration (10"6M) angiogenesis was not affected by
spironolactone and this concentration did not alter the angiostatic effects of
corticosterone or 11-dehydrocorticosterone (Figure 3.7). In addition aldosterone (10"



























Figure 3.7 Glucocorticoid-induced angiostasis is GR dependent
Angiogenic responses of aortic rings from C57BI6 mice (a) Incubated with (filled columns) or
without (open columns) RU38486 (10~6 M) and glucocorticoids (600 nM). Results are mean ±
SEM for n=4-6 experiments. # p<0.01 versus corresponding vehicle. RU38486 alone had no
effect, (b) Incubated with (filled columns) and without (open columns) spironolactone (1pM)
and glucocorticoids (600nM). Spironolactone had neither an effect on angiogenesis in
comparison to vehicle nor on the influence of glucocorticoids. Results are mean ± SEM for
n=6 experiments. #p<0.02 versus corresponding vehicle.
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3.3.2.4 Influence of 11 pHSD-1 on the angiostatic effect of glucocorticoids
Pharmacological inhibition of 11flHSDs- The non-selective 11 (IIISD inhibitor
carbenoxolone at high concentration (10"4M) abolished all growth in aortic ring
cultures (data not shown). At a lower concentration (10"6M) carbenoxolone did not
inhibit angiogenesis and did not influence the angiostatic effects of corticosterone
(600nM). In contrast this concentration of carbenoxolone attenuated the angiostatic
effect of 11 dehydrocorticosterone (600nM) (Figure 3.8a).
Transgenic deletion of 11 fillISD I - Angiogenesis was similar in vehicle-treated
control aortic rings from C57B16 compared to lipHSDl -/- mice. As before
corticosterone and 11 dehydrocorticosterone inhibited angiogenesis in wild type
aortic rings. In contrast 1 lpilSDl transgenic deletion abolished the angiostatic effect




































Figure 3.8 (a-b) Influence of 11(3HSD-1 on angiogenesis
a) Effect of glucocorticoids (600nM) on angiogenesis in aortic rings from C57BI6 mice with
(filled columns) and without (open columns) carbenoxolone (10"6 M). Data are mean ± SEM.
n=5 #p<0.01 versus corresponding vehicle. *p<0.04 for the effect of carbenoxolone in the
presence of 11-dehydrocorticosterone. Carbenoxolone had no effect in the presence of
corticosterone or vehicle alone.
b) Aortic rings from wild type (open columns) or 11 (3HSD1 -/- (filled columns) mice with and
without glucocorticoids (600nM). Data are mean ± SEM n=7 #p<0.01 versus corresponding
vehicle. **p<0.01 for differences in angiogenesis between wild type and 11PHSD1 -/- mice.
Angiogenesis was not difference between strains in the presence of vehicle or corticosterone
but was inhibited by 11dehydrocorticosterone in C57BI6 but not 11|3HSD1 -/- mice.
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3.3.3 11 pHSD activity in aortic rings in vitro
• • • T
Reductase activity was demonstrated by the conversion of l,2,6,7-[ H4]-11-
Dehydrocorticosterone to [ Fl4]-Corticosterone; dehydrogenase activity was
"2 T
demonstrated by the conversion of l,2,6,7-[ H4]-Corticosterone to [H4]-ll-
Dehydrocorticosterone in intact aortic rings and control tissues. Both lipHSD
reductase and dehydrogenase activities were present in intact aortic rings. Results are


























Figure 3.9 11BHSD enzyme activities in aortic rings from wild type mice
Rings were incubated with [3H4]-corticosterone (dehydrogenase) (solid bars) or [3H4]-11-
dehydrocorticosterone (reductase) (open bars) and conversion to the relevant product
measured after 24 hours. Dehydrogenase and reductase activities were detected in aortic
rings (*p<0.04 vs negative control (=zero by definition), #p<0.01). Aortic ring dehydrogenase
and reductase activities were not significantly different from equivalent wet weights of kidney
or liver, respectively. Results are mean ± SEM (n=4-6).
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3.3.4 Glucocorticoid inhibition of endothelial cell signaling in vitro
This work was performed as a pilot study to gain an insight into the mechanisms for
glucocorticoid induced angiostasis. Consequently the following data represent
preliminary findings (n=2-3). To demonstrate the degree of variability in the data
intracellular calcium concentrations are presented as the mean ± SEM from
individual cells. Results were obtained for 10-15 cells per preparation n=2-3.
Therefore data are mean ± SEM for 20-30 values.
3.3.4.1 VEGF induced calcium transients in endothelial cells
VEGFAi65 (lOng/ml) stimulated a transient biphasic intracellular calcium response in
HUVECs. The biphasic response was characterised by an initial sharp peak followed
by a second sustained rise (Figure 3.10a) as previously described (Faehling et al.
2002b). The time to initial peak was 48.8 ±1.9 seconds and the duration of the
response was 4.67 ±0.16 minutes.
3.3.4.2 Influence of glucocorticoids on HUVEC intracellular calcium
responses to VEGF
Pharmacological concentrations of glucocorticoids- In the presence of
pharmacological concentrations of Cortisol (16pM) a biphasic response was not
observed. The secondary sustained rise seen in the presence of vehicle was abolished
in 86% of cells incubated with Cortisol (Figure 3.10b). Quantification of intracellular
calcium responses from 20-30 cells on 3 coverslips (analysed by repeated measures
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ANOVA) indicated that Cortisol (16pM) reduced the intracellular calcium response
to VEGF (p<0.001) (figure 3.11). d otal change in intracellular calcium (area under
the curve) was reduced by Cortisol (A Ca2+ 224 ± 45 nM minutes) in comparison to
vehicle (A Ca2+ 586 ± 64 nM minutes; p<0.01).
Physiologically relevant concentrations ofglucocorticoids-ln comparison to vehicle
Cortisol (600nM) did not alter the character of the VEGF Ai65 (lOng/ml) stimulated
biphasic intracellular calcium response in HUVECS but did reduce the amplitude
(Figure 3.13). Quantification of intracellular calcium responses from 20-30 cells on
2-3 coverslips (analysed by repeated measures ANOVA) indicated that Cortisol
reduced the intracellular calcium response (p<0.01) (Figure 3.12). Total change in
intracellular calcium (area under the curve) was also reduced by physiologically
94-
relevant concentrations of glucocorticoids (A Ca was 586 ± 64 nM minutes for
vehicle and A Ca2+ 396 ± 44 nM minutes for Cortisol (600nM) n=2-3 coverslips,
p<0.03).
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Figure 3.10 Effects of VEGF on HUVEC intracellular calcium transients
Representative traces of the intracellular calcium transients in HUVECs stimulated by
VEGFA165 (10ng/ml) in a) the presence of vehicle b) In the presence of Cortisol 16 pM. The
black arrow indicates moment of VEGF administration. Each graph represents traces from
10-15 cells on a single coverslip. A biphasic response was observed in vehicle treated cells,










Figure 3.11 Influence of glucocorticoids on HUVEC intracellular calcium
responses to VEGF
Intracellular calcium responses in HUVECs to VEGF stimulation in the presence (solid line)
or absence (dashed line) of Cortisol (16pM). High concentrations of Cortisol (16pM) impaired
the intracellular calcium response to VEGF stimulation in comparison to vehicle (Data are
mean ± SEM intracellular calcium response traces from 20-30 cells on 3 coverslips n=3,
*p<0.001 by repeated measures ANOVA).
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0.8 a) Single cell intracellular calcium transients in
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Figure 3.12 Endothelial cell intracellular calcium responses in the presence of
physiological concentrations of Cortisol (600nm)
(a) Representative traces of the intracellular calcium transients in HUVECs stimulated by
VEGFAi65 (10ng/ml) in the presence of Cortisol (600nM). The graph represents traces from 4
cells on a single cover slip. A reduced amplitude biphasic response was observed, (b)
Intracellular calcium responses to VEGF in the presence (solid line) or absence (dashed line)
of Cortisol (600nM). Cortisol reduced VEGF induced intracellular calcium transients (Data are
mean ± s.e.m from 20-30 cells on 2-3 coverslips, *p<0.01 by repeated measures ANOVA).
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3.4 Discussion
in this chapter through the development of an in vitro angiogenesis assay using
mouse aortic rings it was determined that physiologically relevant concentrations of
glucocorticoids inhibit angiogenesis in a glucocorticoid receptor dependent manner.
Furthermore local metabolism of glucocorticoids by 11 (3HSD1 was demonstrated in
the vessel wall using intact aortic rings and 11 dehydrocorticosterone, a substrate for
11(3HSD1 which does not activate corticosteroid receptors, also impaired
angiogenesis in a glucocorticoid receptor dependent manner but only in the presence
of lipHSDl. Therefore lipHSDl, through the regeneration of active
glucocorticoids, was found to amplify the angiostatic effects of steroids in vitro.
3.4.1 Adaptation of the mouse aortic ring assay
From the available in vitro angiogenesis assays the mouse aortic ring model was
selected for it combines many of the components of angiogenesis that are represented
individually in other cell culture models. Thus the mouse aortic ring model includes
elements of cell proliferation and migration; tube formation, branching, remodelling
and luminisation. Reviewers have acknowledged the value of incorporating all these
facets of angiogenesis into a single assay and recognised that the aortic ring in vitro
assay most closely resembles in vivo physiology (Auerbach et al. 2003; Staton et al.
2004). Importantly for this thesis the model could also be used with rodent tissues
and thus enable the use of genetically modified mouse aortae for example from
1 lpHSDl-/- mice. Glucocorticoids had not been used in conjunction with the model
in mice but had been applied to rat aortic rings in a collagen-based matrix (Nicosia &
Ottinetti 1990) and under these conditions hydrocortisone 1 pg/ml was angiostatic.
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A recognised disadvantage of the model is that nascent new vessels are generated
from the aorta, a large conduit artery (Staton et al. 2004) whereas in vivo
angiogenesis occurs through vascular remodelling at a microvascular level (Conway
et al. 2001). How the large artery vessel wall gives rise to capillary outgrowths has
also been questioned (Nicosia et al. 1992) and whether the outgrowths derive from
luminal endothelial cells, adapted mural-periendothelial cells or from vasovasorum is
unclear (Akita et al. 1997). It would appear that a degree of cellular
transdifferentiation or un-differentiation is required for promoting new vessel growth
from aortic ring explants (Akita et al. 1997; Nicosia et al. 1992). Human embryonic
aortae contain pluripotent VEGF receptor 2 (VEFGR2/Flkl) positive cells that are
capable of differentiating into endothelial or mural cells in response to VEGF or
platelet derived growth factor (PDGF-BB) raising the possibility that a component of
the de novo formation of new vessels in aortic rings is from a vascular progenitor
stem cell (Iurlaro et al. 2003; Akita et al. 1997). Although these pluripotent cells
have not been isolated in rodent studies, the endothelium in rat aortae has been
shown to exhibit considerable plasticity to differentiate into a microvascular
angiogenic endothelium and mural cells (Nicosia et al. 1992). The mural cells of
aortic ring outgrowths display mixed cell markers of vascular smooth cells and
endothelial cells and these so called mural precursor cells support the developing
endothelial tubes through angiopoietin signalling via Tie-2 rather than via PDGF
chemotactic recruitment (Iurlaro et al. 2003; Villaschi et al. 1994). Despite the
controversies surrounding the origin of the endothelial and mural cells of the aortic
ring outgrowths, these recent studies confirm the initial electron microscopy studies
that identified new vessel growth from aortic rings to consist of endothelial lined
luminised tubes that were covered in mural supporting cells (Nicosia & Ottinetti
1990).
In the study presented in this chapter cells labelled with Dil-Ac-LDL were present on
the aortic explant distributed in a pattern consistent with luminal endothelial cells. In
addition cells were also labelled with the fluorescent probe on outgrowths scattered
in a pattern consistent with endothelial cell distribution. Dil-Ac-LDL can be taken-up
by either endothelial cells or by macrophages however neither aortic ring nor
outgrowth labelling was consistent with macrophage staining (Voyta et al. 1984).
Further attempts to identify outgrowth cells by extracting RNA in the Matrigel
mouse aortic ring model proved unsuccessful despite extensive method refinements.
Reasons for failing to extract RNA from the outgrowths in the present study included
the relatively low number of cells, the difficulties with dispersing Matrigel and the
fact that aortic rings cultures were embedded within the Matrigel not grown on the
surface. Matrigel resistance to penetration may also explain the necessity to increase
the incubation time for Dil-Ac-LDL and precluded the use of standard
immunohistochemistry stains to identify cells.
Growth factor requirements for the sprouting vessels were carefully evaluated in the
course of method development. Conditions were optimised to produce sufficient new
vessels to be able to inhibit angiogenesis with glucocorticoids but not too much
growth as to make quantification inaccurate. Preliminary studies were performed in
the presence of the EGM-2 bullet kit as a previous study had indicated that without it
angiogenesis would be too sparse to evaluate an angiostatic compound (Rohan et al.
2000). Growth with the inclusion of all components was too prolific to quantify
beyond day 3, thus a process of growth factor selection was commenced to achieve
optimum media conditions. Initially FBS was excluded along with hydrocortisone;
in part this was to control steroid concentrations but also to encourage the selective
growth of endothelial microvascular sprouts in favour of fibroblasts (Nicosia &
Ottinetti 1990). Although serum free conditions did permit sufficient and quantifiable
growth to contemplate the use of angiogenesis inhibitors the presence of the
remaining growth factors (VEGF, FGF, IGF-1 and EGF) it concealed any putative
effects of glucocorticoids.
Previous work in the rat aortic ring model and pilot studies (by Miss Katrin Burger)
using VEGF immunosorbent assay in our lab (data not shown) indicated that the
aortic rings generate sufficient VEGF and also FGF whilst in culture to promote
angiogenesis and probably did not require exogenous addition of these factors
(Villaschi & Nicosia 1993; Nicosia et al. 1997; Nicosia et al. 1994a). In addition
IGF and EGF, although both acknowledged to promote angiogenesis in aortic ring
models, are less potent than VEGF and FGF and in the dose ranges supplied are
probably not effective (Villaschi & Nicosia 1993).
Exclusion of VEGF, FGF, IGF and EGF from the incubating media did not limit the
angiogenic response and sufficient growth occurred to investigate the effects of
glucocorticoids, indomethacin and LNNA. The observed inhibition of angiogenesis
by glucocorticoids, concealed by the presence of exogenous growth factors but
manifest in their absence, suggests an interaction between glucocorticoid and the
growth factors. It is possible that exogenous addition of factors was able to overcome
glucocorticoid-induced impairment of growth factor production. Further discussion
regarding the possible mechanisms of glucocorticoid angiostatic effects will follow.
EGM-2 components heparin and ascorbic acid were used to supplement MCDB-131
media along with antibiotics. Heparin although not required for the angiostatic
effects of high concentrations of glucocorticoids in rat aortic rings (Nicosia &
Ottinetti 1990) was included in this model because of earlier reports of an as yet
unexplained ability to interact with glucocorticoids to inhibit angiogenesis (Folkman
et al. 1983; Aranyi & Machovich 1985; Sakamoto et al. 1987; Derbyshire et al.
1996; Crum et al. 1985). Ascorbic acid was included because of reports that this
compound promotes angiogenesis in aortic ring cultures and maintains new vessel
structure: possibly by influencing collagen basement membrane synthesis (Nicosia et
al. 1991).
Choice of basement membrane matrices to be used in the studies was decided as a
result of pilot studies comparing a standard and growth factor reduced (GFR)
preparation of Matrigel. Previous investigators had used standard Matrigel (Rohan et
al. 2000) but as other groups began to utilize the mouse aortic ring assay, use of GFR
Matrigel appeared (Reynolds et al. 2002). In these latter reports using GFR Matrigel
the number of vessels was smaller than in our initial studies with standard Matrigel
so we compared the 2 formulations. We found, however, that angiogenesis was
equally prolific using either formulation under the conditions developed in this
chapter. Nevertheless as we had observed the influence of glucocorticoids using the
standard preparation and as a consequence of availability problems with the GFR
formulation, standard Matrigel was adopted as the matrix of choice.
Recognition of discrepancies in the number of vessels recorded in mouse aortic ring
models in the literature and the work presented here also prompted a review of
quantification techniques. Angiogenesis quantification has been performed by
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counting new vessels using published guidelines (Nicosia & Ottinetti 1990). In fact
one reason for the inconsistencies with vessel numbers in the literature and this work
is in the day chosen to assay angiogenesis; other authors have found approximately
50 vessels on day 5 of culture (Rohan et al. 2000) which in fact is similar to the
vehicle treated aortae in the current studies at that time point. Other quantification
techniques were developed in the model including diameter of growth and maximum
diameter of growth; these were used as a measure of the branching ability of the new
vessels. Longer vessels might be expected if branching were inhibited. Since this
work was completed other groups have begun to examine vessel length as a measure
of branching in recognition of the importance of this process to vascular remodelling
(Huang & Kontos 2002). Computer analysis techniques have been use to count
vessels in the aortic ring assay although their use is not widespread (Nissanov et al.
1995). In this current study computer assessed vessel density was not reliable or
consistent however other image analysis quantification methods corroborated the
findings of vessel counting. Each technique showed a similar pattern of growth, an
inhibition of growth by glucocorticoids and a similar degree of inhibition. However,
in line with established techniques in the literature, vessel counting was used in these
studies as the method of angiogenesis quantification. Since vessel counting was time
consuming it was decided to examine vessel counts on day 7 alone as the preliminary
findings indicated that angiogenesis rate slowed beyond that time point and because
by day 7 the effects of angiostatic compounds (LNNA, and glucocorticoids) were
significant. This was similar to but not identical to time points chosen to quantify
angiogenesis in other studies (Rohan et al. 2000), however the reasons for the
different time points is not made clear in these reports. Growth in our work even in
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the absence of exogenous growth factors was more prolific than published reports
(Rohan et al. 2000; Nicosia & Ottinetti 1990): the reasons for this are uncertain but
may reflect different practices in terms of vessel preparation, size of incubating
wells, and amount of Matrigel used. Great care was taken not to damage the
endothelium during dissection with the use of sharp instruments and minimal vessel
handling. Transfer time from tissue extraction from the animal and embedding in
Matrigel was reduced with practise and may account for the increased angiogenesis
seen in experiments as the technique was perfected during the course of this study.
3.4.2 Influence of glucocorticoids
Assessment of the suitability of the assay to examine the role of putative
angiogenesis inhibitors was confirmed by using acknowledged angiogenesis
inhibitors LNNA and indomethacin (Babaei et al. 1998; Dormond et al. 2001;
Papapetropoulos et al. 1997). In the current study LNNA and indomethacin were
used at concentrations that had previously been shown to alter vascular function
(Babaei et al. 1998; Leyssac et al. 1975). LNNA inhibited angiogenesis confirming
that in vitro NO is an important regulatory factor of new vessel formation (Lee et al.
1999; Zhao et al. 2002). In contrast at the concentration of indomethacin used
angiogenesis was not inhibited. Although recognised to inhibit vessel wall
production of prostanoids at the concentration used the reported anti-angiogeneis
effects were noted at five times this concentration (Dormond et al. 2001; Jones et al.
1999). Other reasons for a lack of inhibition by indomethacin could be an effect of
the assay conditions or as a consequence of compensation by NO. NO generation by
eNOS reportedly compensates for reduced prostanoid production in endothelial cell
culture however the converse effect from inhibition of NO does not occur (Vassalle
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et al. 2003). The lack of angiogenesis effect from a cyclo-oxygenase inhibitor may
also reflect the absence of systemic inflammation in this model and it may be that, in
the presence of other facets of angiogenesis including cellular inflammatory
responses, inhibition of prostaglandin and thromboxane generation would be
effective.
Physiologically relevant concentrations of glucocorticoids were used to examine the
relevance of glucocorticoid-induced angiostasis to physiology and pathophysiology.
Angiogenesis in aortic ring cultures was inhibited by glucocorticoids at
concentrations equal to and greater than 30nM with no inhibition at 3nM. It is likely
even at nadir concentrations that glucocorticoids would be of the order of 30nM and
thus influence angiogenesis (Harris et al. 2001). Although the angiostatic effects of
endogenous glucocorticoids have not been examined there are examples of
angiogenesis associated processes being impaired in the presence of excess
endogenous glucocorticoids for example impaired wound healing in Cushing disease
patients (Gordon et al. 1994). In addition excess production of endogenous
glucocorticoids in functional adrenal cortex adenomas is associated with reduced
vascularity in comparison to normal adrenal cortex (Sasano et al. 1998; Bernini et al.
2002).
The ability of 1 ldehydrocorticosterone to inhibit angiogenesis was also noted
although no threshold concentration was determined. The concentrations of
11 dehydrocorticosterone were chosen to parallel those for corticosterone. However
physiological intracellular concentrations of 11 dehydrocorticosterone are difficult to
predict for although 11 dehydrocorticosterone is present at 50nM concentrations in
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plasma in mice (Kotelevtsev et al. 1997) the intracellular concentration may vary
greatly depending on the balance of 11 (3HSD1 and 2 activity.
The ability of 1 ldehydrocorticosterone to inhibit angiogenesis raised the possibility
that these compound were working either by a non-genomic mechanism, or via GR,
MR or the putative 11 dehydrocorticosterone receptor (Sheppard et al. 1998). At
relevant concentrations neither mineralocorticoid receptor agonism nor antagonism
influenced angiogenesis. Previously the mineralocorticoid receptor antagonist
spironolactone had been found to inhibit angiogenesis; however these reports should
be interpreted with caution since they were performed using supra-therapeutic
concentrations and the effect was explained by inhibition of endothelial cell
proliferation; without an effect on endothelial cell migration (Klauber et al. 1996;
Gardiner et al. 1989; Guggino et al. 2003; Guggino et al. 2002). In the current
studies similar large concentrations dramatically reduced angiogenesis and, although
no direct measurements were taken of endothelial cell apoptosis or proliferation, the
appearance of cultures suggested a toxic effect of spironolactone.
In contrast, the glucocorticoid and progesterone receptor antagonist RU38486 had no
effect on angiogenesis consistent with previous reports (Yamamoto et al. 1994).
Since progestogens were not added to the assay the progesterone receptor effects of
RU38486 were not relevant in this model. RU38486 abolished corticosterone and
11 dehydrocorticosterone-induced angiostasis and therefore glucocorticoid-induced
inhibition of new vessel formation is glucocorticoid receptor dependent.
Conversion of 11 dehydrocorticosterone to active glucocorticoid by lipHSDl was
confirmed by the intact aortic ring activity assay. Dehydrogenase and reductase
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activities were recorded in intact aortic rings; however, since 11 (3HSD2 is an
exclusive dehydrogenase (Seckl & Walker 2001), the reductase activity was
performed by lipHSDl. Additional work has subsequently provided further
evidence that 1 lpHSDl functions in the vessel wall as a reductase enzyme since in
aortae from lipHSDl deficient transgenic mice no measurable reductase activity
was recorded.
Pharmacological inhibition of lipHSDl by carbenoxolone attenuated the effects of
11 dehydrocorticosterone to inhibit angiogenesis but had no effect on the influence of
corticosterone. Carbenoxolone at high concentration prevented any growth reflecting
the reported endothelial toxicity of this compound at higher concentrations (Ullian et
al. 1996).
The effect of transgenic deletion of 1 ipHSDl on glucocorticoid-induced angiostasis
was also examined. Aortic rings form mice deficient in 1 lpHSDl (1 lpHSDl -/-) had
angiogenic responses similar to wild type aortic rings. Corticosterone inhibited
angiogenesis in both lipHSDl -/- mice and wild types, however
11 dehydrocorticosterone no longer inhibited angiogenesis in lipHSDl -/- mice.
Thus the presence of lipHSDl was necessary for the angiogenic effect of
11 dehydrocorticosterone. Therefore, lipHSDl influences the angiostatic effects of
glucocorticoids through the regeneration of active glucocorticoid from inactive
1 lketo-compounds. In this fashion lipHSDl amplifies the angiostatic effects of
glucocorticoids in vitro. The effect of 1 lpHSDl required the presence of exogenous
glucocorticoids and it will be important to pursue these findings in vivo to examine
the effects of 11PHSD1 in the presence of endogenous glucocorticoids.
The molecular mechanisms of glucocorticoid-induced angiostasis are unclear but
*
may involve glucocorticoid anti-inflammatory, anti-proliferative, anti-migratory and
anti-collagen type actions. To begin to investigate a direct effect of glucocorticoids
on key angiogenesis factors, physiologically relevant concentrations of
glucocorticoids were used in HUVEC culture to see if the calcium responses of these
cells following VEGF stimulation could be influenced. Local attempts to isolate and
culture mouse aortic endothelial cells have proved unsuccessful (Christy et al. 2003),
however a locally available surplus of human endothelial cells encouraged the use of
human cells for these studies. HUVECs have previously demonstrated a bi-phasic
,/ • 2"Eintracellular calcium [Ca ]i response to VEGF stimulation (Cunningham et al. 1999;
Faehling et al. 2002; Jiang et al. 2001) . VEGF elicits this response through the
VEGF-2 receptor (VEGFR2) (Cunningham et al. 1999). Although the function of
other VEGF receptors in endothelial cells (for example VEGFR-1) is unclear
available data suggest that the intracellular calcium responses are not induced
through VEGF stimulation of this receptor (Cunningham et al. 1999). Inhibition of
this response has been associated with impaired endothelial cell proliferation and
migration (Cunningham et al. 1999; Faehling et al. 2002; Jiang et al. 2001).
v Furthermore in the course of this thesis it came to light that other endogenous
I
angiogenesis inhibitors impaired [Ca ]i responses (Jiang et al. 2001) . Thus the
effects of pharmalogical and endogenous concentrations of glucocorticoids on
endothelial cell calcium responses were studied. The results represent a pilot study
and are preliminary findings. Pharmacological doses of glucocorticoid markedly
attenuated the second phase of the intracellular calcium response whereas
endogenous concentrations reduced the amplitude of this phase response to a lesser
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degree. The biphasic response is generated from an initial reaction to liberate
intracellular calcium stores through inositol 1,4,5 trisphosphate (IP3) and
diacylglycerol (DAG). IP3 interacts with IP3 receptors on the endoplasmic reticulum
to release stored calcium (McLaughlin & De Vries 2001; Faehling et al. 2002;
Berridge 1987). The second phase is ascribed to extracellular calcium entry via
storage-operated channels (SOC). The transduction system that triggers SOC
opening is still unclear but is thought to be effected by increases in [Ca2+]i, DAG,
IP3, or all three (Berridge 1987; Nilius & Droogmans 2001).
Glucocorticoids appear to influence the entry of extracellular calcium ions. The
channels activated by VEGF are believed to be different to those activated by other
endothelial vasomotor agonists (for instance ATP) (Pocock et al. 2004). In fact the
SOC are a diverse group of channels and are encoded by the gene family transient
receptor potential 1-7 (TRPI-7). TRP 1-6 are expressed in mammalian endothelial
cells (Nilius & Droogmans 2001). There is evidence for the involvement of these
channels in VEGF responses: TRP-6 inhibition does attenuate VEGF stimulated
fluctuations in [Ca2+]i (Pocock et al. 2004) however its presence in HUVECs
remains undetermined. TRPI and 3 are expressed in HUVECs, however the absence
j of a specific antagonist has limited further investigation of their roles and their role
in VEGF responses has not been examined. A further candidate for glucocorticoid
action may be TRP-4: endothelial cells from TRP-4 -/- mice lack a store dependent
calcium current and exhibit intracellular calcium responses similar to those seen in
Cortisol exposed HUVECs (Plant & Schaefer 2003). TRP proteins are activated
probably by several means including by IP3, DAG by intracellular calcium or via
receptor generated phosphorylation pathways. It is unclear which of these pathways
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glucocorticoids might interrupt and this was beyond the scope of this thesis although
the experimental findings are being followed up through the work of a new PhD
student.
Further studies with the models presented in this chapter are planned for a new
project with the aim to elucidate some of the mechanisms to explain the results. The
aortic ring assay will be used to assay glucocorticoid interactions with key
angiogenesis factors including NO, VEGF and FGF. Identification of NO
metabolites in aortic ring culture medium by chromatography and FGF and VEGF by
ELISA studies are being considered. The aortic ring assay has also been use in a
hypoxic chamber that became available during the course of these studies.
Controversy regarding the effects of glucocorticoid on angiogenesis factors in
hypoxic conditions exists (Kodama et al. 2003) and this chamber will allow
experimentation to investigate some of these controversies in vitro. Furthermore
hypoxic studies of angiogenesis are also useful to examine the role of endogenous
glucocorticoids in pathophysiology, for example in tumours and in infarcted tissue.
The hypoxic environment of such pathologies will produce different angiogenesis
conditions and the effect of glucocorticoids to regulate angiogenesis in these
conditions will need to be assayed.
Extraction of RNA from aortic rings in Matrigel has proved difficult. This may
reflect the Matrigel or the small amount of cellular material. Plans have been
discussed to trial the collagen gels or learn the techniques performed by Nicosia et al
(Nicosia et al. 1994b) that allow them to isolate the cells grown from the aortic rings.
This will allow us to elucidate the expression of lipHSD-1 and examine the
expression of key angiogenesis factor e.g. VEGF, eNOS to see if glucocorticoids
influence these. Finally following criticisms of the aortic ring model because of
apparent controversies regarding the nature of the outgrowths attempts are being
considered to perform electron microscopy (Nicosia & Ottinetti 1990) to establish
whether the outgrowths are endothelial lined luminised tubes.
The data in this chapter provide evidence for the establishment of a novel in vitro
assay to examine the effects of putative angiostatic factors and examine the effects of
physiologically relevant concentrations of glucocorticoids on angiogenesis.
Glucocorticoids at these concentrations inhibited angiogenesis in a glucocorticoid
receptor dependent manner. Furthermore, the inert 11 ketocompound
1 ldehydrocorticosterone, a substrate for 11 (3HSD1, also inhibited angiogenesis in a
glucocorticoid receptor dependent manner. The effect of 11 dehydrocorticosterone
was attenuated by pharmacological inhibition or gene deletion of lipHSDl.
Glucocorticoids at physiological relevant concentrations inhibited the intracellular
calcium concentrations of endothelial cells in responses to VEGF. Thus
physiological concentrations are sufficient to inhibit angiogenesis and are modulated
by the effects of vessel wall 1 lpHSDl. It is important to verify these findings in vivo
to confirm whether lipHSDl influences the effects of endogenous glucocorticoids
to regulate angiogenesis, and to examine whether this regulatory mechanism has a
role in controlling angiogenesis in pathology.
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Chapter 4
11 p Hydroxysteroid Dehydrogenase





Whilst physiologically relevant concentrations of steroids inhibited new vessel
formation in vitro it remained unclear whether endogenous glucocorticoids influence
angiogenesis in vivo. Previously, compounds that have inhibited endothelial cell
migration or proliferation or differentiation in vitro have not necessarily regulated
endothelial cell activity in vivo (Liekens et al. 2001). Therefore, although novel, the
in vitro results described in Chapter 3 required further justification in vivo in order to
assess their physiological relevance.
In vivo models of angiogenesis differ from in vitro assays by incorporating systemic
factors, including: inflammation, hormones, metabolic homeostasis and circulating
vascular-precursor cells. These different conditions found in vivo are particularly
pertinent to the studies described in this thesis since glucocorticoids influence
inflammation (Barnes 1998), are hormones that act at distant sites, they regulate
tissue metabolism (Wake & Walker 2004), alter cell differentiation(Amanatullah et
al. 2002) and mobilisation of progenitor-cells (Mao et al. 2004). Thus the
development of a suitable in vivo model was essential to confirm the influence of
endogenous glucocorticoids on angiogenesis.
There are several in vivo models applicable to rodent studies that might be relevant,
such as the corneal model and chamber or dorsal sac assays (Staton et al. 2004).
These, however, are expensive, technically demanding and in the main utilise cancer
cells. As the study of angiogenesis in tumours was not the focus of this thesis, these
techniques were not pursued. Instead a subcutaneous implant assay was adopted.
There was a choice of implant assays as both Matrigel and sponge models are
established in the literature (Andrade et al. 1987; Biancone et al. 1997; Hague et al.
2002). Whilst Matrigel is expensive and quantification of implanted gels is
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technically demanding, costly and inconsistent (Staton et al. 2004); polyester sponge
*
implantation used in this chapter, is simple to perform, relatively inexpensive and
angiogenesis is quantified by using simple histology. Refinements of the sponge
implantation assay were necessary because of technical difficulties associated with
the manner of drug administration (Hague et al. 2002; Hori et al. 1996). This model
was adapted to reduce animal stressors by developing a silicon pellet impregnated
with treatment that could be placed into the centre of the sponges. The importance of
reducing animal stress was to examine the influence of physiological, rather than
stressed, concentrations of glucocorticoids on angiogenic responses and determine
the receptor responsible for these effects. For, although therapeutic concentrations of
glucocorticoids inhibit angiogenesis (Hori et al. 1996), it is unclear whether this is a
glucocorticoid or mineralocorticoid receptor mediated effect. Although by using
pellets it was possible to administer steroids, the final concentrations of
glucocorticoids within an implant would be determined by 11PHSD metabolism. In
vitro lipHSDl influenced the angiostatic effects of glucocorticoids, however, a
similar role for this isozyme in vivo had not been shown. Transgenic lipHSDl
deficient mice are ideal models to investigate the influence of lipHSDl on
angiogenesis in vivo. Although these animals have no developmental vascular
abnormalities (Kotelevtsev et al. 1997; Hadoke et al. 2001) it is not unusual for
angiogenesis factor gene deletions to be associated with normal adult vasculature
(Carmeliet & Collen 2000). In some cases the importance of factors only become
noticeable upon tissues stress either following injury, infarction, or tumour
implantation.
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Therefore the aims of this study were to establish an in vivo assay of angiogenesis to
examine the influence of endogenous glucocorticoids to modulate angiogenesis. In
addition the model was used to identify the receptor responsible for glucocorticoid-
mediated angiostasis and investigate the influence of lipHSDl on angiogenesis in
vivo.
4.2 Methods
Experimental procedures were adopted and refined from previous models (Hori et al.
1996; Hague et al. 2002) to establish a more suitable in vivo assay to examine the
effect of endogenous glucocorticoids on angiogenesis. Implantation technique, drug
delivery, experiment duration, methods for quantification of steroids within the
sponge and quantification of angiogenesis all underwent extensive development as
detailed in the following sections.
4.2.1 Development of the subcutaneous sponge implant assay
(Please refer to section 2.7)
Mice- Male 10-12 week old, C57B16 and homozygous null 1 lp-HSD 1 (bred to be
congenic) male mice were used.
Sponges- White, grade XE1700V polyester sponge was used (Caligen Foam Limited,
UK). Other sponge samples were sourced locally (Didcock Bros, UK) but proved
unsuitable because of differences in porosity, colouring, grade and thickness.
Implantation procedure- (See section 2.7.3) Training in sponge implantation
techniques was kindly provided by Mrs Sandra Peak at the Imperial Cancer Research
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Fund Clare Hall Laboratories (Potters Bar, UK). The anaesthetic and implantation
techniques learnt at training were initially employed with minor alterations: animals
received an intraperitoneal anaesthetic fentanyl/ fluansone and midazolam (as
Hypnorm (Janessen, UK) /Hypnovel (Roche, UK) 0.1ml/ lOg of a solution
containing Hypnorm 1.0 ml + Hypnovel 1.0ml + sterile water 2.0 ml). This was used
instead of intraperitoneal tribromoethanol (Avertin) that had been administered at
Clare Hall to avoid reported peritoneal adhesions, liver damage and post operative
mortality (Zeller et al. 1998). Anaesthetized mice underwent subcutaneous sponge
implantation with each mouse receiving 2 sponges; one on each flank. This was an
adaptation of established procedures using mice in this assay (Hague et al. 2002;
Illanes et al. 2002) but similar to the original descriptions in rats (Hori et al. 1996).
With practice, the need for intraperitoneal anaesthesia with a long half-life was
reduced and Halothane inhalation anaesthesia was adopted as standard procedure.
4.2.2 Administration of steroids
Several different routes of drug delivery have been used with subcutaneous sponge
implants (Hori et al. 1996; Hague et al. 2002; Illanes et al. 2002). In the current
study a silastic pellet containing steroid or vehicle was used, these pellets could
release steroid at a controlled rate for 3 weeks (Cleasby et al. 2003) and could be
placed adjacent to or within implanted sponges promoting localised delivery and
reduction in handling and housing stresses.
Implant manufacture- (See section 2.7.1) Steroid was added to Silastic elastomer
(Dow Corning Corporation) mixed and cured overnight at 25°C either in the 1ml
syringe or following injection into capillary tubing (1.2mm-0.76mm) (Portex Ltd,
UK). Placebo, control pellets were manufactured in the same manner without the
addition of steroid. Following curing, capillary tubing was split and pellets cut into
lcm pieces weighing 10-12mg, the 1ml syringe was cracked open and the pellet cut
into 0.5cm pieces weighing 50mg each.
Drug Administration- Initial studies using pellets containing Cortisol or placebo, were
performed by placing the pellet adjacent to the sponge in the subcutaneous pocket.
Curing of pellets within capillary tubing enabled the manufacture of thin tubes of
silicon containing steroids that could be inserted into the centre of the sponge
cylinder. This technique was adopted as standard procedure for the remainder of the
experiments (See section 2.7.1). Drug dosages were calculated following preliminary
experiments in which a high dose of corticosterone (25mg) had been used. Large
concentrations of corticosterone were associated with systemic side effects. Steroid
dosages were therefore titrated to reduce the incidence of systemic side effects yet
influence new vessel formation.
Experiment duration- Studies in rats indicated that the subcutaneous tissues
underwent a predictable response to sponge implantation (Andrade et al. 1987).
Angiogenic responses in these studies and in mouse models of the assay (Illanes et
al. 2002; Hague et al. 2002) were measured 3 weeks after sponge implantation and
thus this time point was used in the current studies.
Assessment of the systemic effects of administered agents- Subcutaneous wounds
were regularly inspected to examine hair growth, wound granulation and wound
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apposition. In addition, animals were weighed daily and their water intake measured
to monitor their welfare and assess the systemic effects of administered drugs.
Tissue collection- (See section 2.8. 3 weeks following implantation (Hori et al.
1996), mice were decapitated, trunk blood collected into lithium heparin tubes,
sponges and organs excised and inserts removed. Sponges were bisected; one half
was fixed in 10% formalin, embedded in paraffin wax and cut using a microtome
(Hague et al. 2002). Sections (8pm) were stained with haematoxylin and eosin
(H&E) for quantification of angiogenesis.
To determine the concentration of steroid or protein in sponges, the remaining half of
the sponge was weighed and placed in ice-cold phosphate buffer solution (PBS) and
homogenised. The homogenate was centrifuged, 40pl of the supernatant were used to
determine sponge protein colormetrically using the Bradford assay (Bradford 1976)
(See section 2.7.6). A further 750pl of the supernatant were removed, added to 7.5
ml of ethyl acetate vortexed and allowed to settle. 7ml from the viscous phase of this
mixture were removed, dried and then assayed for steroid concentration.
Steroid Quantification-The concentration of steroid in the sponges and mouse plasma
was determined by radioimmunoassay (See section 2.8.5). However, as anti-
cortisone anti-bodies (used in the radio-immuno assay to detect cortisone) cross-react
with Cortisol a further purification step was required (Table 4.1(Lloyd-MacGilp et al.
1999)). Cortisone and Cortisol in dried samples were separated using high-
performance liquid chromatography (HPLC) (Walker et al. 1991) (see section 2.8.8).
144
Separation of Cortisol and cortisone in the chromatography column allowed separate
collection of each steroid at a time point defined by control standards.
Ultra violet light detection was used for samples from lipHSD-1 -/- mice to
determine the absence of Cortisol in cortisone treated sponges. As no Cortisol was
detected in 11(3HSD-1 -/- mice that had received cortisone (Figure 4.11) the HPLC
step in quantifying steroids from these animals was discontinued.
4.2.3 Quantification of angiogenesis in sponges
In preliminary experiments both histological and immunohistochemical techniques
were tested to determine the best method for identifying blood vessels within the
sponge matrix. Attempts to stain endothelial cells with either anti-CD31 (BD
Biosciences, UK) or anti-vWF (Dakocytomation, UK) antibodies proved, despite
extensive adjustment of the staining protocols, to be unsuccessful. In contrast, blood
vessels were readily visible in sections stained with haematoxylin and eosin (H & E).
In preliminary reports of the sponge implant model (Andrade et al. 1987; Edwards et
al. 1960) vessels had been identified using simple haematoxylin and eosin staining
and following discussions with a leading angiogenesis investigator this method was
adopted. Initially, quantification was performed using 2 different counting protocols:
firstly, 3 high power fields (xlOO) from 2 sections of same sponge were assessed and
the mean calculated. Following this, vessel density determination by Chalkley
counting (Fox et al. 1995) was measured. The mean of triplicate Chalkley counts on
2 sections per sponge was used. Comparison of the 2 vessel counting techniques
demonstrated that both were reliable, reproducible and produced similar findings. As
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Chalkley counting is more time efficient it was adopted as standard procedure (See
section 2.8.4) (Figure 4.1).
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Figure 4.1 Chalkley Reticule
Chalkley counting at high power (x250) (Fox et al. 1995). Chalkley counting is performed using a 25-
point Chalkley eyepiece reticule (Graticules Ltd, Kent UK). At low power the 3 most vascular areas
were identified and analyzed using the graticule at 250x magnification. The graticule was rotated until
the highest number of Chalkley reticule points were aligned with vessels and a score out of 25 was
achieved. From each section three Chalkley scores were recorded thus a total of six Chalkley scores
were obtained for each sponge and the mean of these was used as the Chalkley count.
147
Cortisol Cortisone Corticosterone
Cortisol RIA 100% 0.1% 0.2%
Corticosterone RIA 10% 0.8% 100%
Cortisone RIA 6% 100% 0.5%
Table 4.1 Cross reaction of Cortisol, cortisone and corticosterone in radio
immunoassays
Cortisol present with samples may bind to Cortisol antibodies in the Cortisol RIA. In addition
Cortisol may also bind to corticosterone or cortisone antibodies in RIAs for these other
steroids. Thus, samples from mice that received Cortisol or cortisone underwent high
pressure liquid purification so that the Cortisol could be separated and removed (RIA radio
immunoassay) (Lloyd-MacGilp et al. 1999).
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4.2.4 Application of the assay: examining the angiostatic effects of
endogenous glucocorticoids and the influence of 1 ipHSD-1
Validation of control sponge conditions - Control sponges were placebo-treated
sponges that had been implanted in the opposite flank from a treatment sponge. To
validate this novel approach, angiogenesis in the placebo treated sponge was also
compared to new vessel formation in a sponge from an animal that had received no
exogenous steroid (Figure 4.2).
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Placebo-impregnated Steroid-impregnated
C57B16 mouse with bilateral C57B16 mouse with placebo-impregnated
placebo impregnated sponges and steroid-impregnated sponges
Figure 4.2 Method development: Validation of control sponges in mice that had
received steroid
Control sponges were placebo-treated sponges that had been implanted in the opposite
flank from a steroid-impregnated sponge. To validate this novel approach, angiogenesis in
placebo-impregnated sponges (a) was compared with new vessel formation in placebo-
impregnated sponge in animal that had also received steroid (b). The steroid used for this
comparison was a high concentration of corticosterone (25mg).
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Effect ofexogenous glucocorticoids- (See section 2.8) To determine the influence of
glucocorticoids on angiogenesis in vivo, C57B16 male mice received a sponge
impregnated with a steroid pellet on the right flank and a placebo impregnated
sponge implanted on the left flank. Steroids used included 25mg of corticosterone,
2.5mg of Cortisol or 2.5mg of cortisone. Following the initial experiments with high
concentrations of corticosterone, smaller concentrations of human equivalents to
corticosterone (Cortisol) and 1 ldehydrocorticosterone (cortisone) were used. Three
weeks following implantation, mice were decapitated, trunk blood collected, sponges
and organs excised and processed, as described (section 2.8).
Influence of endogenous glucocorticoids- (See section 2.8.2) The influence of
endogenous glucocorticoids was examined using adrenalectomy or pharmacological
antagonism. C57B16 mice underwent bilateral adrenalectomy or sham procedure
(Livingstone et al. 2000a) followed by bilateral sponge implantation under the same
anaesthetic. Dr Patrick Hadoke performed the surgery in these animals.
Antagonism of endogenous glucocorticoid action was examined using RU38486 or
spironolactone. C57B16 male mice received bilateral sponge implants: a sponge
impregnated with 5.25mg of RU38486 or 5.25mg of spironolactone was implanted
on the right flank whereas the left flank received a placebo-impregnated sponge.
Moderation of the influence of endogenous glucocorticoids by 11J3HSD-1- C57B16
and 11 (3HSD-1 -/- male mice received bilateral sponge implants: a sponge
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impregnated with Cortisol (2.5mg) or cortisone (2.5mg) was implanted on the right
tlank whereas the left flank received a placebo-impregnated sponge. Three weeks
following implantation sponges were collected and processed.
4.2.5 Statistics
Data are mean ± SEM. Comparisons were made by ANOVA with least squares




Pilot studies using high dose corticosterone pellets assessed several features of the in
vivo assay. The results from these preliminary investigations confirmed the
suitability of the model to examine the influence of glucocorticoids on angiogenesis
and are detailed below.
Validation of control sponges (Figure 4.2)- Angiogenesis in placebo-impregnated
sponges implanted into animals that received exogenous glucocorticoids
(corticosterone 25mg via a steroid-impregnated sponge on the opposite flank) was
not different (p=0.36) from angiogenesis in placebo-impregnated sponges from mice
that received no steroid treatment (Figure 4.3).
Localised drug delivery- Quantification of corticosterone concentration in
corticosterone-impregnated sponges compared to the contralateral placebo
impregnated sponge demonstrated that steroid treatment was localised. In addition
there was no evidence of cross-contamination with steroid to alter angiogenesis
conditions for the sponge on the opposite flank (Figure 4.4).
Quantification of angiogenesis- Quantification of angiogenesis by the Chalkley
method was compared to high power field (xlOO) vessel counting in preliminary
studies to investigate the effects of glucocorticoids on angiogenesis. Using either
technique corticosterone inhibited angiogenesis. In addition the degree of inhibition
was similar for both techniques. However the Chalkley count was better established
(Hague et al. 2002) and more time efficient and therefore was adopted as the
standard method (Figure 4.5)
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No Steroid Steroid
Figure 4.3 The influence of contra-lateral steroid implantation on angiogenesis
in control sponges
Comparison of angiogenesis in placebo impregnated sponges from mice subjected to
implantation of a sponge containing either a steroid (solid bar) or placebo (no steroid; open
bar) insert on the contralateral flank. The number of vessels in placebo sponges was not
affected by the presence of a contralateral implant containing 25mg corticosterone (p=0.36





































Figure 4.4 Localized drug delivery: corticosterone concentration within sponges
Corticosterone concentrations were markedly (**p<0.001) elevated in sponges containing
corticosterone implants (solid bar), compared with contralateral placebo controls (open bar).
Data are mean ± SEM. Comparisons were made by ANOVA (n=4).
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Figure 4.5 Comparing quantification techniques
Angiogenesis in sponges impregnated with corticosterone (25mg) was compared to new
vessel formation in sponges impregnated with placebo using a) high power (x100) field
vessel counting and b) the Chalkley method. Using either technique corticosterone was
noted to inhibit angiogenesis. The degree of inhibition was similar in both methods. Data are
mean ± SEM. Comparisons were made by ANOVA n=4-6.
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Drug dosing- Calculation of appropriate drug dosages was performed following
observations made using a high concentration of corticosterone. Initially 25mg
corticosterone pellets were chosen for similar pellets had been seen to be effective in
delivering glucocorticoids over 4 weeks (Cleasby et al. 2003) and furthermore it was
anticipated that, by using a high concentration, an angiostatic effect would be
observed (i.e. proof of principle). With this dose of steroid there was a dramatic
effect on sponge appearance (Figure 4.6). Three weeks following implantation,
corticosterone-treated sponges were white with few, if any, vascular structures
visible on gross examination. In contrast the contralateral placebo-treated sponges
upon excision were pink with numerous vascular structures visible (Figure 4.5).
These findings were confirmed at low power histology (Figure 4.6) and following
quantification of angiogenesis (Figure 4.5). At this concentration corticosterone also
had systemic effects: it reduced the weight of glucocorticoid sensitive organs,
suppressed plasma levels of corticosterone as previously reported (Cleasby et al.
2003) (Figure 4.7) and influenced hair regrowth over subcutaneous incision wounds
(not formally quantified).
In further studies, reduced doses of exogenous glucocorticoids, Cortisol and
cortisone, were used. The human equivalents of rodent glucocorticoids were
employed to distinguish these steroids from endogenous glucocorticoids. 2mg pellets
of Cortisol and cortisone did not affect glucocorticoid-sensitive organ weights (figure
4.7a) or wound healing, did not alter plasma corticosterone (Figure 4.7b) but did
inhibit angiogenesis to a similar degree to corticosterone both on gross examination
and microscopic evaluation (Figure 4.8a-d).
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a) Gross appearance of placebo or corticosterone treated sponges
and eosin stained sections
ii)
Figure 4.6(a-b) Assessing drug concentrations: corticosterone is angiostatic
Corticosterone (25mg) inhibited angiogenesis in sponges implanted subcutaneously in mice.
On gross inspection (a) corticosterone sponges were avascular and white in appearance in
contrast placebo treated sponges were pink and appeared to be highly vascular. At low
power magnification (b) these findings were confirmed, numerous vessels were seen (black












a) Systemic effects of steroid pellets on organ weights
Thymus Spleen Adrenals
300 -i b) Influence of steroid pellets on plasma corticosterone
Placebo Corticosterone Cortisol
Figure 4.7 Assessing drug concentration: systemic effects of corticosterone
Systemic effects of using different concentrations of corticosterone (25mg) or Cortisol (2mg)
impregnated sponges, Pellets containing corticosterone 25 mg (solid bar) had systemic
effects on glucocorticoid-sensitive organ weights (a) and plasma corticosterone (b) versus
animals who received no steroid (clear bars), or Cortisol (2.5mg) (vertical lined bars). Data
are mean ± SEM *p< 0.04, #p<0.01. Comparisons were made by ANOVA with least squares
difference post hoc tests, n=4-9.
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a) Gross appearance of placebo (i) and Cortisol (ii) impregnated sponges
b) Low power (x50) haematoxylin and eosin stained sections
Figure 4.8(a-c) Glucocorticoids inhibit angiogenesis in vivo
Images from placebo (i) and Cortisol (2.5mg) (ii) impregnated sponges. Placebo treated
sponges appeared vascular on gross inspection (a), many vessels were seen at low
magnification (b) at high magnification mature vessels were seen. In contrast Cortisol
impregnated sponges were white on gross inspection (a), few if any vessels were seen at
low magnification (b) however at high magnification an inflammatory infiltrate persisted (c),
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^ 41 d) Glucocorticoids inhibit new vessel growth in vivo
Placebo Cortisol
Figure 4.8d Glucocorticoid inhibit angiogenesis in vivo
In comparison to placebo impregnated contra lateral controls, sponges impregnated with
glucocorticoids (2.5mg Cortisol or cortisone) inhibited angiogenesis quantified by Chalkley
counting. Data are mean ± SEM #p<0.01. Comparisons were made by ANOVA with least
squares difference post hoc tests, n=6.
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Influence of glucocorticoids on protein concentrations within sponges - Protein
concentrations were not different in corticosterone, Cortisol or cortisone impregnated
sponges compared to contralateral placebo controls (Figure 4.9). The absence of an
effect on sponge protein concentration, despite the evident effect on angiogenesis,
indicated that this was an unreliable method of assessing the angiostatic effects of
glucocorticoids and therefore was discontinued.
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0.03-,
Figure 4.9 Sponge protein concentrations
Impregnation of sponges with glucocorticoids did not affect sponge protein concentration in
comparison to relevant control sponges. Solid bars represent steroid impregnated sponges
(B is corticosterone 25mg; F is Cortisol 2.5mg, E is cortisone 2.5mg n=6). Bracketed clear
bars represent contra lateral placebo impregnated controls. Data are mean ± SEM n=4-6
p>0.23 for comparisons with relevant controls, comparisons were made by ANOVA with
least squares difference post hoc tests.
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4.3.2 Moderation of the influence of endogenous glucocorticoids by
11 |3HSD-1
Endogenous glucocorticoids repress angiogenesis- The absence of adrenal glands at
post-mortem examination and reduced plasma corticosterone concentrations
(156.1±25.1nM in sham versus 46.7±6.5nM (below level of detection for this assay
which is 50nM (Cleasby et al. 2003)) for adrenalectomised animals n=5, p<0.001 by
ANOVA) confirmed the success of adrenalectomy. The number of blood vessels in
sponges from mice that had undergone adrenalectomy was increased in comparison
to sham-operated controls (Figure 4.10a).
Sponges impregnated with the glucocorticoid receptor antagonist RU38486 had
increased angiogenesis in comparison to placebo-impregnated controls (Figure
4.10b). An assessment of the systemic effects of glucocorticoid receptor antagonism
indicated that RU38486 reduced plasma corticosterone (93.5±32.3nM in RU38486
versus 225.8 ± 39.9nM in controls, n=6, p<0.01 by ANOVA) but did not alter the
weight of glucocorticoid-sensitive organs (data not shown).
Spironolactone had no effect on angiogenesis in sponges (3.94±0.55 Chalkley count
in controls versus 3.78±0.24 Chalkley count in spironolactone treated sponges, n=3).
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a) Adrenalectomy increased angiogenesis
Sham operation Adrenalectomy
10-0-1 b) Influence of glucocorticoid receptor antagonism
Placebo RU38486
Figure 4.10 Endogenous glucocorticoids repress angiogenesis
(a) Sponges implanted into mice post-adrenalectomy (solid bar) were more vascular than
control sponges implanted post sham operation (clear bar). The angiostatic influence of
endogenous glucocorticoids is glucocorticoid receptor-dependent (b): sponges impregnated
with RU38486 (solid bar) were more vascular than contra lateral placebo impregnated
controls (clear bar). Data are mean ± SEM #p<0.01 and *p=0.02. Comparisons were made
by ANOVA, n=6.
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11 /3HSD1 tonically represses angiogenesis in vivo -To determine 11 [3HSD reductase
activity in implanted sponges, radioimmunoassay of steroid fractions separated by
HPLC was performed. This confirmed 1 lpHSD reductase metabolism in cortisone-
impregnated sponges from C57B16 mice by detection of Cortisol (Table 4.2). No
reductase activity however was seen in cortisone-impregnated sponges from
11 (3HSD1 -/- mice (Figure 4.11 and Table 4.2).
Sponges impregnated with Cortisol or cortisone and implanted in C57/B16 mice had
impaired angiogenesis in comparison to placebo-impregnated sponges (Figure 4.12).
In lipHSDl-/- mice new vessel formation was inhibited in cortisol-impregnated
sponges, whereas angiogenesis was not affected in cortisone-treated sponges (Figure
4.12). In addition angiogenesis was greater in placebo-sponges from lipHSDl-/-
mice compared to wild types (Figure 4.12).
4.3.3 Inter and intra-assay variation
Inter-assay variation was calculated as the variation in angiogenesis between mice. It
was assessed in mice with 2 sponges containing placebo by measuring the coefficient
of variation between Chalkley counts for each mouse and finding the mean of these
values which was 8± 3% (n= 6). Intra-assay coefficient of variation was quantified as
the variation in angiogenesis between sponges in the same animal. It was calculated
in mice with 2 sponges containing placebo by measuring the variation between
Chalkley counts of each sponge in the same animal and finding the mean of these
from n= 6 mice and it was 12 ± 3%.
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Figure 4.11 Absence of lipHSD reductase activity in lipHSD 1-/- mice
Strain
Steroid Impregnated
Cortisol level (ng/g sponge)
Ipsilateral steroid Contralateral placebo
Treated sponge Treated sponge
Wild type Cortisol
Cortisone
4271±186 # 161 ±18
295 ±25#** 98 ±19
llpHSDl Cortisol
Cortisone
3775±1703 # 135 ±46
87±11 90 ±30
Figure 4.11 and Table 4.2 lipHSD reductase activity in lipHSD 1-/- mice
Cortisol was not detected in cortisone-impregnated sponges from 11pHSD1 -/- mice. (Figure
4.11) HPLC Chromatogram with uv absorbance detection, green trace represents standard
(E cortisone, F Cortisol) red trace is sponge extract from cortisone-impregnated sponge from
an 11 (3HSD1 -/- mice. No Cortisol was detected in the sample. Table 4.2 Cortisol
concentrations in sponge extracts from C57/BI6 and 11PHSD1 -/- mice. Cortisone was not
converted to Cortisol in 11 pHSD1 -/- mice. Results are mean ± SEM for n=3-6 experiments. #






Figure 4.12 lipHSD-1 represses angiogenesis in vivo
Sponges from C57BI6 wild type (open columns n=12) or 11PHSD1 -/- (filled columns n=6)
mice with and without glucocorticoids. Results are mean ± SEM. #p<0.001 versus
corresponding vehicle. *** p<0.001 for differences between wild type and 11PHSD1 -/-.
Placebo impregnated sponges exhibited an increased angiogenic response in 1ipHSD1 -/-
compared to wild type mice. Angiogenesis was not different between strains in the presence
of Cortisol but was inhibited by cortisone in sponges from wild type but not 11 pHSD1 -/- mice.
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4.4 Discussion
The results described in this chapter confirm the findings from chapter 3 that
endogenous concentrations of glucocorticoid are sufficient to inhibit angiogenesis in
a glucocorticoid receptor-dependent manner. Furthermore, consistent with in vitro
findings, local glucocorticoid regeneration by lipHSDl reductase activity impairs
new vessel formation in vivo. In addition, in the absence of exogenous steroid,
1 lpHSDl inhibited angiogenesis indicating that 1 lpHSDl regulates angiogenesis by
tonically repressing new vessel formation.
4.4.1 Modification of the sponge implantation angiogenesis assay
Sponge implantation has been performed in rats to demonstrate the effects of
therapeutic concentrations of glucocorticoids to influence angiogenesis (Hori et al.
1996). However in this model steroids were delivered by a cannula that was sewn
into the sponge and fed out through the skin. Drug delivery by this method meant
that animals had to be housed singly. Such housing is an acknowledged stressor for
mice, causes an elevation of glucocorticoid concentrations and has been associated
with delayed wound healing (Glasper & DeVries 2005). Other techniques for drug
administration in this assay include daily injection directly into the sponge (Hague et
al. 2002) or by subcutaneous pellet implantation (Fajardo et al. 1992). Subcutaneous
injection generates handling and procedure stresses and thus was avoided through the
use of subcutaneous pellets. Silicon pellets previously developed to investigate
glucocorticoid replacement in adrenalectomised rats (Livingstone et al. 2000a) were
used to perform pilot angiogenesis studies in the sponge implant model. Steroid
release from such pellets is consistent and occurs up to 4 weeks after implantation
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(Cleasby et al. 2003). Although this type of drug administration helped to localise
delivery it was unclear how much drug was present in the environment of the
sponges. Measurement of sponge Cortisol concentrations indicated that steroid
release from the sponge was localised and did not affect contralateral sponges. In the
established models (Hori et al. 1996; Illanes et al. 2002) drug delivery by injection
either by cannula or into the sponge was assumed to be localised to the vicinity of the
sponge because of the formation of a fibrous capsule around the sponges (Andrade et
al. 1987a). In those studies a l-2mm thick, fibrous, collagen-rich capsule consistently
grew over the sponge over the first 6 days following implantation; vessel growth
within the sponge also proceeded at a predictable rate with a lag phase of 3-4 day
after implantation, followed by exponential growth over the next 14-16 days with
growth reaching a plateau from day 21 (Andrade et al. 1987). Consequently, in the
experiments described in this chapter, sponges were excised 3 weeks following
implantation.
Similar to the concerns surrounding localisation of drug delivery; validation for the
method of using contralateral placebo-impregnated sponges as controls does not
appear to have been performed (Hori et al. 1996). Thus mice that received no
exogenous steroid, but had sponges implanted bilaterally, were compared to mice
that received corticosterone on the right flank and placebo on the left. The results
from these studies indicated that there was no difference in angiogenesis in the
placebo treated sponges. Therefore, placebo and steroid could be assessed in the
same mouse. These pilot studies indicated that large concentrations of
glucocorticoids inhibited angiogenesis in vivo but also that these concentrations had
systemic side effects: plasma corticosterone was suppressed, the weights of
glucocorticoid-sensitive organs were decreased and wound healing was impaired.
These systemic effects were similar to findings reported from previous work using
this concentration of corticosterone (Cleasby et al. 2003). The decreased plasma
corticosterone is thought to be a consequence of an impaired glucocorticoid stress
response secondary to tonic release of steroid from the pellet (Cleasby et al. 2003).
Concentrations of glucocorticoids were subsequently adjusted to maintain an
angiostatic influence but reduce the systemic effects.
Despite the striking changes in angiogenesis seen with high concentrations of
corticosterone, the protein assay did not detect any differences between
glucocorticoid- and placebo-treated sponges. Protein was quantified as a marker of
angiogenesis and the results indicated that this was not a reliable indicator of new
vessel formation when measured using the Bradford assay. This particular assay
measures the change in light absorption associated with binding of a colorimetric dye
(Coomassie Blue G-250) to proteins and has been used extensively because it is
highly sensitive and easy to perform (Sapan et al. 1999). Protein binding to dye is
reliant on protein composition as well as quantity, and factors such as amino-acid
content, degree of glycosylation and protein conformation have been shown to alter
binding characteristics (Sapan et al. 1999). Thus the limitations of the assay rather
than the absence of any differences in protein concentrations may explain the data.
Other methods of protein quantification may have provided further information but
these were not pursued because consistent results were obtained by vessel counting.
Vessels were counted using 2 techniques: either high power field counting or
Chalkley count determination. Both methods were simple to perform reliable
reproducible and both detected the inhibition of angiogenesis by glucocorticoids.
However Chalkley count is better established (Hague et al. 2002; Fox et al. 1995)
and more time efficient and thus was adopted as the method of choice.
Vessels were identified by haematoxylin and eosin staining as in previous
investigations (Andrade et al. 1987; Edwards et al. 1960). Extensive attempts were
made to label endothelial cells within the sponges using either anti-CD31 or anti-
vWF antibodies (Datta et al. 1995; Newman & Newman 2003). For both of these
antibodies rigorous method development of staining protocols, including varying
antigen retrieval techniques, altering buffers, incubation times and antibody
concentrations failed to establish a satisfactory staining method. More recently a
publication examining different endothelial cell markers has indicated that the lack of
success may have been associated with the use of 10% formalin fixation, although
other groups claim to have success with this (Illanes et al. 2002; Ismail et al. 2003).
Following discussion with a leading angiogenesis investigator vessels were identified
using haematoxylin and eosin staining alone although in the light of recent
information (Ismail et al. 2003) future studies might consider the use of a different
fixative agent. Following extensive method development the sponge implant model
was used to investigate the influence of endogenous glucocorticoids to regulate
angiogenesis.
4.4.2 Endogenous glucocorticoids inhibit angiogenesis
The role of endogenous glucocorticoids was evaluated by performing adrenalectomy
immediately prior to sponge implantation. Plasma corticosterone concentrations
confirmed the efficacy of surgery and in the absence of measurable plasma
corticosterone sponge vascularity increased. Sponges implanted in sham-operated
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animals had fewer new vessels in comparison to sponges from adrenalectomised
animals. Therefore endogenous glucocorticoids repress angiogenesis and
adrenalectomy facilitates sponge vascularisation.
To confirm these findings, but also to determine the receptor responsible for the in
vivo angiostatic effects of glucocorticoids, sponges were treated with a
glucocorticoid or a mineralocorticoid receptor antagonist. The mineralocorticoid
receptor antagonist spironolactone had no effect on angiogenesis in the implanted
sponges. This in contrast to reported effects suggesting that spironolactone inhibits
angiogenesis (Klauber et al. 1996; Guggino et al. 2003; Guggino et al. 2002).
However, these reports should be interpreted with caution as the concentrations of
spironolactone used were supra-therapeutic. The concentration of spironolactone
administered to sponges in the present study was calculated by extrapolating from
glucocorticoid doses. The absence of an effect of spironolactone on angiogenesis is
in agreement with findings using therapeutic concentrations in vitro as observed in
aortic ring cultures (Chapter 3).
Glucocorticoid receptor antagonist, RU38486, treatment of impregnated sponges
increased angiogenesis, confirming that endogenous glucocorticoids inhibit
angiogenesis. In addition, increased sponge vascularity in the presence of a
glucocorticoid receptor antagonist indicated that the effects of endogenous
glucocorticoids on angiogenesis are glucocorticoid receptor dependent. This is
consistent with the findings in vitro in aortic ring culture where RU38486 abolished
the angiostatic effects of exogenous glucocorticoids.
173
RU38468 stimulation of angiogenesis in sponges was associated with decreased
plasma corticosterone. Clinically RU38486 increases plasma glucocorticoids by
inhibiting feedback to the hypothalamic-pituitary-adrenal axis (Byrne et al. 2004) .
In animal studies RU38486 also increased plasma corticosterone (Wade et al. 1988).
However, there are reports that RU38486 inhibits adrenal steroidogenic enzymes to
impair steroid production (Albertson et al. 1994). More recently RU38486 has been
associated with impaired responses to recurrent stress, such that plasma
corticosterone fails to rise with repeated stress (Moldow et al. 2005). Whether
inhibition of steroidogenic enzymes or impairment of stress responses accounts for
the current results requires further evaluation. It is, however, unlikely that the
reduced plasma corticosterone levels are as a consequence of drug cross-reactivity in
the radioimmunoassay for this would have led to an increase rather than decrease in
the measured concentration of steroid.
Previous studies using RU38486 to explore the effects of endogenous
glucocorticoids on wound healing and inflammation have shown conflicting results
(Tcacencu 2002; Padgett et al. 1998; Bitar et al. 1999; Leech et al. 2000a; Vinson et
al. 1998; Tjandra et al. 1996; Laue et al. 1988; Leech et al. 2000b; Kohli et al.
1998). RU38486 consistently increases the inflammatory response but the effect of
this on wound healing is variable. The different consequences of increasing
inflammatory responses may reflect the dissimilarity of in vivo models used.
Differences in vascularity, for example, may determine the influence of increased
inflammatory cell migration and re-vascularisation of inflamed tissue. Although
disparate in some of their findings, these studies indicate that endogenous
glucocorticoids influence processes associated with angiogenesis with subsequent
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effects on tissue healing. Whether this associates with endogenous glucocorticoid
regulation of angiogenesis in pathology will require further investigation.
RU38486 is also recognised to be a progesterone receptor antagonistYamamoto et
al. 1994). It is unlikely that progesterone antagonism is responsible for the data
presented in this chapter since male mice were used that have low levels of
progestogens. In addition, RU38486 antagonism of progesterone receptors would be
expected to be associated with an impairment of angiogenesis as progestogens are
associated with increased new vessel formation (Hague et al. 2002).
4.4.3 11PHSD1 tonically represses angiogenesis
Whether glucocorticoid-mediated regulation of angiogenesis could be influenced by
11PHSD1 was investigated using placebo- or glucocorticoid-impregnated implants in
wild type and 1 lpHSDl deficient mice. 1 lpHSDl reductase activity was confirmed
in sponges from wild type mice by using human corticosteroids, Cortisol and
cortisone, to allow differentiation from endogenous steroids. In the presence of
Cortisol and cortisone, angiogenesis was inhibited in wild type mice. In contrast in
sponges from lipHSDl deficient mice reductase activity was absent and,
furthermore, although Cortisol inhibited angiogenesis the angiostatic effect of
cortisone was abolished in these mice. Thus glucocorticoids impair angiogenesis in
vivo and lipHSDl moderates glucocorticoid-induced angiostasis through the
regeneration of active glucocorticoids. In addition, in a comparison of placebo-
impregnated sponges from wild type and lipHSDl deficient mice, lipHSDl was
found to repress angiogenesis. lipHSDl therefore tonically inhibits angiogenesis in
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vivo and adds a further tier of control to the regulation of angiogenesis by
endogenous glucocorticoids.
The tonic regulation of angiogenesis was a novel finding in vivo that has not been
observed in vitro in aortic rings (Chapter 3). This could be a consequence of the
systemic factors that are unique to the in vivo setting such as the presence of
inflammation or the metabolic environment of the implants/subcutaneous tissue or
the contribution to angiogenesis that circulating precursor cells may make.
Inflammation is closely linked to angiogenesis (Conway et al. 2001) and,
furthermore, inflammatory cytokines are acknowledged to increase vascular smooth
muscle cell llpHSDl activity and expression (Cai et al. 2001). In addition
lipHSDl is potentially a key regulator of inflammation resolution not only as a
result of local glucocorticoid regeneration but also as regulator ofmacrophage ability
to phagocytose neutrophils. Whether the absence of local glucocorticoid regeneration
in the vessel wall or impaired macrophage phagocytic function is sufficient to
increase the inflammatory response and alter the angiogenic cascade in lipHSDl
deficient mice will require further investigation.
Future work to examine the nature of the inflammatory cell infiltrate of sponges may
reveal differences between the strains that may help to account for the altered
angiogenesis responses. Other groups in the past have analysed sponge fluid for
cytokine concentrations to explore whether the observed effects of glucocorticoids
might be as a consequence of anti-inflammatory effects (Hori et al. 1996). Extracts
of sponge homogenates in the studies from this chapter have been stored and could
be examined. However, altered levels of VEGF, FGF or cytokines may indicate an
effect of steroids or simply the differences in sponge cellularity and further
evaluation of these samples is not currently planned. Application of the sponge
technique to other transgenic mice might help to dissect the importance of different
components of the angiogenesis cascade. Previously the corneal angiogenesis model
has, for example, been applied to severe combined immunodeficient mice or natural
killer cell-deficient mice to explore the role of inflammation in angiogenesis
(Kenyon et al. 1996). Applying the sponge implant model to these mice with steroid
impregnated sponges might help to dissect out the anti-inflammatory effects of
steroids from their effects on cell migration, proliferation and collagen metabolism.
If further studies with sponges were planned it would be beneficial to continue to
refine endothelial cell immunohistochemistry techniques. Altering the solution used
to fix tissue may help to preserve antigens and therefore also be useful in the
attempts to identify inflammatory cells.
In summary, with extensive model development the subcutaneous sponge implant
assay has been used to demonstrate that endogenous glucocorticoids inhibit
angiogenesis in vivo. In addition lipHSDl, through the regeneration of
glucocorticoids, tonically repressed angiogenesis and therefore adds a further tier to
the regulation of angiogenesis by glucocorticoids. These data are consistent with in
vitro findings (Chapter 3) but also indicate a physiological role for glucocorticoids
and lipHSDl in the regulation of angiogenesis. Sponge implants have been
associated with a non-specific immune reaction which could be argued not to a
physiological response to injury (Andrade et al. 1987). Therefore further work











Physiologically relevant concentrations of glucocorticoids were found to inhibit
angiogenesis and their effects were modulated by vessel wall llpHSDl in vitro
(Chapter 3). Furthermore in vivo endogenous glucocorticoids repressed the
angiogenic response in sponges, which was also tonically impaired by lipHSDl
(Chapter 4). However to establish whether these findings are relevant in pathology
requires validation in a pathological model of angiogenesis.
Differences exist between in vivo models that rely upon infiltration (models such as
the subcutaneous sponge, Matrigel or tumour subcutaneous angiogenesis assays) and
other methods where a tissue angiogenic response to injury is examined (for example
retinal, corneal, cutaneous wound healing or ischaemic limb models). In these latter
models tissue insult results in hypoxia or ischaemia (Singer & Clark 1999; Heba et
al. 2001). Hypoxia may be induced by reducing oxygen tension and ischaemia may
be imposed by tissue or arterial injury. In angiogenesis in pathology it is the vascular
response of an endogenous tissue to hypoxia or ischaemia and subsequent
inflammation that distinguishes these assay from other in vivo assays that use foreign
body implantation.
Angiogenesis in pathology is part of an organised wound healing response that
establishes a new network of blood vessels with a recognised hierarchy (Jain 2003).
This type of organised response is in contrast to pathological angiogenesis that is
found in primary vascular tumours and other tissue malignancies (Carmeliet & Jain
2000). Vessel formation in the latter situations appears to be dysregulated, vascular
organisation is lost, and vessels of different shapes and sizes chaotically assemble
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into an inefficient structure. Although the regulation of pathological angiogenesis is
important, especially in the development of new chemotherapies, this thesis concerns
with the physiological regulation of angiogenesis by glucocorticoids and 1 lpHSDl.
Therefore in this chapter studies are performed examining the effects of tissue
ischaemia on angiogenesis in the heart and skin.
Mouse chronic coronary ligation technique is well established (Yang et al. 2002;
Wang et al. 2004; Lutgens et al. 1999; Lu et al. 2004) and has been used to
document the effects of different gene deletions on the myocardial response to
ischaemia. The model involves the creation of cutaneous thoracotomy incision that
also allows a study to be made of the angiogenic response of the skin from the same
animal. Although the mouse model is well established, and despite myocardial
revascularisation remaining a therapeutic goal of ischaemic heart disease, little is
understood regarding the appearance of new vessels in the ventricle immediately post
infarct. An angiogenic reaction has been noted to occur by the presence of increased
vessels 7-10 days following infarction and numerous attempts has been made to
promote this response to improve revascularisation and ventricular function (Symes
et al. 1999; Solomon & Gersh 1993; Orlic et al. 2001; Michael et al. 1999; Hodgson
et al. 2004; Heymans et al. 1999; Helisch & Schaper 2003; Hao et al. 2004). In an
attempt to ameliorate the inflammatory response in the healing myocardium and
salvage myocardiocytes, glucocorticoids have been used therapeutically and in
animal studies; however the results from these studies are inconsistent (Kones 1975).
It is also not clear whether therapeutic glucocorticoids inhibit angiogenesis in the
infarcted tissue.
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The data from chapters 3 and 4 indicate that endogenous glucocorticoids might
repress angiogenesis in infarcted myocardium and that systemic anti-glucocorticoid
therapy may improve myocardial revascularisation. However, the influence of
endogenous glucocorticoid to modulate the angiogenic response to myocardial
infarction has not been considered previously. An anti-glucocorticoid agents might
improve the angiogenic response and potentially improve tissue recovery after
infarction, but it would be risky to administer a systemic anti-glucocorticoid at the
same time as the significant stressor ofmyocardial infarction.
However preventing the local regeneration of glucocorticoids by inhibiting
11 (3HSD1 may provide an alternative strategy targeted to limited tissues.
Unfortunately there are no readily available specific inhibitors for 11(3HSD1 (Seckl
& Walker 2001) but the genetically modified lipHSDl deficient mouse provides a
useful model to investigate whether local regeneration of glucocorticoids is an
important determinant of angiogenesis in pathology.
Therefore the aims of this chapter were to develop 2 assays of angiogenesis in
pathology that would enable investigation of the influence of endogenous
glucocorticoid to modulate tissue revascularisation. The models were used to




Both models underwent extensive method development before applying them to
further investigations examining the influence of glucocorticoids on angiogenesis in
pathology. Adaptations were made to surgical technique, length of experiments,
vessel identification and assessment of revascularisation and are all detailed below.
5.2.1 Chronic coronary artery ligation
(Refer to section 2.9) Myocardial infarction in rodents can be induced in recovery
surgical procedures through injuring a major coronary artery by several different
mechanism including suturing (Li et al. 1997), cauterization (Moskowitz et al. 1979),
or cryo-injury (Ciulla et al. 2004; Huwer et al. 1999). More recently ischaemia
reperfusion models in mice have been developed with the aim of better reflecting the
clinical experience of infarct and revascularisation (Michael et al. 1999). However
chronic coronary ligation was selected for these studies because of the reliability of
this technique to reproduce large infarcts in a predictable territory and generate a
sustained hypoxic insult that would stimulate myocardial angiogenesis (Lutgens et
al. 1999).
Mice- Male, C57B16J wild type controls and 1 ipHSD-1 homozygous null (-/-) mice
aged 8-10 weeks were used (Charles River, UK)
Surgery- Expertise in the surgical techniques required for these models was obtained
under the supervision of Dr Isam Sharif (Centre for Cardiovascular Science
Edinburgh University) and practiced using non-recovery procedures on anaesthetised
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animals. A formal assessment of the technique was made by Dr Jane Conole,
University of Edinburgh Veterinary Surgeon.
Mice were anaesthetised by intraperitoneal injection of xylazine (0.018mg/kg),
ketamine (lOOmg/kg), and atropine (600mcg/kg) (Mora et al. 2003). Surgery was
performed as described in the methods (Section 2.9.2) (Lutgens et al. 1999). Briefly
following endotracheal intubation and mechanical ventilation, superficial tissues
were dissected, a 2cm incision made in the 4th intercostal space, the pericardium
divided and the left main descending artery ligated with 6.0 prolene suture. In sham
operated animals the suture was not ligated. The thoracic wall was closed by layered
suturing; the skin was stitched with a continuous suture using 5-0 Mersilk with a
10mm 3/8c round-bodied needle. On completion of surgery animals received
intraperitoneal atipamazole (5mg/kg) and subcutaneous buprenorphine (0.05mg/kg).
At the end of the experiment animals were re-anaesthetised, underwent
echocardiography followed by intracardiac catheterisation for pressure measurements
and intra-cardiac blood collection and were sacrificed. Excised hearts and cutaneous
wounds were processed for histology.
Experiment length- Initially, to record the timing of new vessel appearance in
infarcted myocardium, animals were sacrificed on days 1, 3, 5, 7 or 14. These initial
data indicated that angiogenesis was well established by day 7 and this time point
was adopted as the standard experiment length.
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Histology- At excision hearts were bisected, weighed and placed in 10% formalin
and processed for histology by paraffin embedding and sectioning at 8pm (Mora et
al. 2003)(See section 2.8.5). Sections were subsequently stained with haematoxylin
and eosin to measure infarct size, van Gieson stain to record the deposition of
collagen and immunohistochemistry techniques to identify endothelial cells.
Endothelial cell identification- Rat anti-mouse anti-CD 31 antibodies (Pharmingen)
were initially used to identify endothelial cells. However labeling with this antibody
was not satisfactory despite repeated attempts to refine the methods by altering
antigen retrieval techniques, antibody concentrations, incubation times and buffers
(see Section 2.9.5). Instead, rabbit anti-human von Willebrand factor antibodies
(Dakocytomation, UK) were used and consistent staining was observed using
primary antibody dilutions of 1:200. Staining for von Willebrand factor detected
small and medium size vessels but did not detect the microvasculature. Nevertheless
it was possible to document an angiogenic response to infarction with time using
these antibodies and therefore this technique was used as the standard protocol for
these experiments.
Quantification ofangiogenesis - Vessels were counted at x 400 magnification in the
4 most vascular fields, (2 endocardial, 2 epicardial), using a 0.0625mm2 reticule; the
borders of the reticule were within the infarct as previously described (Virag &
Murry 2003). The numbers of small-medium size vessels counted using this
technique were similar to previous observations (Hao et al. 2004).
Infarct size measurement (see section 2.9.8) Infarct size was determined as a
percentage of left ventricular area. It was quantified by measuring the area affected
by infarction as indicated by the region of disrupted myocardial architecture,
proliferating cells and inflammatory cell infiltrate on haematoxylin and eosin stained
sections (Virag & Murry 2003). Measurement was performed using captured images
(Research Systems Photometric camera) from light microscopy and analysed using
in house scripts (Lutgens et al. 1999).
Assessment of left ventricular remodelling-Mouse echocardiography was performed
to examine the effect of infarction and treatment on left ventricular parameters (See
Section 2.9.3). Before sacrifice animals were re-anaesthetised and echocardiography
was performed using a Diasus ultrasound machine (Dynamic Imaging Livingston
UK) (Mora et al. 2003). Images were stored on an optical disk and analysed offline
using Diasus software (Dynamic Imaging). Left ventricular (LV) parameters (see
Table 5.1) were measured at the mid- papillary level on live 2-D images and
averaged from 2 cardiac cycles. Left ventricular function as assessed by ejection
fraction (EF) ([(LVEDA-LVESA)/LVEDA] x 100) and fractional shortening (FS)
([(LVEDD-LVESD)/LVED] x 100) (Mora et al. 2003) was quantified as a measure
ofmyocardial performance.
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Left Ventricular Parameters Abbreviation
left ventricular end diastolic diameter LVEDD
left ventricular end systolic diameter LVESD
left ventricular end diastolic area LVEDA
left ventricular end systolic area LVESA
posterior wall thickness at end diastole PWD
posterior wall thickness at end systole PWS
ejection fraction EF
fractional shortening FS
Table 5.1 Left ventricular parameters measured by echocardiography
Left ventricular (LV) parameters were measured at the mid- papillary level on live 2-D
images and averaged from 2 cardiac cycles. Images were stored on an optical disk and
analysed offline using Diasus software.
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Left Ventricular Pressures Dr Isam Sharif performed these procedures. In
preliminary studies following echocardiography, the right carotid artery was
cannulated using a pressure-transducer tipped catheter (1.4F, Millar Instrument Inc,
USA) for measurement of blood pressure and heart rate. The catheter was then
advanced into the left ventricle for measurement of left ventricular pressure. The left
ventricular diastolic pressure was not raised in mice that had undergone chronic
coronary ligation procedures 7 days previously as previously noted (Lutgens et al.
1999) therefore this technique was not used in further experiments.
5.2.2 Cutaneous Wound Healing Assay
Thoracotomy wounds from mice undergoing chronic coronary ligation that had been
sutured with 5.0 mersilk (Ethicon, Johnson & Johnson, UK) using a 1mm round-
bodied needle were used in these studies. At sacrifice 7 days following chronic
coronary ligation the thoracotomy cutaneous wounds were removed by wide
excision, placed in 10% formalin and processed for histology. Paraffin embedded
skin was sectioned (8pm) and stained with haematoxylin and eosin for
morphological analysis or with an endothelial cell marker to quantify angiogenesis.
As in the infarcted myocardium anti-CD31 (BD Biosciences, UK) did not
satisfactorily identify endothelial cells despite considerable method development.
Small and medium sized vessels were identified successfully using anti-von
Willebrand antibodies (Dakocytomation, UK).
Quantification ofAngiogenesis in cutaneous wounds Thoractomy wounds from mice
(in both placebo versus RU38486 treatment groups, or wild type versus 1 ipjJSD-1 -
/- mice groups) were used. Vessel density was determined in the dermis at x250 light
microscopy using the mean of triplicate Chalkley counts on 2 sections per wound
(Fox et al. 1995).
5.2.3 Influence of endogenous glucocorticoids and 11PHSD1 on
angiogenesis in pathology
RU38486 (a glucocorticoid receptor antagonist) was used to investigate the
endogenous effects of glucocorticoids on myocardial revascularisation and wound
healing angiogenesis. Silastic pellets impregnated with 5.25mg of RU38486 or
placebo were prepared as described in Chapter 2. The pellets were implanted through
a 0.5cm incision on the back of the mouse under halothane anesthesia. The incision
wound was sutured closed with 5.0 mersilk (Ethicon, Johnson & Johnson, UK). A
week later the mice underwent chronic coronary artery ligation. Animals were
sacrificed 7 days post coronary artery ligation. Prior to sacrifice animal were
anaesthetised, underwent echocardiography and had blood collected by intra-cardiac
puncture for the measurement of plasma corticosterone and RU38486 concentrations.
Cutaneous thoracotomy wounds and hearts were excised and processed for histology.
Plasma Analysis- (See section 2.8.7) Blood was collected into a heparin coated
syringe, and transferred to a 1.5ml eppendorf on ice, centrifuged and the plasma
removed and stored at minus 80°C. Plasma corticosterone was quantified by radio-
immuno-assay (section 2.8.7) (Cleasby et al. 2003).
Plasma RU38486 was assayed with liquid chromatography with mass spectroscopy
(LCMSMS) (section 2.9.6) detection monitoring for an ion characteristic of
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R.U38486. For this assay, the range of detection was <30ng/ml to >0.5ng/ml. Dr
Natalie Homer performed the LCMSMS quantification technique.
11/3HSD1 regulation ofangiogenesis in pathology- Coronary artery ligation or sham
procedures were performed on male aged matched C57B16J and llpHSD-1
homozygous null (-/-) mice. Mice were sacrificed 7 days following surgery. Prior to
sacrifice mice were re-anaesthetised and underwent echocardiography. At sacrifice
hearts and cutaneous thoracotomy wounds were excised and processed. Skin was
placed in 10% formalin. Hearts were bisected by cutting through the long axis of the
heart through middle of the infarct; half was stored in 10% formalin for histology,
half was placed immediately on to dry ice and stored at -80°C for an lipHSD
activity assay.
llfHSD activities in mouse heart- (See section 2.9.7)
An assay developed for use in tissue homogenates was used to assess lipHSD
activity in the heart (Jamieson et al. 1995). Both reductase and dehydrogenase
activities were assessed (Sandeep & Walker 2001; Cai et al. 2001). Heart tissue from
C57B16 mice that had undergone coronary artery ligation or sham surgery 7 days
previously was placed in buffer and homogenized. lOpl of homogenate was taken for
protein quantification by the Bradford assay (Section 2.8.6). Sample protein
concentration was used to standardize the amount of sample added to the assay.
Tritiated steroid was added to the appropriate co-factor and a buffered solution of
sample such that the final concentration of sample was 0.2mg protein/ml. 3H-
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11 dehydrocorticosterone and cofactor NADPH were used for the reductase reaction;
the dehydrogenase response was driven by 3H-Corticosterone and cofactor NAD.
Samples were incubated in a water bath at 37°C for 2.5 or 5 hours for the reductase
reaction and 5 or 16 hours for the dehydrogenase response. Steroids were extracted
with ethyl acetate, dried, resuspended in ethanol, separated by TLC and estimated by
scintillation counting. Enzyme activity in each direction was expressed as the percent
conversion to product (Jamieson et al. 1995).
5.2.4 Statistics
Data are mean ± SEM. Comparisons were made by ANOVA with least squares
difference post hoc tests. Inter-assay- and intra-assay coefficients of variation in wild
type mice were 19 % (n=ll) and 10 % (n= 11) in day 7 infarcts and 7% (n=4) and
12% (n=4) for day 7 wounds. Intra-assay variation was measured by calculating the
coefficient of variation between readings for each section and finding the mean of
this value. Inter-assay variation was calculated by dividing the standard error of the
means by the standard deviation of the means and expressed as a percentage.
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5.3 Results
5.3.1 Method development: establishing standard procedures
A thorough programme of education and practice of anesthetics and surgical
techniques supplemented module 4 of the Personal Licensee Training Course and
was completed over 20 weeks. At the end of this period the pilot study to determine
the appearance of new vessels with time was performed. From this study data was
also obtained regarding operative morbidity and mortality.
Operative morbidity and mortality- Average weight loss in C57B16 mice was
greatest 3 days following coronary artery ligation (Figure 5.1). Pre-operative weight
was regained at day 5 in sham operated animals and between days 8-14 in animals
under going coronary artery ligation. There were no operative deaths in the sham
group in the coronary artery ligated animals mortality was 18% (7/39).
Endothelial cell Identification- Anti von Willebrand factor antibodies labelled
endothelial cells lining blood vessels in the myocardium and skin (Figure 5.2a-c) and
was used to document the appearance of new vessels.
Experiment Length- The myocardial vascularity of sham operated animals was
consistent at each of the time points examined and appeared not to be influenced by
the surgery (Figure 5.3). In coronary artery ligated hearts vascularity increased with
time until day 7. This time point was used to measure angiogenesis in the remaining
studies. Collagenisation of infarcted tissue was also documented in a qualitative pilot
study using Van Gieson staining. Collagen deposition was not observed until day 5
(Figure 5.4).
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Figure 5.1 Coronary artery ligation or sham operation and body weight
(A) Body weight was reduced following coronary artery ligation (filled bars) or sham (open
bars) procedure in C57BI6 mice (n=18) . Reduction was marked in both groups at day 3 but
animals returned to pre-operative weight earlier following sham procedure. Weight gain in
excess of pre-operative weight occurs between days 8-14. Data are expressed as mean ±
standard error.
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a)Sham (i) and infarcted (ii) left ventricle
b) Infarcted left ventricle
c) Thoracotomy wound skin
Figure 5.2(a-c) Identification of blood vessel in paraffin embedded sections
Anti-von Willebrand factor antibodies with fast red chromogen labelling of endothelial cells in
heart (a-b) and skin (c) 7 days following surgery, (a) (x50) sham (i) and infarcted (ii) left
ventricle (Iv). Scattered large vessels (black arrows) are seen in thick wall of sham left
ventricle(i), in contrast to thin infarcted wall of left ventricle (ii) numerous small vessel are
seen (black arrows), (b) High power x100 view of infarcted left ventricle numerous vessel are
seen (black arrows), (c) Skin from thoracotomy wounds (i) haematoxylin and eosin cross
section (x50) (ii) endothelial cells within vessels (black arrows) (x100).
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Figure 5.3 Angiogenic response to coronary artery ligation
Vascularity of myocardium following coronary artery ligation (filled columns n=3-11) or sham
surgery (open columns n=2-6) in C57BI6J mice. Sham operated animals showed a constant
vascularity in contrast to ligated animals in which vessel counts were increased such that
angiogenesis was well established by day 7. Data are expressed as mean ± SEM.
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a) Left ventricle day 3 post infarction
b) Left ventricle day 5 post infarction
c) Left ventricle day 7 post infarction
im
V v C V ' <
•J**
/ * ■1' y
\. r,\ *
Figure 5.4 Van Gieson staining of infarcted left ventricle
Left ventricular sections from day 3 (a), day 5 (b) and day 7 (c) following coronary artery
ligation in C57BI6 mice. Van Gieson stain colours collagen pink. A dramatic increase in
collagen deposition is seen by day 7.
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5.3.2 Application of methods: Endogenous glucocorticoids inhibit
angiogenesis in pathology
Morbidity and Mortality- RU38486 or placebo pellet implantation was tolerated
well; there was no difference in weight change between the 2 treatment groups prior
to coronary artery ligation (0.67±0.54g for RU38486 treated animals n=9 versus
0.22±0.25g for placebo treated animals n=4 p=0.16). Both treatment groups
underwent chronic coronary ligation surgery no sham procedures were performed.
More mice in the RU38486 treated group died following coronary artery ligation
than in the placebo treated group, however the study was not powered to detect a
significant difference in mortality with treatment (5/9 deaths treated with RU38486,
4 of which were from ventricular rupture: versus 1/4 treated with placebo as a result
of ventricular rupture; p= 0.34). Weight change following surgery was similar in
both treatment groups (-1.9±1.6g for placebo (n=3) compared to -0.65±1.8g for
RU38486 (n=6) p=0.44).
Plasma Analysis- Corticosterone concentration in plasma was higher in placebo
treated animals that had undergone coronary artery ligation (487±24nM for placebo
treated animals versus 253±27nM for RU38486 treated animals n=4 p<0.01)
compared to RU38486 treated animals.
In plasma samples processed for quantification of RU38486, alfaxalone was
successfully recovered from control and treatment group plasma samples. RU38486
was only detected in samples from animals that had received RU38486 treatment in
which the concentration was 12.6±2.68ng/ml (n=4).
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Infarct size- At day 7 the proportional area of the left ventricular myocardium
affected by coronary artery ligation was similar in both treatment groups (41.8±6.2%
for vehicle, 45.5±4.8% for RU38486, n=3-6).
Left Ventricular Dimensions and Function - Compared to vehicle, RU38486
treatment did not alter the influence of coronary artery ligation on LV parameters
(Table 5.2). Left ventricular ejection fraction (EF) and fractional shortening (FS)
were similar in RU38486 and vehicle treated controls (Table 5.2).
Ventricular Angiogenesis Myocardial revascularisation was enhanced in RU38486
treated mice in comparison to vehicle treated controls (Figure 5.5).
Cutaneous WoundHealing-Thoractomy wounds from placebo and RU38486 treated
mice exhibited no differences in gross appearance. Hair re-growth appeared to be
similar as was the extent of granulation tissue; wound dehiscence did not occur.
Cutaneous Angiogenesis New vessel formation in the dermis of cutaneous wounds




Surgery INFARCT (n=3) INFARCT (n=4)
LVEDD (mm) 4.54±0.2 5.1±0.2
LVESD (mm) 3.5±0.2 4.2±0.3
LVareaED 23.3±1.7 27.5±3.2
LVareaES 17.7±1.9 21,4±2.9
PWD (mm) 0.7±0.1 0.4±0.1
PWS (mm) 0.8±0.1 0.7±0.1
FS 22.7±4.9 19.3±3.2
EF% 24.3±3.8 22.6±1.6
Table 5.2 Left ventricular dimensions following coronary artery ligation in
vehicle and RU38486 treated mice
There was no difference in left ventricular (LV) parameter between vehicle and RU38486
treated mice. Left ventricular ejection fraction and fractional shortening were similar in the 2
treatment groups. (Results are mean ± SEM, n=3-4). Left ventricular end diastolic diameter
(LVEDD), LV end systolic diameter (LVESD), LV end diastolic area (LVEDA), LV end systolic
area (LVESA), posterior wall thickness at end diastole (PWD) posterior wall thickness at end
systole (PWS)]. Left ventricular ejection fraction (EF) ([(LVEDA-LVESA)/LVEDA] x 100) and





Figure 5.5 Ventricular angiogenesis following myocardial infarction
C57BI6 mice treated with RU38486 (solid bar) had greater new vessel formation following
chronic coronary ligation than placebo treated controls (clear bar). Data are mean±SEM




Figure 5.6 Angiogenesis in cutaneous wounds
Thoracotomy skin wounds from animals that had undergone coronary artery ligation 7 days
previously. No visible differences were seen in the amount of tissue granulation, hair re-
growth or wound dehiscence. However dermal angiogenesis was increased in mice treated
with RU38486 (solid bar) in comparison to placebo (clear bar). Data are mean±SEM n=4-6
p<0.01.
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5.3.3 Application of methods: 11 pHSD1 inhibits angiogenesis in pathology
Morbidity and Mortality- 1 lpHSDl deficient mice have not been found to have any
abnormalities of vascular development, vascular function or congenital heart disease
compared to wild type mice (Hadoke et al. 2001; Kotelevtsev et al. 1997).
Weight reduction at day 7 post operatively in sham and coronary artery ligated
animals was greater in 1 ipHSD-1 -/- mice in comparison to wild types (Figure 5.7).
However, there was no difference in mortality at day 7 between strains following
coronary artery ligation (18% (7/39- 3 of which were due to ventricular rupture) in
C57B16 versus 18.75% (3/16- 2 of which were due to ventricular rupture) in
lipHSDl deficient mice); there was 1 death in sham-operated animals, which
occurred in an 1 lpHSDl deficient mouse.
11/3HSD activity- Reductase and dehydrogenase activity was detected in
homogenates of hearts from C57B16 mice that had undergone chronic coronary
ligation (n=6) and sham procedures (n=4). Activity increased with time for both
reaction directions (p<0.03 for reductase assay n=10, p<0.01 for dehydrogenase
assay n=10 analysed by repeated measures ANOVA). Infarction did not influence
11 pHSD activities in comparison to sham procedure (Figure 5.8).
Infarct size- At day 7 the proportional area of the left ventricular myocardium
affected by coronary artery ligation was similar in both strains of mice (44.2±3.4%





Figure 5.7 Influence of lipHSDl on weight loss following surgery
Weight loss recorded at 7days post procedure. Both stains of mice undergoing sham (clear
bar) or chronic coronary artery procedure (solid bar) lost weight. 11(5HSD-1 deficient
(11PHSD1 n=15) had a greater reduction in weight compared to C57BI6 (wild type n=18)





Figure 5.8 Effect of Coronary Artery Ligation on lipHSD Activity
11PHSD activities are expressed as the percentage conversion of [3H]-substrate by
homogenates of mouse heart at standard protein concentrations (n =10). 11PHSD reductase
activity was measured after 2.5 and 5 hours incubation; 11 pHSD dehydrogenase activity was
measured after 5 and 16 hours incubation.
The conversion of 3H substrate increased with time in both reductase (p<0.03 by repeated
measures ANOVA; n=10) and dehydrogenase (p<0.01 by repeated measures ANOVA;
n=10) reactions. Surgical treatment with coronary artery ligation (filled columns n=6) in
comparison to sham (open columns n=4) did not alter reductase or dehydrogenase 11PHSD
reactions.
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Left Ventricular Dimensions and Function - There was no difference in baseline left
ventricular (LV) parameters between sham-operated C57B16 and 1 lpHSDl deficient
mice. In comparison to sham operation, coronary artery ligation affected all
measured parameters of LV dimensions in C57B16 and lipHSDl deficient mice
(Table 5.3). Coronary artery ligation was associated with left ventricular dilatation
and thinning of the left ventricular posterior wall in both strains. Coronary artery
ligated 1 ipHSD-1 deficient mice had reduced thinning of the posterior wall and less
dilation of the LV cavity in comparison to wild type controls (Table 5.3). Left
ventricular ejection fraction (EF) and fractional shortening (FS) were reduced by
coronary artery ligation in wild type and 1 lpHSDl deficient mice but the reduction
was less in 1 ipHSD-1 deficient mice (Figure 5.9).
Ventricular Angiogenesis - No difference was recorded in myocardial vascularity
between sham-operated C57B16 and lipHSDl deficient mice. In contrast following
coronary artery ligation lipHSDl deficient mice exhibited enhanced
revascularisation in comparison to controls (Figure 5.10).
Cutaneous Wound Healing- Thoracotomy wounds from C57B16 and lipHSDl
deficient mice 7 days following the procedure on gross inspection appeared similar.
No differences were noticed in coat re-growth, extent of granulation tissue or wound
dehiscence.
Angiogenesis The dermal angiogenic response was greater in 1 lpHSDl deficient
mice (5.1 ±0.27 Chalkley count) in comparison to C57B16 controls (3.5±0.25
Chalkley count; n=6 p<0.01. by ANOVA).
Strain Wild Type 11pHSD1
Treatment Sham (n=7) Infarct (n=10) Sham (n=6) Infarct (n=9)
LVEDD (mm) 3.4±0.1# 4.8±0.1 3.5+0.3# 4.310.2*
LVESD (mm) 2.1±0.1# 3.8±0.1 2.1+0.2# 3.210.2**
LVareaED 15.9±1.1# 24.4±1.3 13.6+1.0# 17.910.9**
LVareaES 6.6±0.7# 17.711.4 4.5+0.5# 11.1+0.8**
PWD(mm) 1.0±0.1# 0.710.1 1.3+0.1# 1.110.0**
PWS(mm) 1.4±0.1# 0.9+0.1 1.7+0.0# 1.4+0.0**
FS 37.0±2.8# 18.712.1 38.5+2.5# 24.7+2.4**
EF% 58.0±3.5# 27.813.2 66.313.7# 38.8+3.2*
Left ventricular end diastolic diameter (LVEDD), LV end systolic diameter (LVESD), LV end
diastolic area (LVEDA), LV end systolic area (LVESA), posterior wall thickness at end
diastole (PWD) posterior wall thickness at end systole (PWS)]. Left ventricular ejection
fraction (EF) ([(LVEDA-LVESA)/LVEDA] x 100) and fractional shortening (FS) ([(LVEDD-
LVESD)/LVED] x 100)
Table 5.3 Left ventricular dimensions in wild type and 1 ipHSD-1 -/- mice
There was no difference in baseline left ventricular (LV) parameters between sham-operated
wild type and 11 pHSD-1 -/- mice. Coronary artery ligation influenced all measured indices of
left ventricular dimensions and decreased left ventricular ejection fraction and fractional
shortening in comparison to sham procedure in wild type and 11 pHSD-1 -/- mice. Relative to
wild type controls 11 pHSD-1 -/- mice that received coronary artery ligation had relative
preservation of many left ventricular parameters including left ventricular ejection fraction.
(Results are mean ± SEM n=6-10. # p<0.01 versus corresponding infarct. **p<0.01 or





Figure 5.9 Left ventricular ejection fraction (EF)
Left ventricular function was quantified as ejection fraction (EF) by the equation [(LVEDA-
LVESA)/LVEDA] x 100 where LVEDA and LVESA represent left ventricular end diastolic and
end systolic areas respectively. Coronary artery ligation (filled columns) in C57BI6 (wild type)
and 11PHSD1 deficient (11|3HSD1-/-) mice decreased EF in comparison to sham (open
columns) (wild type n=6 sham, n=10 ligations and 11PHSD1 -/- n=5 sham, n=9 ligations).
Relative to wild type controls 1ipHSD-1 -/- mice that received coronary artery ligation had
relative preservation of left ventricular EF. (Results are mean ± SEM. ** p<0.01 versus
corresponding sham; # p<0.01 for differences between wild type and 11PHSD1 -/-).
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0
Wild Type 11pHSD-1 -/-
Figure 5.10 Myocardial angiogenesis following coronary artery ligation
Angiogenesis quantified as vessel/mm2 assessed in Day 7 hearts from wild type and
11pHSD1 -/- mice. Ligation (filled columns) in C57BI6 (wild type) and 11PHSD1 deficient
(11PHSD1 -/-) mice increased angiogenesis in comparison to sham (open columns) (wild
type n=6 sham, n=11 ligations and 11pHSD1 -/- n=5 sham, n=10 ligations). Results are
mean ± SEM. # p<0.001 versus corresponding sham. *** p<0.001 for differences between
wild type and 11PHSD1 -/-.
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5.4 Discussion
Data presented in this chapter demonstrate that endogenous glucocorticoids inhibit
angiogenesis in pathology in a glucocorticoid receptor dependent manner. Both
myocardial revascularisation and cutaneous angiogenesis were increased in the
presence of systemic anti-glucocorticoid therapy. In addition local glucocorticoid
regeneration by 11(3HSD1 regulated angiogenesis in these conditions. lipHSDl
deficient mice exhibited increased revascularisation in cutaneous wounds and in the
heart following myocardial infarction. Thus prevention of local regeneration of
glucocorticoids produced an anti-glucocorticoid influence with similar effects on
angiogenesis as systemic anti-glucocorticoid therapy. However, although both
therapies were associated with improved revascularisation only 1 lpHSDl deficiency
was associated with a preservation of left ventricular function and parameters. How
lipHSDl modulates left ventricular healing requires further evaluation but it
appears that the improvements are not solely due to changes in revascularisation.
5.4.1 Assay development
Both a cutaneous and a myocardial angiogenesis model were used in these studies to
allow the investigation of different tissues with distinct mechanisms of injury and
dissimilar microenvironments for angiogenesis. Thus the results from these studies
would be complimentary and may indicate important tissue and injury specific
differences in angiogenesis regulation.
Choosing the time point post operatively to evaluate angiogenesis was important in
these studies. Healing responses in both tissues are recognised to progress with time
through inflammatory, proliferative and remodelling phases (Lutgens et al. 1999; Li
et al. 2003; Virag & Murry 2003). Tissue revascularisation was expected to be
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maximal at the end of proliferation and prior to remodelling with scar tissue
formation (Singer & Clark 1999; Virag & Murry 2003). Appearance of new vessels
with time in incised subcutaneous wounds in mice had been previously documented
to be maximal at day 6 (Thompson et al. 1991) and the numbers of new vessels was
not diminished by scar formation for up to 14 days (Galeano et al. 2003).
The appearance of new vessels with time following myocardial infarction in mice
has not however been recorded previously. For although studies using genetically
deficient mice have investigated effects on myocardial revascularisation, evaluation
of angiogenesis has often been at an arbitrary time point and secondary to
evaluations of structure, function infarct size or mortality (Lutgens et al. 1999;
Carmeliet et al. 1996; Carmeliet & Collen 2000; Heymans et al. 1999). Therefore the
current study recorded myocardial post-infarct angiogenesis with time and found
revascularisation was well established by day 7. As a consequence of the
sychronicity between the time of new vessel appearance in skin and heart,
postoperative day 7 was chosen for tissue collection. Thus, mice undergoing
coronary artery surgery provided both heart tissue and cutaneous thoracotomy
wounds for angiogenesis study.
For both cutaneous and myocardial studies different techniques were available to
initiate injury. Cutaneous wound healing has been evaluated following injury using
sutured incision wounds (Thompson et al. 1991), or skin grafts (Gruss et al. 2003) or
punch biopsy (Graiani et al. 2004). In this chapter cutaneous sutured incision wounds
were used because of the established time scale of angiogenesis with this method
(Thompson et al. 1991) and to make efficient use of animals undergoing surgery for
coronary artery ligation. Similarly myocardial infarction can be induced by coronary
artery cauterisation or cryo-injury or ligation however ligation was chosen because it
reliably creates an infarct of predictable size and causes minimal myocardial damage
at application (Lutgens et al. 1999). Chronic ligation was adopted rather than an
ischaemia/ reperfusion model because ischaemia/reperfusion models are associated
with less predictable infarct sizes and inflammatory responses (Ytrehus & Downey
1993).
Identification of vessels in paraffin embedded sections from skin and heart required
considerable method development. Vessels identified that were labelled by von
Willebrand factor (vWF) appeared to be small to medium sized and not
microvascular capillaries. Capillary detection may have been a more sensitive
measure of angiogenesis since new vessel formation is acknowledged to be a
microvascular response (Conway et al. 2001), however neither vWF nor CD31
antibody stains allowed detection of these vessels in the paraffin embedded sections.
An explanation for these difficulties was published at completion of the surgeries and
indicated that failure of these stains was probably as a result of the fixative used
(Ismail et al. 2003). In this study 10% formalin was associated with poor antigen
retrieval for most endothelial cell markers; in fact vWF was one of the few that
produced any endothelial cell labelling with this fixative. Better results for
endothelial cell antigen retrieval in mouse tissues were achieved with
1 %paraformaldehyde or Zinc buffer fixatives (Ismail et al. 2003). Nevertheless in the
studies presented in this chapter the numbers of vessels labelled with vWF and
identified at x400 were consistent with previous reports of small to medium size
vessel density at this magnification (Hao et al. 2004).
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Infarct size was used in this chapter to evaluate the reliability and consistency of the
injury to ensure all mice received similar infarcts. Infarct size measurement has been
evaluated by several methods including assessment of haematoxylin and eosin
stained sections (Virag & Murry 2003) but also by evaluating the size of infarct scar
as indicated by collagen staining (Lutgens et al. 1999; Heymans et al. 1999).
Collagen staining techniques were not used to evaluate infarcts in these studies
because, although infarct size appears not to alter beyond a week (Lutgens et al.
1999), scar collagen deposition can continue to alter for up to 21 days (Lu et al.
2004; Yang et al. 2002). At these latter points infarct size measured by collagen can
be used to determine differences in remodelling (Heymans et al. 1999) rather than
consistency of surgery. Data from anatomical studies (Ahn et al. 2004; Yang et al.
2002; Lutgens et al. 1999) indicate that proximal ligation of the left main descending
artery consistently induces infarction involving 40-45% of the left ventricle, thus the
infarcts induced for the investigations of this chapter are consistent with established
techniques.
Left ventricular remodelling occurs over 21 days in the murine model although the
greatest changes occur over the first 7 days (Lutgens et al. 1999). The changes in left
ventricular dimensions and function have been well characterised for C57B16 mice
(Lutgens et al. 1999; Yang et al. 2002). A dramatic thinning of the left ventricular
free wall occurs following infraction and is well established by day 7 (Lutgens et al.
1999). The loss ofmyocardium predisposes to ventricular rupture and left ventricular
dysfunction. As a consequence of the loss of tissue and function the ventricle
reshapes to accommodate the akinetic segment with hypertrophy of viable tissue and
alteration of synchronicity of contraction (Lutgens et al. 1999; Yang et al. 2002).
211
Preservation of left ventricular function and cardiomyocyte mass is the function goal
of revascularisation therapy (Michael et al. 1999). Prompt revascularisation is
associated with preserved left ventricular dimensions and function (Pfeffer &
Braunwald 1990). Therefore in these studies left ventricular dimensions and function
were used as an evaluation of revascularisation. However this technique does not
accurately quantify the functional ability of new vessels and techniques using
fluorescent or radio labelled microspheres (van Royen et al. 2003) or magnetic
resonance imaging (Streif et al. 2005) to detect collateral circulation would be
required for this type of evaluation.
Similarly differences in cutaneous wound healing angiogenesis have been evaluated
in several ways either by simple morphological analysis (Thompson et al. 1991), by
examining tensile strength (Roman et al. 2002) or using laser doppler flow methods
(Roman et al. 2002). Although tensile wound strength is affected by impaired
angiogenesis in delayed wound healing (Li et al. 2003) whether enhanced
angiogenesis improves wound strength is not clear (Roman et al. 2002) and therefore
this technique was not adopted.
Laser Doppler assessment of flow was not available to measure collateral circulation
in the healing skin and furthermore there were concerns regarding the use of this
technique to assess capillary flow in the mice studied. It is possible that remaining
wound sutures at 7 days may have created ultrasound shadows and distorted Doppler
recordings. In addition the silk sutures may have contributed to an irritant effect that
is known to cause an increased inter assay variation with this technique (Eun 1995).
Therefore in this chapter wound angiogenesis was quantified by using morphological
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analysis but also assessed by observing coat re-growth and tissue apposition and
granulation.
Thus through the development of two different models performed by one procedure
on the same animal, angiogenesis in a pathological setting could be examined in
distinct yet linked environments. Both models were used to investigate the influence
of glucocorticoids to regulate angiogenesis.
5.4.2 Application of models
RU38486 was used as a glucocorticoid receptor antagonist to investigate the
influence of endogenous glucocorticoids on angiogenesis in pathology. Confirmation
of systemic absorption of RU38486 was obtained by the measurement of plasma
RU38486 and corticosterone concentrations. The range of RU38486 in mouse
plasmas was lower that levels obtained clinically (Zhang et al. 1991) but is of the
same order as that found in rodents given therapeutic doses (lOmg/kg) of the drug
(Heikinheimo et al. 1994).
Corticosterone plasma concentrations were elevated in both placebo and RU38486
treated animals as a consequence of sampling under stressful conditions following
intraperitoneal injection and echocardiography under anaesthesia. However
RU38486 treated animals had lower levels of plasma corticosterone than placebo
controls. Whether this reflects inhibition of steroidogenic enzymes in the adrenal
gland, an impaired stress response or partial agonist activity by RU38486 (Albertson
et al. 1994; Schulz et al. 2002; Moldow et al. 2005) is unclear; but the findings in
this chapter are consistent with those in chapter 4 that at this dose RU38486 reduces
plasma corticosterone as measured by radioimmuno-assay.
Angiogenesis was enhanced in the presence of RU38486, indicating that endogenous
glucocorticoids inhibit angiogenesis via a glucocorticoid receptor dependent
mechanism. These data are consistent with results from other in vivo studies in
Chapter 4 and also with previous reports of the effects of endogenous glucocorticoids
on healing responses in rodents (Laue et al. 1988; Grose et al. 2002). However our
current findings are novel in that they consider endogenous glucocorticoid effects on
angiogenesis in the pathologies of cutaneous wounds and infarcted myocardium
where new vessel formation is regulated by inflammation and ischaemia (Singer &
Clark 1999; Heba et al. 2001).
In spite of improving angiogenesis RU38486 did not improve left ventricular
remodelling or function. In addition there was a trend for an increase in the number
of animals dying that had received RU38486 treatment, secondary to ventricular
rupture, although the study was not powered to detect differences in mortality.
The trend for detrimental effects on mortality may be a reflection of the effects of
systemic glucocorticoid antagonism to impair the stress response to myocardial
infarction. In addition RU38486 may unbalance local glucocorticoid activities in the
heart since glucocorticoids are ligands for mineralo- and glucocorticoid receptors
both or which are found in cardiomyocytes (Escoubet et al. 1996; Sheppard 2003).
Certainly over-expression ofmineralocorticoid receptors in cardiomyocytes in rats is
associated with detrimental effects on cardiomyocyte function (Le Menuet et al.
2004; Beggah et al. 2002). 1 lpHSDl, in contrast, is predicted to alter activation of
any intracellular corticosteroid receptors, be they glucocorticoid or mineralocorticoid
receptors. Whether selective glucocorticoid receptor antagonism in these cells by
RU38486 is producing a similar effect by exposing the cells to unbalanced
glucocorticoid-mediated mineralocorticoid receptor activation will require further
determination.
Other models have been used to examine the influence of therapeutic concentrations
of glucocorticoids on myocardial ischaemia. The results from these studies are
inconsistent, with some finding reduced infarct size (Hafezi-Moghadam et al. 2002;
Kawabata et al. 1995; Valen et al. 2000) others demonstrating impaired healing
(Scheuer & Mifflin 1997; Wexler 1976) and ventricular aneuryism (Vyden et al.
1974; Bulkley & Roberts 1974) . The variation in outcomes may represent the
differences in species, dose of glucocorticoid, administrative protocols and
mechanisms of infarct injury (LeGal & Morrissey 1990). Although mortality
differences were not significant in the studies in this chapter the lack of improvement
of function and remodelling despite improved revascularisation suggest that
revascularisation alone is not sufficient to preserve cardiac function post myocardial
infarction.
The angiogenic influence of a different anti-glucocorticoid approach was tried by
using lipHSDl deficient transgenic mice. Prevention of local glucocorticoid
regeneration by lipHSDl augmented the new vessel formation in ischaemic
myocardium and injured skin and improved left ventricular function after infarction.
lipHSDl is thus able to influence angiogenesis and modulate tissue repair in
hypoxia and inflammation.
lipHSDl activity was examined in homogenised heart to determine the effects of
infarction on enzyme activity, since lipHSDl activity and expression is increased
by inflammatory cytokines (Cai et al. 2001) and 11PHSD2 is regulated by hypoxia
(Heiniger et al. 2003). Both dehydrogenase and reductase reactions were assayed
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since although 11PHSD2 is an exclusive dehydrogenase, lipHSDl in homogenised
tissue can exhibit both reductase and dehydrogenase activity. 11PHSD activity was
not influenced by myocardial infarction: the absence of an effect may be as a
consequence of cell loss or insufficient viable peri-infarct tissue or reflect the early
time of tissue collection. lipHSDl has been documented in several cell types that
would be present at different stages in the healing infarct, including mouse vascular
smooth muscle cells (Christy et al. 2003), macrophages and rat cardiomyocytes
(Sheppard & Autelitano 2002) and cardiac fibroblasts (Slight et al. 1993). The time
of sampling may be critical in determining which cells are present for 1 lpHSDl may
well be differentially regulated in these different cell types. The absence of an effect
may also be as a consequence of the tissue sampling technique. After bisection of
hearts along the long axis and through the infarct half of the heart was utilised in the
activity assay. Thus non-ischaemic un-infarcted left ventricle may have contributed
to 11 PHSD 1 activity therefore created a false impression of activity in the infarct.
1 lpHSDl activity in the skin has not previously been considered to influence wound
healing in mice, although endogenous glucocorticoids are recognised to impair
wound healing and adrenalectomy or RU38486 therapy has ameliorated wound
repair in rodent models of impaired wound healing (Padgett et al. 1998; Glasper &
DeVries 2005; Bitar et al. 1999). In other species 1 lpHSDl is thought to influence
inflammation in cutaneous tissues (Johnson et al. 2004). Whether absence of
1 lpHSDl in vascular smooth muscle cells alone accounts for the enhance angiogenic
responses observed in 11 PHSD 1 deficient mice is unclear. Certainly other cells
within the cutaneous layer are acknowledged to express lipi lSDl in other species
including within the epidermis (Kenouch et al. 1994) or macrophages (Thieringer et
al. 2001) and it may be that local regulation of glucocorticoid concentration by these
cells types also influences wound revascularisation.
Tensile strength of wounds was not measured as wound healing was not impaired in
wild types. However, left ventricular function was used in the coronary artery
ligation model to detect functional differences resulting from enhanced angiogenesis.
lipHSDl deficiency in mice was associated with preserved left ventricular
remodelling and preservation of left ventricular dimensions post myocardial
infarction in comparison to wild type controls, ft is unlikely that these responses are
solely as a consequence of improved revascularisation, particularly in light of the
results of treatment with RU38486. Instead remodelling may have been improved as
a consequence of lipHSDl deficiency in inflammatory cells, cardiomyocytes or
fibroblast (Christy et al. 2003; Sheppard & Autelitano 2002; Thieringer et al. 2001;
Slight et al. 1993). lipHSDl transgenic deletion impairs macrophage phagocytic
function that could prolong the acute inflammatory reaction or reduce the clearance
of ailing cardiomyocytes (Chapman et al unpublished).
Other examples of 1 lpHSDl deficiency protecting cells subjected to metabolic stress
have been recorded, for example in neurons where lipHSDl deficiency reduced
cognitive decline in aging mice (Yau et al. 2001) and inhibition of 1 lpHSD protects
neurons in cell culture from chemical toxicity (Rajan et al. 1996). However contrary
arguments that lipHSDl in fact safeguards tissues from excess inflammation are
emerging from studies in the human ovary (Thomas et al. 1998; Rae et al. 2004;
Tetsuka et al. 1999; Hillier & Tetsuka 1998). It is proposed that in the ovary
1 lpHSDl up-regulation in follicular cells or surface epithelial cells at ovulation may
repress peri-ovulatory inflammation in the corpus luteum. The significance of these
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findings in mice is unclear since lipHSDl deficient mice are not infertile or
susceptible to implantation failure as a result of luteal dysfunction (Kotelevtsev et al.
1997).
Alternatively the effects of 1 lpHSDl transgenic deletion to improve left ventricular
function may reflect metabolic consequences. lipHSDl deficient mice are noted to
have differences in cellular and hepatic glucose metabolism that may be beneficial
following myocardial infarction. 1 lpHSDl deficient mice have reduced activation of
hepatic gluconeogenesis enzymes in response to stress resulting in blunted
hyperglycaemia (Kotelevtsev et al. 1997). Clinical studies improving glucose
regulation post infarction have indicated that controlled glucose plasma
concentrations are associated with improved mortality (Malmberg 1997).
The investigations in this chapter confirm that lipHSDl influences endogenous
glucocorticoid regulation of angiogenesis, and have generated data that requires
further evaluation in future studies. In myocardial infarction there is a striking effect
of 1 lpHSDl on left ventricular remodelling that was absent in RU38486 studies and
appears not to be explained by revascularisation alone. Investigations to explore
these differences are planned, particularly to examine the effect of combined
mineralocorticoid and glucocorticoid antagonism on myocardial revascularisation
and remodelling. Further investigations are planned to use the wound healing model
to explore the role of lipHSDl in the integumentary system. Although gross
observation did not detect any impairment of wound healing in C57BL6 mice, and
thus the influence of 1 lpHSDl was only apparent at histology, 1 lpHSDl deficiency
applied to a model of impaired wound healing (eg in Streptozocin induced diabetes
(Bitar et al. 1999) might further reveal the significance of lipHSDl in cutaneous
tissues.
In summary in this chapter systemic anti-glucocorticoid therapy enhanced cutaneous
and myocardial angiogenesis in pathology in a glucocorticoid receptor dependent
manner. However, improved myocardial revascularisation was not associated with
improved ventricular remodelling or function in these animals. In contrast in the
presence of local anti-glucocorticoid effects in the lipHSD-1 deficient mice,
enhanced cutaneous and myocardial revascularisation was associated with
preservation of left ventricular function and dimensions. The data on angiogenesis in
pathology is consistent and complimentary with data in Chapters 3 and 4 indicating
that endogenous glucocorticoids are sufficient to regulate angiogenesis modulated by
the influence of lipHSDl. The improvements in ventricular remodelling in
lipHSDl deficient mice offers a novel approach to enhance myocardial





Despite the extensive use of glucocorticoids, scientifically and clinically, to inhibit
angiogenesis over the last 20 years, the influence of endogenous glucocorticoids on
blood vessel growth has remained obscure. Furthermore, the ability of 1 lpHSDs to
regulate new vessel formation by metabolism of glucocorticoids within the vessel
wall has not been considered previously. Thus, the aim of the work described in this
thesis was to determine whether metabolism of endogenous glucocorticoids in the
vessel wall inhibits angiogenesis through the development and use of in vitro, in vivo
and pathological models.
6.1 Materials and methods
Whether in aortic rings, subcutaneous sponge implant or wound healing models
glucocorticoids at physiological concentrations inhibited angiogenesis. Three
different models were used in order to demonstrate the constancy of the effect of
glucocorticoids and to highlight the influence on angiogenesis of factors peculiar to
each assay. The aortic ring model was used to examine the effects of glucocorticoids
in the absence of systemic inflammation or ischaemia. The subcutaneous sponge
implant assay was used to determine the angiostatic effects of endogenous
glucocorticoids in vivo in the presence of an inflammatory response. Finally the
subcutaneous injury and myocardial infarct models were used to assess the
angiostatic effects of endogenous glucocorticoids in inflammation and ischaemia. By
comparing the effects of glucocorticoids to influence angiogenesis in these three
different models it is possible to draw some conclusions regarding the models
themselves.
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The aortic ring model was chosen from several available in vitro angiogenesis assays
because it simulates most aspects of the angiogenic response and in comparison with
other in vitro assays is perhaps most closely comparable to the situation in vivo
(Carmeliet et al. 1998). Using this model angiogenesis was inhibited by
physiologically relevant concentrations of glucocorticoids and these results were
subsequently noted to be consistent through in vivo and pathological angiogenesis
models. Thus the current findings confirm previous observations regarding the
usefulness of the aortic ring model and indicate that this is a valuable tool to study
angiogenesis.
The sponge implant model has been used as a wound healing assay to examine the
effects of test substances on sponge collagenisation, fibrovascular infiltration and
inflammatory cell invasion as measures of skin repair processes (Puolakkainen et al.
2005; Efron et al. 2001; Bradshaw et al. 2001). In this thesis both sponge
implantation and cutaneous wound healing assays have been used. In comparing
these models it could be concluded that the consistency of effect of glucocorticoids
on angiogenesis in both indicates that the sponge model is a useful assay to examine
angiogenesis in wound healing. However what has not been examined in this thesis
are the other aspects of wound healing including inflammatory cell responses and
scar formation with collagen deposition. In order to fully appreciate the strengths of
the sponge implant model as a wound-healing assay these other aspects ought to be
considered.
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6.2 Inhibition of angiogenesis by glucocorticoids
Several different methods were used to investigate the influence of endogenous
glucocorticoids. Physiologically relevant glucocorticoid concentrations were used in
vitro whereas adrenalectomy and glucocorticoid receptor antagonism were used in
vivo. In each case the influence of glucocorticoids at these concentrations was
similar and always glucocorticoid receptor dependent. There was no deviation in the
tissue specificity of the effect: cardiac, cutaneous and aortic tissues were all sensitive
to the angiostatic effects of glucocorticoids and uniformly it was the glucocorticoid
receptor that was responsible for these effects across these different tissues.
6.3 Influence of 11PHSD-1 on glucocorticoid induced angiostasis
Consistently through the models studied inhibition of lipHSD-l enhanced
angiogenesis. lipHSD-l therefore impairs angiogenesis in aortic, cutaneous and
myocardial tissue. Although lipHSD-l is expressed in mouse aortic tissue (Christy
et al. 2003) and in this thesis we observed 1 lpHSD reductase activity in aortic and
heart tissue it may not be expressed across all vascular beds or tissues. It is unclear
whether lipHSD-l regulates angiogenesis in tissues where there is considerable
expression of 11PHSD-2. In the kidney for example where 11 pHSD-2 is highly
expressed by the distal convoluted tubules, angiogenesis control by 1 ipHSD-1 may
be less significant.
Nevertheless in aortic tissue we did consider the effect of 11 pHSD-2 by examining
the action of the non-selective 1 lpHSD inhibitor carbenoxolone on the influence of
corticosterone. The absence of an effect suggested that in aortic tissue in vitro
lipHSD-7 does not influence angiogenesis. Whether ll[3HSD-2 in vivo could
directly influence angiogenesis in a tissue specific manner for example in the kidneys
may be difficult to dissect from the effects of lipHSD-2 on hypertension and
vascular function.
6.4 Potential clinical application of the results
Angiogenesis is an important determinant in many diseases: in cancer aberrant
angiogenesis regulation contributes to tumour size and metastases (Garcea et al.
2004). In diabetes mellitus impaired cutaneous revascularisation impairs healing and
leads to the formation of cutaneous ulcers (Galiano et al. 2004). In contrast in the
retina of diabetic patients angiogenesis produces proliferative diabetic retinopathy
and may lead to blindness. In cardiovascular disease revascularisation remains a
therapeutic target not just in myocardial ischaemia but also in stroke and peripheral
vascular disease. How might the findings from this thesis be projected into clinical
applications?
Clinically glucocorticoids are already employed in the treatment of vascular tumours
to inhibit angiogenesis (Hasan et al. 2000). The data in this thesis suggest that the
effects of glucocorticoids on angiogenesis in these tumours are glucocorticoid
receptor dependent.
There may be other indications for glucocorticoids to treat tumours in situations
where tumour shrinkage is required, or if a decrease in tumour vascularity desirable.
This would be the case for example prior to debulking procedures or surgical
resection. Conceivably there might be a role for glucocorticoids to be used following
such procedures to reduce metastatic growth. However there could be problems with
wound healing post surgery with systemic glucocorticoid therapy.
Whether all tumours are susceptible to the effects of glucocorticoids is unclear and
tissue specific expression of lipHSDs could be significant in determining tumour
sensitivity to glucocorticoid therapy. For example since 11|3HSD2 is highly
expressed in the colon (Takahashi et al. 1998) and inactivates glucocorticoids
glucocorticoid-regulation of angiogenic processes in colonic cancer may be
significantly reduced. There is some circumstantial evidence for this type of effect in
that expression of 11PHSD2 in ACTH producing small cell lung carcinomas is
thought to contribute their glucocorticoid-resistance phenotype (Parks et al. 1998).
Not withstanding these arguments however, there is often dysregulated gene
expression within tumours that may alter the tissue specific expression of 11 pHSDs
to change the susceptibility to glucocorticoid angiostasis.
In fact in many tumours there is absent or low expression of lipHSD-1 but high
expression of 1 ipHSD-2 [see table 6.1 (Rabbitt et al. 2003)]. This may represent a
change in gene expression associated with de-differentiation or could be a primary
event in tumour development contributing to cell proliferation and the persistence of
undifferentiated cells. In either case these observations are not in disagreement with
our current findings that suggest if a tumour down regulated lipHSD-1;
angiogenesis would be enhanced. Thus tumour cells with such expression would be
selected, as unregulated angiogenesis in this setting would be advantageous for
tumour growth and haematogenous metastatic spread.
The observed trend for expression of 1 ipHSD-2 and reduced or absent expression of
lipHSD-lin tumours (see table 6.1) suggests that many cancers will be resistant to
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the angiostatic effects of glucocorticoids. Whether 1 lpHSD- 2 specific inhibitors or
gene therapy with 1 ipHSD-1 could alter this phenotype remains unclear. The data in
this thesis compliments the impression that is evolving with regard to the effects of
lipHSD-1 as a differentiation inducing, anti-proliferative and now an anti-
angiogenic factor. If it were possible to harness these features of 1 ipHSD-1 activity,
1 ipHSD-1 would make a potential target for chemotherapy.
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Table 6.1
















Colon carcinoma - +
Colon cancer cell lines
(Caco-2, Ht-29)
+
Breast tumour specimens " +
Pituitary ademoma - +
Squamous cell carcimona
of the head and neck
1
Table 6.1 Summary of lipHSD 1 isozyme expression in neoplastic tissues and
cell lines (Rabbitt et al. 2003)
(-) Represents no detectable expression (+) indicates expression is present (J.) denotes
reduced expression.
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In diabetes mcllitus and the metabolic syndrome 11(3HSD-1 expression and activity
in adipose tissue has been identified as a potential therapeutic target. In obese
humans and rodents there is increased expression of lipHSD-1 in adipose tissue
(Wake et al. 2003; Masuzaki et al. 2001). This increased expression appears to be of
pathogenic importance because transgenic mice over-expressing lipHSD-1
selectively in adipose tissue exhibit a full metabolic syndrome with visceral obesity,
dyslipidaemia, insulin-resistant diabetes, and hypertension (Masuzaki et al. 2001).
Although lipHSD-1 inhibition might be attractive to improve metabolic parameters
in diabetes the data in this thesis suggest that 1 ipHSD-1 inhibition could be contra-
indicated in some diabetics for it may enhance angiogenesis in patients at risk of
proliferative diabetic retinopathy. Whether specific vascular beds could be targeted
with 1 ipHSD-1 inhibitors might be a possibility with gene therapy. Viral vectors to
deliver gene therapy are being designed to recognise endothelial peptides that
identify specific vascular beds (Trepel et al. 2002; Kolonin et al. 2001). Thus in
diabetics targeted therapy could deliver lipHSD-1 anti-sense gene therapy to
adipose tissue vascular beds to improve metabolic indices in diabetes. In addition in
patients with diabetic ulcers lipHSD-1 anti-sense gene therapy directed to the
cutaneous vasculature may ameliorate ulcer healing by enhancing angiogenesis. Thus
the findings in this thesis, although adding to the complexity of the influence of
11PHSD-1 in diabetes, have revealed a potential harmful side effect of lipHSDl
inhibitor therapy. Therefore upon identification of specific lipHSD-1 inhibitors in
the future; careful screening and subsequent follow up of potential clinical trial
patients would need to be undertaken to identify those at risk of diabetic retinopathy.
Glucocorticoid receptor antagonism or 11 (3HSD-1 deficiency improved myocardial
revascularisation following coronary artery ligation. Improved revascularisation was
not however solely responsible for preserved left ventricular function: for the
ventricular remodelling outcomes in 11 (3HSD-1 -/- mice in comparison to RU38486
treated mice were strikingly different. The preservation of left ventricular function
following coronary artery ligation in lipHSD-1 -/- mice requires further
investigation but may reflect differences in cellular immunity, or altered
glucocorticoid activity at mineralocorticoid receptors in cardiomyocytes. Clinically
mineralocorticoid receptor antagonist have been introduced for the treatment of
ventricular dysfunction in acute myocardial infarction following the success of a
recent clinical trial (Pitt et al. 2005). Despite the success of this therapy the
mechanisms for its benefit remain obscure. The endogenous ligand acting at the
mineralocorticoid receptor in cardiac tissue is yet to be determined. The greater intra¬
cellular availability of glucocorticoids in comparison to mineralocorticoids and in the
absence of significant cardiac expression of lipHSD-2 suggests that the active
ligands are glucocorticoids. Thus lipHSD-1 may present a novel target to improve




In summary, the research present in this thesis demonstrates that endogenous
glucocorticoids regulated by 1 lpHSDl are sufficient to inhibit angiogenesis in vitro,
in vivo and in pathology in inflammatory and ischaemic conditions. The findings of
these studies propose a novel role for vascular lipHSDl in the regulation of
angiogenesis. In addition, the influence of 11|3HSD1 to modulate tissue repair as
well as revascularisation following infarction suggests that the function of 1 lpHSDl
in repairing tissues maybe more complex than first appreciated.
6.6 Future Studies
The studies presented in this thesis have provided a basis for future work aimed at
the elucidation of mechanisms for glucocorticoid-induced angiostasis and further
explanation of the influence of 1 lpHSDl on tissue remodelling
Mechanism- Plans to explore the mechanism of glucocorticoid actions are being
developed with the framework that glucocorticoids may influence proliferative and
mitotic factors, cell migration, inflammation or the extracellular matrix.
Proliferative and mitotic factors- It is proposed to use the aortic ring model of
angiogenesis to investigate potential interactions with glucocorticoids and key
mediators of angiogenesis, such as VEGF and nitric oxide. Adaptation of this model
to use collagen based gels in order to facilitate cell recovery and subsequent RNA
extraction will aid these studies.
The pilot HUVEC data is to be extended to examine the influence of glucocorticoids
on intracellular calcium transients and begin to elucidate how glucocorticoids may
disrupt the entry of extracellular calcium. Other sources of endothelial cells could be
used for this work although previous attempts to obtain primary cultures of mouse
aortic endothelial cells have been difficult. One possible approach is to use sponge
implants as a source of mouse endothelial cells which could be exploited to provide
primary cultures with which to further examine the effect of glucocorticoids on
VEGF signalling.
Cell migration- Although primary mouse endothelial cell cultures are not currently
available the influence of glucocorticoids on HUVEC migration is being investigated
as part of a new study to determine the mechanism of glucocorticoid-induced
angiostasis.
Inflammation- A reason for the initial proposals to concentrate on in vitro studies
using endothelial cells has been to remove systemic and local inflammatory
influences from angiogenesis conditions and, therefore, explore whether
glucocorticoids have direct angiostatic effects.
Extracellular Matrix- It is aimed to investigate interactions between glucocorticoids
and matrix metalloproteinases using initially the aortic ring assay but also in the
chronic coronary artery ligation model.
Tissue Remodelling- Further investigation is proposed to determined the causes of
the dramatic difference between systemic glucocorticoid antagonism and the effects
of lipHSDl deficiency on left ventricular remodelling post infarction. The
preservation of left ventricular function with lipHSDl deficiency requires further
evaluation to dissect out the contributions from possible interactions with
angiogenesis, inflammation and matrix remodelling.
Furthermore it is hoped that with the successful development of selective 11|3HSD1
inhibitors that are being formulated by biotech and pharmaceutical companies,
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Angiogenesis restores blood flow to healing tissues, a process that
is inhibited by high doses of glucocorticoids. However, the role of
endogenous glucocorticoids and the potential for antiglucocorti-
coid therapy to enhance angiogenesis is unknown. Using in vitro
and in vivo models of angiogenesis in mice, we examined effects
of (i) endogenous glucocorticoids, (//) blocking endogenous glu¬
cocorticoid action with the glucocorticoid receptor antagonist
RU38486, and (Hi) abolishing local regeneration of glucocorticoids
by the enzyme 11^-hydroxysteroid dehydrogenase type 1
(110HSD1). Glucocorticoids, administered at physiological concen¬
trations, inhibited angiogenesis in an in vitro aortic ring model and
in vivo in polyurethane sponges implanted s.c. RU38486-enhanced
angiogenesis in s.c. sponges, in healing surgical wounds, and in the
myocardium of mice 7 days after myocardial infarction induced by
coronary artery ligation. 11/8HSD1 knockout mice showed en¬
hanced angiogenesis in vitro and in vivo within sponges, wounds,
and infarcted myocardium. Endogenous glucocorticoids, including
those generated locally by 11/3HSD1, exert tonic inhibition of
angiogenesis. Inhibition of 11/JHSD1 in liver and adipose has been
advocated to reduce cardiovascular risk in the metabolic syndrome:
these data suggest that 110HSD1 inhibition offers a previously
uncharacterized therapeutic approach to improve healing of isch¬
emic or injured tissue.
myocardial infarction | wound healing
Angiogenesis, the formation of new vessels from existingones, is a key factor in many common diseases (1-4), and
manipulation of angiogenesis is an important therapeutic target
(5, 6). Supraphysiological concentrations of glucocorticoids have
been used in vitro and in vivo to inhibit angiogenesis (7-11). It is
unknown, however, whether physiological concentrations of
endogenous glucocorticoids (principally Cortisol in humans and
corticosterone in mice) regulate angiogenesis.
The influence of glucocorticoids on their target tissues is
regulated in a tissue-specific manner by the isozymes of 11/3-
hydroxysteroid dehydrogenase (11/3HSD) (12). lljSHSD type 1
functions predominantly as an 11-oxidoreductase converting
inactive 11-keto metabolites (cortisone in humans; 11-
dehydrocorticosterone in mice) into active 11 -hydroxy glucocor¬
ticoids (Cortisol and corticosterone) (13). 11/3HSD-1 is highly
expressed in liver, adipose tissue, and regions of the central
nervous system, where it amplifies intracellular glucocorticoid
concentrations and thereby maintains glucocorticoid receptor
activation (13). 1 lfSHSD type 2 is an exclusive llj3-dehydroge-
nase, inactivating Cortisol or corticosterone in distal nephron,
colon, and sweat glands, thus preventing inappropriate access of
glucocorticoids to mineralocorticoid receptors (12). Both
11 jSHSD isozymes are expressed in the blood vessel wall (14-18).
In mouse and rat aorta, llj8HSD-2 is localized in endothelial
cells and 11/3HSD-1 in vascular smooth muscle (15, 16).
Glucocorticoids have diverse effects on vascular function,
altering vasoconstrictor responses (19), impairing endothelium-
dependent vasodilatation (19), and inhibiting inflammation and
cell proliferation (20, 21). We recently reported studies of
vascular function in knockout mice deficient in either llfJHSD
isozyme (22). In aortae from 11/3HSD-2 —/- mice, endotheli-
um-dependent vasodilatation was impaired, suggesting that
11/3HSD-2 protects endothelial cell receptors from glucocorti¬
coids. However, there was no abnormality of vascular tone in
11/3HSD-1 —/— mice, so the role of the type 1 isozyme in the
vessel wall remained unclear. At that time, Cai et al. (23)
demonstrated that 11/3HSD1 expression in vascular smooth
muscle is up-regulated in response to proinflammatory cyto¬
kines, raising the possibility that increased local generation of
glucocorticoids contributes to feedback regulation of vascular
inflammation.
Given that inflammatory cytokines can promote angiogenesis
(24) and pharmacological doses of glucocorticoids have antian-
giogenic activity, we hypothesized that 110HSD-1 modulates
angiogenesis by determining the local regeneration of active
glucocorticoid in the vessel wall. If so, then manipulation of
110HSD-1 may provide a novel therapeutic tool to alter angio¬
genesis. Here, we have tested this hypothesis by using in vitro,
in vivo, and pathological models of angiogenesis in mice.
Methods
Mice. Male, C57B16J wild-type and 11/3HSD-1 homozygous
null (—/—) mice aged 8-10 weeks were used (Charles River
Laboratories). Genetic inactivation of llj3HSD-l has been
described in MF-1/129 mice (25); for the current experiments,
mice were backcrossed over >10 generations onto a C57B16J
background (26).
Aortic Ring Preparations. Mice were killed, and thoracic aortae
were removed, washed in serum-free MCDB 131 medium
(Invitrogen), cleaned of periadventitial tissue, and divided into
1- to 3-mm rings.
11/3HSD activities were measured by incubating wild-type
aortic rings for 24 h at 37°C in 1 ml of DMEM-F12 medium
(Invitrogen) containing 3H-steroid supplemented with FBS
(1%), streptomycin (100 p,g/ml), penicillin (100 units/ml), and
amphotericin (0.25 p.g/ml) (27). 1 l(J-Reductase activity was
determined by adding 10 pmol [3H4]-ll-dehydrocorticosterone
[synthesized in-house from l,2,6,7-[3H4]-corticosterone (Amer-
sham Pharmacia Biosciences) by using rat placental homoge-
nate]. Mouse liver (28 ± 5 mg) and medium alone were used as
positive and negative controls, respectively. llfl-Dehydrogenase
activity was determined by adding 10 pmol 1,2,6,7-[3H4]-
corticosterone. Mouse kidney (13 ± 3 mg) and medium alone
served as positive and negative controls. After incubation,
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Fig. 1. Angiogenesis in aortic rings in vitro. (A) Light micros
copy ot new vessels shown sprouting from aortic rings. (/)
Aortic ring incubated for 7 days without glucocorticoid, (ii)
Aortic ring incubated for 7 days in the presence of glucocor¬
ticoid. Thick white arrows indicate the aortic ring; thin white
arrows indicate new vessels. (Scale bar: 0.2 mm.) (Hi) Uptake of
low-density lipoprotein (LDL) is shown by fluorescence micros¬
copy. This ring was incubated for 7 days without steroids.
Thick white arrows indicate the aortic ring; thin white arrows
indicate uptake of fluorescent labeled LDL in endothelial cells
in new vessels; black arrows indicate uptake in endothelial
cells of the aortic ring. (Scale bar: 0.2 mm.) (/V) High power
view of new vessels; thick white arrows indicate the aortic ring
and thin white arrows indicate uptake of fluorescent labeled
low density lipoprotein in endothelial cells (Scale bar: 0.02
mm.) (Bi) Time course and effect of corticosterone on angio¬
genesis. O, results from vessels incubated without steroids; ♦,
results from vessels incubated with corticosterone (600 nM).
Results are mean ± SEM for n = 4 per group. Comparison was
by repeated measures ANOVA; *, P < 0.02. (5/7) Effects of
corticosterone and 11-dehydrocorticosterone. Vessels were
counted after 7-day incubation with steroids. Results are
mean ± SEM. #,P< 0.01 versus vehicle by 2-way ANOVA and
least squares difference post hoc test. (O Influence of receptor
antagonism. (/') Effects of the mineralocorticoid receptor an¬
tagonist spironolactone. Aortic rings from C57BI6J mice were
incubated with (filled bars) and without (open bars) spirono¬
lactone (10-6 M) and glucocorticoids (600 nM). Results are
mean ± SEM for n = 6 experiments. #, P < 0.02 versus corre¬
sponding vehicle. Spironolactone alone had no effect, (ii)
Effects of the glucocorticoid receptor antagonist RU38486.
Aortic rings from C57BI6 mice were incubated with (filled
bars) and without (open bars) RU38486 (10 6 M) and glucocor¬
ticoids (600 nM). Results are mean ± SEM for n = 4-6 exper¬
iments. #P< 0.01 versus corresponding vehicle. ***, P < 0.001
for the effect of RU38486 in the presence of glucocorticoid.
RU38486 alone had no effect. (D) Effects of 11 /3HSD inhibition
(/) Pharmacological inhibitor carbenoxolone. Aortic rings
from C57BI6J mice were incubated with (filled bars) and with¬
out (open bars) carbenoxolone (10-6 M) and glucocorticoids
(600 nM). Results are mean ± SEM for n = 5 experiments. #, P<
0.01 versus corresponding vehicle. *, P < 0.04 for the effect of
carbenoxolone in the presence of 11-dehydrocorticosterone.
Carbenoxolone had no effect in the presence of corticoste¬
rone or vehicle alone, (ii) Transgenic deletion of 11/3HSD1.
Effects of corticosterone and 11-dehydrocorticosterone on
angiogenesis in vessels from 11 /3HSD1 -/- mice. Aortic rings
from C57BI6J wild-type (open bars) or 11/3HSD1 -/- (filled
bars) mice were incubated with and without glucocorticoids
(600 nM). Results are mean = SEM for n = 7 experiments. #, P<
0.01 versus corresponding vehicle. **, P < 0.01 for differences in angiogenesis between wild-type and 11/3HSD1 -/— mice. Angiogenesis was




















steroids were extracted from media by using Sep-Pak Ci8 col¬
umns (Waters Millipore). Aortic rings, which contain only 2-3%
of the added radioactivity, were not included in the extraction
(27). [3H4]-Corticosterone and [3H4]-11-dehydrocorticosterone
were separated by HPLC and quantified by on-line liquid
scintillation counting (16). Enzyme activity was expressed as
conversion after subtraction of apparent conversion in negative
control wells. Both U/3-reductase (0.65 ± 0.24 pmol/mg) and
11/3-dehydrogenase (0.66 ± 0.28 pmol/mg) activities were de¬
tected in aortic rings with similar conversion rates as in positive
controls: liver for 11j3HSD-1 (0.18 ± 0.03 pmol/mg) and kidney
for 11/3HSD-2 (2.13 ± 1.65 pmol/mg).
To quantify angiogenesis, aortic rings were embedded in 200
p.1 of steroid-free Matrigel (Becton Dickinson) (Fig. 1) and
incubated at 37°C in serum-free MCDB 131, with heparin,
ascorbic acid, and GA1000 (Cambrex Biosciences) in the pres¬
ence and absence of corticosterone (3, 30, 300, and 600 nM),
11-dehydrocorticosterone (300 and 600 nM), the glucocorticoid
receptor antagonist RU38486 (10-6 M), the mineralocorticoid
receptor antagonist spironolactone (10-6 M), and/or the non¬
selective 11/3HSD inhibitor carbenoxolone (10 13 M). All drugs
(Sigma-Aldrich) were dissolved in ethanol and diluted in aque¬
ous solution; final ethanol concentration 1-3% vol/vol. Media
were changed every 48 h. Experiments were performed in
triplicate. In initial experiments, new vessels were counted daily
by using light microscopy (ref. 8 and Fig. 1). From these studies,
day 7 was selected as the appropriate time point to examine the
effects of glucocorticoids (Fig. IB).
To confirm the nature of apparent new vessels, endothelial
cells were identified by uptake of fluorescent-labeled acety-
lated low-density lipoprotein (Biogenesis, Poole, U.K.)
(Fig. 1/1).
s.c. Sponge Implant Assay. Mice were anesthetized with halothane,
and a sterilized sponge cylinder (0.5 cm x 1 cm) (Caligen Foam,
Accrington, Lancashire, U.K.) was implanted s.c. on each flank.
Sponges contained a silastic insert (Silastic 20 medical grade,
Dow Corning) impregnated with vehicle, 2 mg of Cortisol or
12166 [ www.pnas.org cgi/doi/10.1073/pnas.0500641102 Small et al.
cortisone, or 5.25 mg of RU38486. Each animal had an inter¬
vention-impregnated sponge (steroid or RU38486) on one side
and a placebo-impregnated sponge (silastic only) on the other.
Such inserts release their impregnated compounds in vivo at a
constant rate for 3 weeks (28). Human steroids (Cortisol and
cortisone, equivalent to corticosterone and 11-dehydrocortico-
sterone) were used to allow distinction from endogenous ste¬
roids. In separate experiments (data not shown), angiogenesis in
placebo-impregnated sponges was not altered by the presence or
absence of a contralateral steroid-treated sponge.
A further cohort ofwild-type mice underwent adrenalectomy
or sham surgery as described (29) at the time of implantation of
untreated sponges. These mice were then maintained on 0.9%
saline in place of drinking water.
Twenty days after implantation (10). mice were killed, sponges
were excised, and inserts were removed. Sponges were bisected;
one half was fixed in 10% formalin and embedded in paraffin
wax. Sections (8 pm) were stained with hematoxylin/eosin for
identification of blood vessels, as described in ref. 30. The second
half of the sponge was weighed, homogenized in 2 ml of sterile
PBS at 4°C, and centrifuged (2,000 x g for 30 min). Steroids were
extracted from the supernatant by using ethyl acetate and
Cortisol quantified by using a specific RIA (Amersham Phar¬
macia Biotech). Sponge vessel density was determined by using
the mean of triplicate Chalkley counts on two sections per
sponge (31, 32).
Chronic Coronary Artery Ligation. Wild-type and 11/3HSD-1 — /—
mice were anesthetized with an i.p. injection of xylazine (0.018
mg/kg), ketamine (100 mg/kg), and atropine (600 mcg/kg) (33).
Surgery was performed as described in ref. 34. Briefly, after
endotracheal intubation and mechanical ventilation (MiniVent,
Harvard Apparatus, Holliston, MA), superficial tissues were
dissected, an incision was made in the fourth intercostal space,
the pericardium was divided, and the left main descending artery
was ligated with 6.0 prolene suture (Ethicon). In sham operated
animals, the suture was not ligated. The thoracic wall was closed
by layered suturing; the skin was stitched with a continuous
suture by using 5-0 Mersilk with a 10-mm 3/8c round-bodied
needle (Ethicon). At the time of surgery completion, animals
received i.p. atipamazole (5 mg/kg) and s.c. buprenorphine (0.05
mg/kg).
A further cohort of wild-type mice received a s.c. 10 mg
implant (28) containing either vehicle or 5.25 mg of RU38486 1
week before coronary artery surgery.
In preliminary experiments, mice were killed on days 1, 3, 5,
7, and 14 after surgery by cervical dislocation. The angiogenic
response was well established 7 days after infarction (see Fig.
3B). so this interval was selected for comparisons between the
groups above. Excised hearts and surgical thoracotomy wounds
were fixed in 10% formalin, paraffin embedded, and sectioned
at 8 gm. Sections were stained with an anti-von Willebrand
factor antibody (DakoCytomation, Cambridgeshire, U.K.) to
label endothelial cells and quantify angiogenesis. Hematoxylin
and eosin was used to stain sections from hearts collected at day
7 after coronary ligation to measure the area of the left ventricle
affected by infarction.
Quantification of vessels within the myocardium was achieved
by counting large- and medium-sized vessels as described in ref.
35. Vessels were identified at X400 magnification (Zeiss) in vWF
(36-38) stained sections. Counting (39) was performed in the
four most vascular fields (two endocardial and two epicardial) by
using a 0.0625-mm2 reticule; the borders of the reticule were
within the infarct. The area of left ventricle affected by infarction
was determined as a percentage of left ventricular wall area (34)
and measured at direct light microscopy; images were captured
by using a Research Systems (Imaging Research. St. Catherine's,
ON, Canada) photometric camera and analyzed by using in-
house scripts.
Wound vessel density was determined in the dermis of vWF-
stained sections at X250 light microscopy by using the mean of
triplicate Chalkley counts on two sections per wound (31).
Statistics. Data are mean ± SEM. Comparisons were made by
ANOVA with least squares difference post hoc tests. Vessel
quantification was performed by investigators "blinded" to the
origin of the sections. Interassay and intraassay coefficients of
variation in wild-type mice were 17% (n - 32) and 22% (n = 18),
respectively, for vessel number in aortic rings after 7 days in
culture; 12% (n = 6) and 12% (n = 6) for vessel density in sponge
implants; 19% (n = 11) and 10% (n = 11) in day-7 infarcts; and
7% (n = 4) and 12% (n = 4) for day-7 wounds.
Results
Effects of Glucocorticoids and 11/3HSD-1 on Angiogenesis in Vitro in
Aortic Rings. Both corticosterone and U-dehydrocorticosterone
inhibited angiogenesis in wild-type mouse vessels across a range
of physiological concentrations (Fig. IB). The angiostatic effect
is mediated by glucocorticoid receptors because it was prevented
by the antagonist RU38486 (which has no effect in the absence
of steroid) but not by the mineralocorticoid receptor antagonist
spironolactone (Fig. 1C).
Measurement of relevant product generation confirmed both
110-reductase (0.65 ± 0.24 pmol/mg) and 11/3-dehydrogenase
(0.66 ± 0.28 pmol/mg) activities in aortic rings with similar
conversion rates as in positive controls, liver for 11/3HSD-1
(0.18 ± 0.03 pmol/mg), and kidney for 11/3HSD-2 (2.13 ± 1.65
pmol/mg). Pharmacological inhibition of ll/3HSDs in aortic
rings was achieved with the nonselective inhibitor carbenoxolone
(10~6M), which had no direct effect and prevented the antian-
giogenic effect of 11-dehydrocorticosterone but not corticoste¬
rone (Fig. ID/).
To confirm the role of llj3HSD-l, aortic rings were obtained
from homozygous 11/3HSD-1 null (—/—) mice congenic on a
C57B16J genetic background (26) and C57B16J controls. Angio¬
genesis in aortic rings from 11/fHSD-l -/— mice was similar to
that in wild-type controls in the absence of steroid and inhibited
to a similar degree by corticosterone. However, 11-dehydrocor-
ticosterone did not inhibit angiogenesis in vessels from
11/3HSD-1 — /— mice (Fig. ID/;).
Effect of Endogenous Glucocorticoids and 11/3HSD-1 on Angiogenesis
in s.c. Sponge Implants in Vivo. Placebo-impregnated sponges
excised after 20 days (10) were red on gross inspection with a
lace-like covering of blood vessels. At histology, there was an
inflammatory infiltrate and an abundance of blood vessels (Fig.
24/). Sponges from adrenalectomized animals and sponges
impregnated with the glucocorticoid receptor antagonist
RU38486 both exhibited enhanced angiogenesis (Fig. 2Bi) in
wild-type mice.
To test the effects of 11-hydroxy and 11-keto-glucocorticoids
we used the "human" steroids Cortisol and cortisone, which
allowed measurement of steroid concentrations within the
sponge independently of endogenous murine corticosterone and
11-dehydrocorticosterone (Table 1). In wild-type C57B16J mice,
both Cortisol and cortisone inhibited angiogenesis in vivo (Fig. 2
Aii and Bit). In 11/3HSD-1 null mice, angiogenesis was increased
in placebo-impregnated sponges. Impregnation with Cortisol
produced similar Cortisol concentrations in wild-type and
110HSD-1 null mice (Table 1) and inhibited angiogenesis to a
similar degree (Fig. 2Bii). However, impregnation with corti¬
sone, in contrast with its effects in wild-type controls, did not
elevate sponge Cortisol concentrations in 11/3HSD-1 null mice
(Table 1) and did not inhibit angiogenesis (Fig. 2Bii).
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RU38486 Adrenalectomy Vehicle Cortisol Cortitone
Fig. 2. Angiogenesis in s.c. implanted sponges. (A) Light
microscopy of hematoxylin/eosin stained sponge 8-pm sec¬
tions from wild-type mice: vehicle (/') and cortisol-treated (/'/)
sponge (Scale bar: 400 pm) and vehicle-treated sponge at high
power (.Hi) (Scale bar: 50 pm.) Sponges were covered with a
fibroblast-rlch fibrous coat and were infiltrated with inflam¬
matory neutrophils and lymphocytes. Placebo-treated
sponges alone were also infiltrated with an organized matrix
and an abundance of blood vessels (black arrows). S denotes
sponge matrix. (Br) Sponges from C57BI6J wild-type (n - 6)
mice. Exposure to RU38486 or adrenalectomy (filled bars)
compared with placebo or sham surgery (open bars). Results
are mean ± SEM. #, P < 0.01 versus vehicle: *, P < 0.02 versus
sham. New vessel formation was greater in RU38486-
impregnated sponges or sponges from adrenalectomized
mice versus their relevant controls. (Bit) Sponges from C57BI6J
wild-type (open bars, n = 12) or 110HSD1 -/- (filled bars, n =
6) mice with and without glucocorticoids. Results are mean ±
SEM. #, P < 0.001 versus corresponding vehicle. «**, P < 0.001
for differences between wild type and 11BHSD1 -/-.Placebo-
impregnated sponges exhibited an increased angiogenic re¬
sponse in 1 ipHSDI -/- compared to wild-type mice. Cortisol
inhibited angiogenesis in both strains, but cortisone inhibited
angiogenesis only in wild-type mice.
Effect of Endogenous Glucocorticoids and 110HSD-1 on Myocardial
Revascularization After Coronary Artery Ligation. At day 7, the
proportional area of the left ventricular myocardium affected by
coronary artery ligation was similar in all treatment groups
(41.8 ± 6.2% in vehicle versus 45.5 ± 4.8% in RU38486 and
44.2 ± 3.4% in wild types versus 44.2 ± 2.6% in 1 l/3HSD-l_/~).
RU38486 increased angiogenesis in the left ventricle after
infarction in wild-type mice (Fig. 35//).
There was no difference in myocardial vascularity between
sham-operated wild-type and 11/1HSD-1 null mice. In contrast.
7 days after coronary artery ligation. 11/1HSD-1 null mice
exhibited enhanced revascularization in the infarcted myocar¬
dium (Fig. 35//),
Effect of Endogenous Glucocorticoids and 11/1HSD-1 on Angiogenesis
in Cutaneous Surgical Wounds. New vessel formation was examined
in cutaneous surgical wounds in mice that underwent thoracot¬
omy for the coronary artery ligation studies (Fig. 3c). The dermal
angiogenic response was greater in RU38486-treated mice
(4.8 ± 0.29 Chalkley count versus vehicle 3.5 ± 0.21; P < 0.01)
and in 11/3HSD-1 null mice (5.1 ± 0.27 Chalkley count; P < 0.01)
in comparison to wild-type controls (3.5 ± 0.25 Chalkley count).
Discussion
Folkman el al. described the angiostatic effects of pharmaco¬
logical glucocorticoids in vitro >20 years ago (11), and these
effects have been confirmed in vivo (3, 10). Here, we show that
the angiostatic effect occurs at physiological concentrations of
Table 1. Cortisol concentration in sponge homogenates from
wild-type and 11/3HSD1 —/— homozygous null mice
Cortisol level (ng/g sponge)
Ipsilateral Contralateral
Steroid steroid-treated placebo-treated
Strain impregnated sponge sponge
Wild type Cortisol 4,271 = 186" 161 ± 18
Cortisone 295 = 25*** 98 ± 19
11 /3HSD-1 -/- Cortisol 3,775 = 1,703* 135 ± 46
Cortisone 87 ± 11 90 ± 30
Results are mean ± SEM for n - 3-6 experiments. #, P< 0.01 versus contralat¬
eral placebo.»«, P < 0.01 for comparison of wild type and 11 /BHSD1 -/-.
glucocorticoids and is mediated by glucocorticoid receptors, and
that endogenous glucocorticoids tonically repress angiogenic
responses. Moreover, we show that 11/3HSD1, by regenerating
active glucocorticoids locally, amplifies the angiostatic effect of
glucocorticoids and, thereby, constrains the angiogenic response
after ischemia and injury.
These observations raise the intriguing possibility that local
variations in Cortisol levels or in tissue sensitivity to Cortisol are
key determinants of angiogenesis in disease. It is well recognized
that, in Cushing's syndrome, glucocorticoid excess is associated
with impaired wound healing (40). More recently, we showed
that exogenous glucocorticoid therapy is associated not only with
increased incidence of myocardial infarction but also with an
unexpected increase in prevalence of heart failure (41, 42),
suggesting an impact on the outcome and the incidence of
cardiovascular disease. More subtle variations in Cortisol secre¬
tion and action, including variations in responses to stress, have
been described in many populations and have been related to risk
factors for occlusive vascular disease, mood, development in
early life, gender, age, etc. (43-45). We now suggest that effects
of Cortisol on angiogenesis could explain the links between these
quantitative traits in the population and the health outcomes
from vascular disease and, perhaps, from other diseases involv¬
ing angiogenesis, including neoplasia. If so, then therapies, which
reduce glucocorticoid action within ischemic tissue, may be
valuable in improving collateral perfusion. This result cannot be
achieved safely with systemic antiglucocorticoid therapy that is
likely to lead to Addisonian crisis after a severe stressor such as
myocardial infarction. The role of 11 /3HSD-1 described here
offers an opportunity for tissue-specific targeting of therapy.
We described the presence of 1 ljlHSD-l in the vessel wall >10
years ago (16), but its importance has remained obscure. The
observations that nonselective 11/1HSD inhibitors influence
vascular tone (27, 46) can be attributed to effects on the
11 /3HSD-2 isozyme that catalyses inactivation of glucocorticoids
within endothelial cells (15,22). Here, we show that regeneration
of glucocorticoids by 11/lHSD-l in isolated aortae amplifies
their angiostatic effect. We found no evidence that dehydroge¬
nase ll/fHSD-2 influences angiogenesis in vitro because the
nonselective 11/3HSD inhibitor carbenoxolone did not potenti¬
ate the angiostatic effect of corticosterone.
In vivo 11/3HSD-1 null mice have no obvious difference in
vascular structure in healthy tissues. Normal vascular devel¬
opment occurs in other models of altered angiogenesis in
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Fig. 3. Effect of injury on angiogenesis in mouse myocar¬
dium and skin. (>A) Light microscopy (x50) of anti-von Wille-
brand factor immunostaining with fast red chromogen sub¬
strate in day 7 wild-type sham (i) and infarcted (ii) hearts.
Scattered medium and large vessels were detected in sham
hearts. In contrast, many more vessels were observed in the
healing myocardium after infarction. Black arrows, vessels; Iv,
left ventricle, es, endocardial surface. (Scale bar: 100 /xm.) (///)
Medium power (x 100) light microscopy of hematoxylin/eosin
staining in day-7 wild-type infarcted heart. (Scale bar: 100
/xm.) (/V) High power (X400) light microscopy of anti-von
Willebrand immunostaining in day-7 wild-type infarcted
heart; (Scale bar: 100 /xm.) The vascularity of the infarcted
myocardium was increased and multiple vessels containing
erythrocytes were observed (black arrows indicate vessels).
(Bi) Vascularity of myocardium of wild-type mouse hearts
after ligation (filled bars, n = 3-11) or sham surgery (open
bars, n = 1-6). Sham-operated animals show a constant vas¬
cularity in contrast to CCL animals in which vessel counts
increase with time, achieving a maximum at day 7. (8/7) Day-7
hearts from wild-type and 11 /3HSD1 -/- mice. Ligation (filled
bars) in wild-type and 11/3HSD1 -/- increased angiogenesis
in comparison to sham (open bars) (wild type, n = 6 sham and
n = 11 ligations; 11/3HSD1—/—, n = 5 sham and n = 10
ligations). Ligations in mice that received RU38486 (dark gray
bars, n = 6) induced greater myocardial angiogenesis in com¬
parison to vehicle-treated ligated controls (light gray bars, n =
3). Results are mean ± SEM. #, P < 0.001 versus corresponding
sham. ***, P < 0.001 for differences between wild-type and
11HSD1 P < 0.02 for differences between coronary
artery ligated wild-type mice treated with RU38486 or vehicle.
(O Identification of blood vessels in 7-day-old cutaneous
wounds from wild-type mice stained with hematoxylin/eosin
(i) or an antibody against von Willebrand factor (ii). (Magni¬
fication: x400; scale bars: 100 /xm.)
which the abnormality is apparent only in adult pathology (47),
thus reflecting the distinct pathways underlying vasculogenesis
and adult angiogenesis. However, when angiogenesis is stim¬
ulated in adult mice, we found that 11|BHSD-1 amplifies the
angiostatic effect of endogenous glucocorticoids. In s.c.
sponge implants, this effect is local, rather than systemic,
because angiogenesis in contralateral sponges was unaffected.
Moreover, Cortisol concentrations in the sponges were lower
after impregnation with cortisone than with Cortisol, suggest¬
ing that it is the generation of Cortisol locally within the cells
that express 11/3-HSD1, rather than levels of Cortisol in the
interstitial fluid of the sponge, which determines the angio¬
static effect. Finally, the relevance of 11/3HSD-1 was con¬
firmed by the demonstration that 110HSD-1 null mice exhibit
greater angiogenic responses in wounds and infarcted myo¬
cardium. In these studies, immunohistochemical localization
of vWF enabled quantification of large- and medium-sized
vessels (35) but not the entire population of endothelial cells
in a section. Thus, all of the vessels included in the quantifi¬
cation are likely to be functional.
It is possible that these observations reflect 11j3HSD-1
activity either within the vessel wall or in the inflammatory
infiltrate that accompanies angiogenesis in all of these in vivo
models. llfiHSD-1 is expressed in macrophages (48), and
regeneration of glucocorticoids enhances phagocytosis of apo-
ptotic neutrophils (49), hence absence of 11 /3HSD-1 may
confer a prolonged and enhanced acute inflammatory re¬
sponse that, in turn, might stimulate angiogenesis. However,
11/3HSD-1 in the inflammatory infiltrate cannot explain the
influence of 11J3HSD-1 in isolated aortic rings. The findings in
the isolated aortic ring model confirm that vessel wall
11/3HSD-1 moderates the angiostatic influence of glucocorti¬
coids and confirms that regeneration of active glucocorticoids
within vascular smooth muscle cell can inhibit angiogenic
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processes. Although the in vivo models validated the isolated
aortic ring findings, it is apparent nonetheless that inflamma¬
tory cytokines induce 11 fiHSD-1 expression in a variety of cell
types (13), including in vascular smooth muscle cells (23), so
that the contribution of llfiHSD-1 within the vessel wall may
be intimately related with the extent of the inflammatory
response.
Angiogenesis is crucially dependent on endothelial cells
producing key factors such as vascular endothelial growth
factor (VEGF) and forming a de novo collagen basement
membrane to allow structured cell proliferation (24). In the
chick chorioallantoic membrane, glucocorticoids alter endo¬
thelial cell morphology and collagen production (7, 9). It has
also been proposed that glucocorticoid effects are mediated by
inhibition of endothelial VEGF transcription and endothelial
nitric oxide production (19, 50). However, in keeping with a
role for 11/3HSD-1, the effect of glucocorticoids may be
mediated within vascular smooth muscle, where inhibition of
matrix metalloproteinase production (51) may alter the effi¬
cacy of endothelium-dependent new vessel formation, and
antiproliferative effects (20) may attenuate formation of vessel
walls around endothelial cell buds.
In contrast to the established effects of supraphysiological
concentrations of glucocorticoids, the influence of endoge¬
nous glucocorticoids on angiogenesis has until now remained
unclear. The current findings in vitro and in vivo confirm a
physiological role for endogenous glucocorticoids to regulate
angiogenesis and highlight the significance of vascular
11/3HSD-1 in modulating this effect. The wider relevance of
these findings to pathology is illustrated in the models of
wound healing and myocardial infarction. These findings may
lead to therapeutic approaches to enhance angiogenesis by
preventing glucocorticoid action. Although systemic glucocor¬
ticoid receptor blockade is unlikely to be successful as a
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treatment in the short term (because of adverse effects of
preventing the normal cortisol-dependent stress response) or
in the long term (because of compensatory activation of the
hypothalamic pituitary adrenal axis), the current data suggest
that manipulation of local 110HSD-1 offers a more targeted
approach to the blood vessel wall. 11/3HSD-1 inhibitors are
already being developed for reducing risk factors for cardio¬
vascular disease (45), including in type 2 diabetes mellitus and
obesity. These results suggest that pharmacological inhibition
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